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Obesity is an epidemic and still growing health problem around the world and 
represents the major challenge to chronic disease prevention. Demographic, 
economic and epidemiological changes have driven to unacceptable rates of obesity 
among adults and children. The accompanying non-alcoholic fatty liver disease 
(NAFLD) has become the most common cause of chronic liver disease and it is 
associated with high morbidity and mortality.  
NAFLD encompasses a wide spectrum of histological findings ranging from simple 
steatosis to non-alcoholic steatohepatitis (NASH) and advanced fibrosis, which could 
progress to cirrhosis, hepatocellular carcinoma and liver failure. Given the extremely 
high prevalence of NAFLD, the significant number of individuals which are 
asymptomatic until their liver begins to fail and the association between NAFLD and 
an increase of all-cause mortality, there is a great need for the development of non-
invasive diagnostic methods which could reduce liver biopsy and overcome its 
drawbacks. 
Current laboratory tests are insufficient and unreliable for the determination of 
NAFLD presence. Moreover, non-invasive imaging techniques to diagnose NAFLD are 
expensive and not suitable for morbidly obese patients. For this reason we aimed to 
discover a rapid and non-invasive method that could improve clinical care. 
Accordingly, Study 1, published in International Journal of Obesity, describes a non-
targeted metabolomics approach on the plasma from morbidly obese patients 
undergoing bariatric surgery to gain a comprehensive measure of metabolite levels. 
Furthermore, on the basis of these findings, we developed a method for the accurate 
quantification of plasma a-ketoglutarate to explore its potential as a novel 
biomarker for the detection of NAFLD. This study elucidated that plasma a-
ketoglutarate is superior to common liver function tests in obese patients as a 
surrogate biomarker of fatty liver disease. Thereby, the measurement of this 
biomarker may potentiate the search for therapeutic approaches, may decrease the 
need for liver biopsy and may be useful in the assessment of disease progression. 
Excessive energy intake is a part of the current human lifestyle. This energy surplus 
alters metabolic homeostasis and leads to a state of low-grade chronic inflammation 
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which has an important role in the pathogenesis of obesity and NAFLD. Accordingly, 
the immune system and metabolism are closely interconnected and an energy 
excess management could compromise this relationship. For this reason, we 
reasoned that searching for an adequate animal model might allow us to better 
understand disease pathogenesis.  
Chemokines are promising candidates for the design of such a model. Chemokines, 
especially Chemokine (C-C Motif) Ligand 2 (CCL2), not only governed the migration of 
immune cells during inflammation but also have a variety of additional functions that 
are involved in the correct functioning of metabolism. Moreover, they are 
overexpressed in non-communicable disease such as obesity and NAFLD so they 
could become a biomarker. Therefore, we hypothesised that challenging an animal 
model that systematically overexpresses CCL2 combined with diets rich in fat and 
cholesterol could help to assess the role of chronic inflammation in response to 
excessive energy. In Study 2, published in Mediators of Inflammation, we present 
the results obtained from the generated targeted CCL2 transgenic mice which 
overexpress CCL2 in all tissues. These data corroborated that CCL2 modifies lipid and 
glucose metabolism, contributes to hepatic steatosis and promotes changes in 
macrophage function and plasticity, mitochondrial biogenesis and autophagy. Thus, 
this study contributed to the knowledge about the relationship between 
inflammation and metabolism and suggested a number of mechanistic questions for 
further studies.  
On the bases of these findings, and in order to determine if the deleterious 
metabolic effects caused by a continuous and ubiquitous expression of CCL2 
combined with energy surplus could be counteract by the absence of its receptor 
(CCR2), we created a novel animal model, a double genetically modified mouse, CCL2 
overexpressor and CCR2 knockout mice. Accordingly, in Study 3 we present the 
preliminary results obtained from these mice which suggest that all metabolic 
disturbances observed in transgenic mice which overexpress CCL2 could be reverted 
by the inhibition of CCL2/CCR2 axis biological function. All this information could be 
really important to establish CCR2 modulators as a new class of therapeutic agents 
to the management of metabolic diseases. 
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1. Obesity: the epidemic of the twenty-first century 
 
Obesity is one of the most common diseases worldwide and has become the 
greatest public health challenge. The World Health Organization (WHO) has 
considered obesity as the “epidemic of the twenty-first century”.  
It is typically defined as the state of having excess body weight. However, this simple 
definition misrepresents an etiologically complex phenotype mainly associated with 
excess adiposity which can manifest metabolically and not just in terms of body size 
[1, 2]. 
Globally, the worldwide prevalence of obesity has considerably increased since the 
early 1980s. According to the WHO, in 2014 more than 1.9 billion of adult population 
was overweight and, of these, over 600 million had obesity (39% and 13% of total 
population, respectively) [3]. In European Union member states approximately 35% 
of all adults are overweight and approximately 17% are classified as obese. In 
addition, most available trend data suggest that, unfortunately, obesity rates are 
continuing to rise [4]. 
There is also an alarming increase in globally prevalence rates of overweight and 
obesity among children and adolescent population. Severe obesity in childhood is 
unfortunately not uncommon. In 2013, 42 million children under the age of 5 were 
overweight or obese [3].  
In Europe, around 1 in 3 children aged 6-9 years old were overweight or obese in 
2010. This is a worrying increase in regard to the experts estimates on 2008, when 
they were talking about 1 in 4 (estimates based on data from the WHO’s Childhood 
Obesity Surveillance Initiative, COSI) [5-7].  
Although overweight and obesity are considered a high-income country problem, 
their prevalence is increasing in lower and middle-income countries, particularly in 
urban surroundings. In these developing countries with emerging economies, the 
rate of this health problem is more than 30% higher than in developed countries [3].  
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1.1 Classification 
 
The most commonly used method in major guidelines for classifying an individual as 
overweight or obese is based on body mass index (BMI), defined as the body weight 
in kilograms divided by height in meters squared.  
In 1997, the WHO standardized the definition of normal weight, overweight and 
obesity and most studies have adopted these definitions [8]. Moreover, the WHO 
distinguishes several BMI categories based on increasing health risks (Table 1) [9]. 
Given this definition, in adults, overweight is defined by a BMI ≥25.0 kg/m
2
, and a 
BMI ≥30.0 kg/m
2 
is categorized as obesity [10-12].  
Table 1. Classification of obesity based on increasing health risk. Adapted from WHO guides [9]. 
 
Weight category BMI (kg/m
2
) Associated health risks 
Underweight <18.5 Low (but risk of other clinical problems) 
Normal weight 18.5-24.9 Average 
Overweight ≥25.0 Increased 
Obese ≥30.0  
Obese class I 30.0-34.9 Moderately increased 
Obese class II 35.0-39.9 Severely increased 
Obese class III ≥40.0 Very severely increased 
 
1.2 Obesity-inducing factors 
 
Obesity arises as the result of an imbalance in energy homeostasis, when caloric 
intake exceeds energy expenditure during an extended period of time and leading to 
excess body weight.  
The increasing prevalence of obesity is influenced by a complex interaction between 
genetic, metabolic, behavioral and environmental factors and also seems to be 
related to a countless social and economic changes inherent to modern society [13-
16]. All of these factors create an obesogenic environment. This term has been 
coined to express the sum of influences, opportunities, or conditions of life that 
produce and support overweight and obesity through several intersecting 
mechanisms [17, 18].  
These obesogenic shifts linked with the globalization and modernization include 
growing availability of abundant, cheap, energy-dense, highly palatable foods and 
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sugar-sweetened beverages. Gathering all of these factors together with improved 
food distribution and highly pervasive and persuasive marketing create a “push 
effect” that drives over-consumption of calories. Moreover, in the past decades, 
environmental changes have reduced physical activity via our service-based 
economy and labor-saving devices which have had a cumulative impact in decreasing 
daily energy expenditure. At the same time, energy expended in leisure-time 
physical activities has decreased because people spend more time doing sedentary 
activities rather than participating in activities that require greater amounts of 
energy expenditure. In addition, the frequent disruption of sleep and circadian 
rhythms and a variety of other cultural and economic factors also predispose to 
weight gain. Finally, hereditary factors such as genetics, family history and 
racial/ethnic differences also lead to the development of obesity [19-23]. 
The relative contribution of each of these factors has been studied extensively. The 
majority of studies conclude that behavioral and environmental factors, such as 
sedentary lifestyles combined with excess energy intake, are primarily responsible 
for the dramatic increase in obesity since population-wide genetic alterations do not 
occur in this relative short period of time in which obesity reached epidemic 
proportions [1, 11]. A summary of major risk factors and determinants of obesity is 
shown in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Major risk factors of obesity. Apart from hereditary factors, both socioeconomic and 
behavioral factors are modifiable. In addition, behavioral factors are the key in the prevention of 
obesity. 
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To sum up, body weight regulation is and should be viewed as a complex interaction 
between environmental, socioeconomic and genetic factors. However personal 
behaviors in response to these conditions continue to play a dominant role in 
preventing obesity. Importantly, apart from genetics, every risk factor discussed 
below could be modified. 
1.3 Costs of obesity 
Comorbidities 
Obesity is considered one of the key risk factors for other chronic diseases together 
with smoking, high blood pressure and high blood cholesterol [24].  
The increasing prevalence of obesity and overweight is associated with the incidence 
of several comorbidities including type-2 diabetes mellitus (T2DM), dyslipidemia, 
hypertension, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and 
cardiovascular disease, nowadays the leading cause of death [24, 25]. Furthermore, 
many studies have examined the link between obesity and cancer and have reported 
that obesity is associated with multiple types of cancer including colorectal, liver, 
esophageal, pancreatic, breast, endometrial, cervical, ovarian, brain, renal, kidney, 
prostate, lymphoma and multiple myeloma [26, 27]. Finally, there is also a 
relationship between obesity and asthma, sleep apnea syndrome, infertility related 
to hormonal disturbances and many of psychiatric disorders, obese individuals suffer 
from social stigmatization, discrimination, and low self-steem [16].  
Although obesity is associated with several metabolic disturbances, all obese 
humans are not equal and approximately 20% of patients with severe obesity have 
normal metabolic profile. The authors called these obese individuals “metabolically 
healthy” obese. However, most obese patients are “metabolically unhealthy”. The 
reasons of these two phenotypes are unknown. Differences in glucose tolerance, 
inflammatory response, adipose tissue distribution, adipokine secretion pattern and 
age may be an explanation to this phenomenon. Thus, obesity could be considered 
as a heterogeneous disorder with variable risk profile [28, 29]. 
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Mortality 
It is well known that obesity is associated with an increased risk of death. Recent 
estimates show that around 2.8 million deaths per year in the European Union result 
from overweight and obesity-related causes [30]. However, the relationship 
between body mass index and longevity remains an area of interest and controversy.  
Numerous studies have demonstrated a ‘U-shaped’ association between BMI and 
risk of death (Figure 2), in other words, lower and upper BMI categories 
(underweight or BMI ≤18 kg/m
2
 and morbidly obesity or BMI ≥40 kg/m
2
) are 
associated with higher mortality than in middle categories. The main point of 
controversy concerns the increased risk of mortality at the low end of the BMI 
continuum. It is inconsistent with the generally relation between BMI and indicators 
of morbidity. Moreover, it stands in contrast to the fairly consistent observation that 
weight loss reduces risks factors for a variety of illnesses. In response to this 
counterintuitive finding, several authors suggested that the elevated risk of mortality 
at lowest BMI categories is an artifact. The two confounding variables most 
frequently cited are smoking and pre-existing “occult” disease which might 
contribute to weight loss and thus increased mortality in underweight people [31-
34].   
Figure 2. Schematic illustration of the association between mortality and BMI. UW, underweight; 
BMI, Body Mass Index. 
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The association between overweight or grade I obesity and obesity-induced 
comorbidities is not clear. Numerous studies have shown an unexpected and 
paradoxical inverse relationship with better prognosis in this patient group than in 
normal-weight group, the so-called “obesity paradox” [35-39]. They revealed that all-
cause mortality among overweight or grade I obesity subjects is significantly lower or 
not higher, compared with normal-weight subjects in general population. For this 
reason, the debate on the “obesity paradox” in different comorbidities such as 
coronary heart disease, heart failure, hypertension, peripheral artery disease, stroke, 
thromboembolism, kidney and pulmonary disease among others is still open [40-56]. 
Conversely, there are numerous meta-analyses that have shown the opposite, an 
increased mortality in obese adults compared with normal weight range [57], so this 
scientific debate is not yet closed. 
Nevertheless, the discussion over the existence of the obesity paradox cannot lead 
to an underestimation of obesity as a crucial risk factor for the development of 
cardiovascular and metabolic diseases that requires comprehensive prevention and 
management strategies. Thereby, it should be emphasized that the obesity paradox 
cannot be the argument against professional treatment of overweight or grade I 
obesity in subjects diagnosed with cardiovascular diseases or other associated 
comorbidities. However, in each case, the decision should be made individually with 
the assessment of potential benefits, including the effect of weight loss on related 
comorbidities and on quality of life [58]. 
1.4 Obesity management 
The global increasing prevalence of obesity and its metabolic complications and 
consequently its health costs emphasize the global need for improved strategies in 
obesity prevention and treatment. 
There is a growing demand that governments and international bodies such as 
United Nations and the WHO take action to reduce the burden of obesity and 
consequently all of its comorbidities.  
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Lifestyle 
interventions 
Pharmacotherapy Bariatric surgery 
As many other chronic diseases, optimal management for obesity consist of different 
intervention steps, starting with the least invasive and progressing to more invasive 
approaches as show in Figure 3 [59]. 
 
 
 
 
 
Figure 3.Three-stepped intensifications of care approaches to weight management. 
 
Lifestyle interventions 
As obesity is the major contributor to many metabolic disorders, there is good 
reason to consider weight loss as a primary therapy. Accordingly, obesity preventive 
and therapeutic interventions are focused on the modification of risk factors 
promoting healthy eating, reducing caloric density, glycemic index and overall calorie 
intake, increasing aerobic and resistance exercise, promoting stress-reduction 
techniques and increasing the quality of nightly sleep. These approaches are lifestyle 
interventions, which are the first step and should be the basis of all obesity 
preventive and therapeutic strategies. Moreover, they are the most accessible and 
economical option because of their non-invasive nature and their weight-
independent benefits [60-63]. Lifestyle interventions can be divided in three broad 
categories: behavioral, community and environmental interventions [64]. 
§ Behavioral interventions have formed the cornerstone of obesity prevention 
and especially of its treatment. They are focused on current behavior-related 
aspects with a particular focus on increasing energy expenditure and 
reducing energy intake to achieve weight loss. These interventions could be 
self-directed but when they prove inadequate, professional guidance can be 
particularly helpful providing ongoing assessment and feedback about 
progress and identifying the most prominent stressors that are likely to 
contribute to obesity and helping to mitigate them. 
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§ Community interventions are implemented in neighborhoods, schools, 
communal sites, social care facilities and cultural centers. They combine 
behavioral measures and local environmental changes to address the supply 
and demand for food and/or physical activity. Some examples of this type of 
interventions are: comprehensive community-based life-style programs 
(health education, seminars, community events, worksite programs), the 
creation of a local environment that emphasized and supported a physical 
active lifestyle, school based interventions, changes in travel behavior (to and 
from school/worksite) and after-school physical activity sessions among 
others. 
§ Environmental interventions modify a target population’s environment and 
are often outside the healthcare sector. They have the potential to reach 
large number of individuals simultaneously and may have a more lasting 
effect on the behavior changes as they become incorporated into structures, 
systems, policies and sociocultural norms: taxes on unhealthy food and 
beverages, front-of-pack traffic light nutrition labeling, regulation of 
advertising of junk food and beverages to children and the implementation of 
educational mass media campaigns to increase health information and 
knowledge. 
The response to this type of interventions is highly variable, some patients exhibit a 
substantial and durable weight loss, but many others are unable to achieve long-
term weight maintenance. Accordingly, adjunctive, alternative and more intensive 
approaches are required. 
Pharmacotherapy is the second-line approach recommended when lifestyle 
interventions are ineffective in yielding significant weight loss. This type of treatment 
is approved in patients with a BMI ≥30 kg/m
2
 or BMI ≥27 kg/m
2
 with obesity related 
comorbidities [59]. 
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Pharmacotherapy 
There are two groups of approved drugs that can be used: 1) medications approved 
from obesity management per se (appetite suppressants or satiety enhancers and 
gastrointestinal blockers and 2) medications that affect body weight for obese 
patients who have metabolic complications and are receiving them for chronic 
disease management (i.e. T2DM) [59, 65, 66]. Medications of these two groups 
approved by U.S Food and Drug Administration (FDA) are listed in Table 2 and in 
Table 3, respectively.  
History of drug treatment of obesity has experienced the rise and fall of several 
therapeutic agents which despite showing promising efficacy in body weight 
reduction and touted as “magic pills” for addressing the obesity epidemic, had to be 
withdrawn from the market due to serious adverse effects [67]. In 1930s, 
amphetamines were first introduced as anorectics. However, amphetamine was 
addictive and had euphoric side effects. By modifying the structure of 
amphetamines, the anorectic effect of the parental compound was maintained while 
the stimulatory properties and potential for addition were reduced. With this 
strategy, in 1960 four noradrenergic agents (phentermine, benzphetamine, 
diethylpropion, phendimetrazine) were approved as adjuncts in the management of 
obesity. Phentermine remains the most often prescribed drug for short-term use (up 
to 12 weeks) for weight loss in the United States [59, 68]. 
Among the currently approved anti-obesity drugs, orlistat was accepted by FDA in 
1999 as the first lipase inhibitor for obesity management. In the past, it was the 
unique drug available for long-term treatment of obesity, and nowadays, it remains 
as the only approved obesity therapy in Europe [67-69]. Subsequently, after a long 
gap of more than ten years, two new therapies, lorcaserin and 
phentermine/topiramate, were approved in 2012. In 2014, FDA finally approved the 
combination of bupropion/naltrexone. All of these new pharmacological treatments 
provide additional options for the management of obesity [59, 67, 69, 70]. 
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Table 2. Weight loss medications approved by U.S. FDA for treatment of obesity. 
 
  
Family and generic name Action 
Short-term use 
Noradrenergic agents  
§ Phentermine 
§ Benzphetamine 
§ Diethylpropion 
§ Phendimetrazine 
 
 
Enhance satiety by inhibiting the reuptake of 
noradrenalin in the synapse and consequently, 
an increase of hypothalamic noraderenaline 
levels.  
Long-term use 
Gastrointestinal lipase inhibitor 
§ Orlistat 
 
Reduces body weight by binding and inhibiting 
lipases produced by pancreas and stomach 
reducing the absorption of ingested dietary fat 
(approximately 30%). 
 
Serotonin-2C receptor activation 
§ Lorcaserin 
 
Stimulates proopiomelanocortin (POMC) 
producing neurons in the hypothalamus 
resulting in generation of a-melanocortin 
stimulating hormone, which acts on 
melanocortin receptors to decrease food 
intake and enhances satiety. 
 
Combined therapy 
§ Phentermine-Topiramate 
extended release (ER) 
 
 
Phentermine reduces appetite trough 
increasing noradrenaline in the hypothalamus. 
However, topiramate effects on reducing the 
appetite are not thoroughly understood. It is 
thought that it has some effects on g-
aminobutyric acid (GABA) receptors. 
§ Bupropion/Naltrexone Bupropion reduces food intake by acting on 
adrenergic and dopaminergic receptors in the 
hypothalamus. Naltrexone is an opioid 
receptor antagonist which inhibits food intake. 
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Moreover, given the relative dearth of effective anti-obesity agents and the lack of 
prospects for new drug development, obesity researchers and clinicians are 
increasingly turning to a drug repositioning strategy in order to expand therapeutic 
options. For this reason, in obesity management nowadays there is an increasing 
utilization of medicaments traditionally used for the treatment of obesity-related 
comorbidities if they also produce weight loss (Table 3) [66, 71]. For example, 
metformin is an antihyperglycaemic agent approved for the treatment of type 2 
diabetes in adults and children aged ≥10 years. There are a lot of clinical trials which 
demonstrated that metformin therapy reduced both energy intake and body weight 
[72-76]. 
Table 3. Other medications studied off-label for obesity prevention or treatment.  
Family and generic name Indication Action 
Biguanide 
§ Metformin 
Glucagon-like peptide-1 
§ Exenatide 
§ Liraglutide 
Treatment of type 2 
diabetes 
Enhances insulin sensitivity. 
Produces small sustained 
weight loss of about 2%. 
Reduce fasting and post-
pandrial glucose levels, slow 
gastric emptying and decrease 
food intake by 19%. 
Antidepressant drug 
§ Bupropion 
Anticonvulsant drug 
§ Topiramate 
 
 
 
Treatment of 
neurobehavioral disorders 
Reduces food intake by acting 
on adrenergic and dopaminergic 
receptors in the hypothalamus. 
Induces appetite suppression 
and satiety via GABA receptors 
mediated inhibitory activity. 
 
To sum up, the ideal anti-obesity agent would selectively reduce body fat stores by 
ameliorating the regulatory or metabolic disturbances involved in the pathogenesis 
of obesity. Furthermore it should exhibit only minor, if any, side effects, be 
preferentially administered orally for long-term use and be widely accessible [66]. 
Care, consideration and close monitoring are essential when prescribing these 
medications but it is obvious that the progression of pharmacotherapy for obesity 
treatment gives us a chance to manage weight problems more effectively. 
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Bariatric surgery 
Bariatric surgery is the third-line approach recommended when the multiple 
attempts at weight loss through lifestyle interventions and/or pharmacotherapy are 
not successful. Currently, bariatric surgery is reserved for patients with severe or 
complex obesity (BMI ≥40 kg/m
2 
or BMI ≥35 kg/m
2 
in the presence of at least one 
obesity-related comorbidity). This treatment approach seems to be the most 
effective treatment in this population; in terms of amount of weight loss achieved 
and weight maintenance, as well as ameliorating obesity-related comorbidities [77-
80]. Although the short-term results of surgery are easily apparent in copious 
amounts of literature, long-term data about the benefits of bariatric surgery are also 
emerging. The Swedish Obese Subjects study has shown that, compared with 
conventional treatment in contemporaneously matched obese controls, bariatric 
surgery is also associated with a long-term reduction in all-cause mortality [78, 81]. 
There are four types of bariatric surgery which are usually performed 
laparoscopically: adjustable gastric band (AGB), sleeve gastrectomy (SG), Roux-en-Y 
gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD-DS) 
(Figure 4). Classically, bariatric surgery has been described as 1) restrictive, which 
aimed to reducing food intake by limiting gastric volume, or 2) restrictive with some 
malabsorption, which reduces stomach size and creates a physiological condition of 
malabsortption. The first group includes AGB and SG and the second includes RYGB 
and BPD [82-84].  
All surgeries have advantages and disadvantages, but all procedures are safe and 
effective. Choice of procedure depends on many factors including local expertise and 
experience in the different bariatric surgery procedures and their aftercare, and the 
complexity and reversibility of the procedure. The following describes each of these 
surgical procedures: 
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§ Adjustable gastric band (AGB): an adjustable band is placed around the 
fundus of the stomach. The restriction of the band is adjusted with fluid via a 
port, connected to the tubing and placed subcutaneously on the anterior 
abdominal wall. This causes early satiety once the pouch is full, and the 
amount of food is restricted until ingested food-stuff has passed through the 
band (Figure 4A).  
§ Sleeve gastrectomy (SG): the stomach is reduced to about 15% of its original 
size due to the stomach is removing leaving a thin tube of lesser curve 
(banana shape) (Figure 4B). This procedure is not reversible. 
§ Roux-en-Y gastric baypass (RYGB): with this technique stomach is divided to 
create a small pouch. The smaller stomach is joined directly to a loop of 
jejunum around one meter distal to the duodenal-jejunal flexure, bypassing 
the rest of the stomach and the upper portion of the small intestine 
(duodenum). The redundant stomach and jejunum are then re-anastomosed 
to the jejunum at a variable distance downstream where digestive juices join 
food (Figure 4C). In normal digestion, food passes through the stomach and 
enters the small intestine where most of the nutrients and calories are 
absorbed. Thus, with this surgery, food is not absorbed and the amount of 
food is restricted by limited size of gastric pouch. 
§ Biliopancreatic diversion with duodenal switch (BPD-DS): it involves a gastric 
restriction by a sleeve gastrectomy and malabsorption results from the small 
intestinal bypass. The duodenum is transected and anastomosed to an 
alimentary limb of ileum. The biliopancreatic limb, which consists of the distal 
duodenum, jejunum, and proximal ileum, contains the biliopancreatic 
secretions and is attached to the alimentary limb (Figure 4D). The BPD-DS has 
a malabsorptive component more important than RYGB surgery. 
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Figure 4. Graphical representation of the most common types of bariatric surgery. A Adjustable 
gastric band. B Sleeve gastrectomy. C Roux-en-Y gastric bypass and D Biliopancreatic diversion with 
duodenal switch (BPD-DS). Adapted from Piche et al. [82].  
To conclude, bariatric surgery has increased in popularity because of its higher ability 
to induce long-term weight loss than medical and pharmacological strategies in 
magnitude and durability. Moreover, bariatric surgery is safe and beneficial in 
severely obese patients as it induces long-term metabolic benefits. Because of the 
low risk of surgery and the unequivocal sustained benefits of surgical-induced weight 
loss, it is likely that bariatric surgery will continue to evolve and to have an 
expanding role in the prevention of obesity and its related comorbidities [85].
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2. NAFLD: the hepatic manifestation of metabolic syndrome 
 
The rapidly increasing prevalence of obesity in both children and adults has also lead 
to the rise in NAFLD, recognized worldwide as the most common cause of chronic 
liver disease [86, 87]. Furthermore, it is thought that NAFLD is set to replace viral 
hepatitis as the primary cause of end-stage liver disease and liver transplantation 
over the next decade [88]. 
NAFLD is defined by the presence of a significant amount of lipid accumulation in the 
liver parenchyma (at least in 5% of hepatocytes), also known as hepatic steatosis, in 
the absence of excess alcohol consumption. These hepatic fatty deposits result in a 
wide spectrum of liver damage ranging from simple steatosis with no symptoms to 
non-alcoholic steatohepatitis or NASH (the presence of fat in liver parenchyma with 
inflammation, hepatocyte ballooning and lobular inflammation) through to fibrosis 
and cirrhosis which can result in hepatocellular carcinoma and liver failure (Figure 5) 
[89, 90].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.Disease spectrum of NAFLD. A Schematic representation of NAFLD progression B Histological 
sections of normal liver, steatosis, NASH, and cirrhosis. Adapted from Cohen et al. [90]. 
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Original histopathologic descriptions of NAFLD date back from 1958 when the 
disease was characterized by Westwater and Fainer in a group of obese patients 
[91]. In 1980, Ludwig et al. described 20 patients who lacked a history of significant 
alcohol consumption but in whom liver histology mimics alcoholic liver disease [92]. 
They first coin the term of “non-alcoholic steatohepatitis” for this condition. After 
much debate, the entity of NASH became accepted [93].  
2.1 Epidemiology 
The worldwide incidence rate of NAFLD is unknown. This disease is usually clinically 
silent and there is a wide variation in the criteria and diagnostic methods used, 
consequently its impact has most likely been underestimated [87, 94, 95]. The 
prevalence of NAFLD in normal weight individuals without any metabolic risk factors 
is around 16%, rising to 43-60% in patients with diabetes, to 91% in obese patients 
undergoing bariatric surgery and up to 90% in patients with hyperlipidemia [89, 96]. 
NAFLD is associated with insulin resistance and other metabolic risk factors such as 
diabetes mellitus, central abdominal obesity, dyslipidemia and cardiovascular 
disease. The prevalence of NAFLD also increases with the age and is influenced by 
genetics. In addition, gender, ethnicity, race and chronic infections seem to be other 
risk factors of this liver disease [86, 87, 97]. Moreover, NAFLD is associated with the 
increase of all-cause mortality, contributed by liver related deaths as well as non-
liver related causes [89, 98]. 
2.2 Pathogenesis and natural history 
The liver is a metabolic organ that performs important biochemical functions 
necessary for metabolic homeostasis and it is one of the principal regulators of 
glucose and lipid metabolism. Insult to any of these processes can lead to liver 
disease. In the case of NAFLD, numerous disorders can be found in liver’s capacity to 
process lipids and it has been linked to multifactorial alterations in genetics, diet, 
adipose tissue, hormone regulation, the immune system and gut microbiota [96, 99].  
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The amount of lipids present in hepatocytes represents a complex interaction 
between: 1) hepatic fatty acid uptake of plasma free fatty acids (FFA) released from 
lipolysis in adipose tissue and from the hydrolysis of circulating triglycerides, 2) de 
novo lipogenesis, 3) fatty acid oxidation and 4) fatty acid exportation within very low 
density lipoproteins (VLDL) [96, 99]. Figure 6 shows a schematic representation of 
the sources and fates of liver fat. Accordingly, in NAFLD the accumulation of fat is the 
result of increased uptake of fatty acids and of de novo lipogenesis and impaired 
fatty acid elimination through oxidation or secretion of triglycerides into VLDL [100, 
101].  
Figure 6. Sources and fates of intrahepatic lipid content. FFA: free fatty acids. VLDL: very low density 
lipoproteins. Adapted from Tiniakos et al. [102]. 
In obesity, caloric balance is positive. Initially, some of the excess energy is stored in 
matured adipocytes which increase in size (hypertrophy). Subsequently, 
adipogenesis, the differentiation of preadipocytes into new adipocytes, is triggered. 
However, the capacity to store energy in adipose tissue is limited. For this reason, if 
chronic positive caloric balance persists, adipogenesis may be overwhelmed [103, 
104]. Thus, reduced capacity for adipogenesis, coupled with increased energy 
storage demand in obesity may account for the switch from hyperplastic (the 
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increase of adipocyte number) to hypertrophic adipocytes which have negative 
implications [105-108].  
Adipocyte hypertrophy entails deregulated adipokine secretion (the balance of pro- 
and anti-inflammatory adipokines is shifted to a pro-inflammatory state), free fatty 
acid secretion, hypoxia, cell death and macrophage infiltration [105, 109-111]. 
Adipose tissue macrophages can be classified in two groups based on their surface 
marker expression and/or their chemokine secretion profile. On the one hand, there 
are “classically activated” macrophages or M1, which promote inflammation and, on 
the other hand, “alternatively activated” macrophages or M2 with anti-inflammatory 
functions. Accordingly, as obesity progresses, the number of macrophages in adipose 
tissue increase and it is accompanied by macrophage polarization from the M2 to 
the M1 phenotype. Consequently, there is an increased expression of pro-
inflammatory adipokines such as tumor necrosis factor-a (TNF-a), interleukin 6 (IL-
6), interleukin-b (IL-b), Chemokine (C-C Motif) Ligand 2 (CCL2) which mediates 
macrophage phagocytic and inflammatory responses (Figure 7) [112, 113].  
Figure 7. Adipose tissue expansion and its resultant inflammation and metabolic dysfunction. 
Weight gain leads to adipose tissue expansion and the infiltration of pro-inflammatory immune cells, 
M1 macrophages and CD8
+ 
T cell. Consequently, adipocytes produce inflammatory cytokines and 
secrete free fatty acids (FFA) antagonizing local insulin signaling in adipocytes an also in distant organs 
such as muscle and liver leading to systemic insulin resistance. Adapted from Ouchi et al. [111]. 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
NAFLD: the hepatic manifestation of metabolic syndrome 
  
43 
 
This imbalance in the expression of these pro-inflammatory adipokines leads to 
various metabolic abnormalities including low-grade inflammation, deregulation of 
fatty acid metabolism and storage and finally, insulin resistance. This failure of 
insulin sensitivity can occur locally and/or in distant organs such as muscle and liver 
(Figure 7) [103, 105, 114, 115]. 
Adipokines induce insulin resistance and low-grade inflammation through the 
activation of stress-related protein kinases, e.g c-Jun NH2 terminal kinase 1 (JNK-1) 
and inhibitor kappa kinase b (IKKb). JNK-1 phosphorylates insulin receptor substrate-
1 protein (IRS-1) inactivating insulin signaling and, IKKb activation leads to the 
translocation of the nuclear factor kb (NF-kb) into the nucleus, resulting in an 
enhanced synthesis of inflammatory cytokines [116].  
In skeletal muscle insulin predominantly induces glucose uptake by stimulating the 
translocation of glucose transporter type 4 (GLUT4) to the plasma membrane and in 
the liver, insulin inhibits gluconeogenesis. Furthermore, in adipose tissue insulin is a 
key regulator of circulating FFA, it decreases lipolysis and thereby reduces FFA efflux 
from adipocytes [117]. Accordingly, in the absent of competent insulin response in 
adipose tissue, excess lipolysis ensues leading to an increased release of free fatty 
acids in the circulation that could be taken by the liver. FFA lipotoxicity involves the 
suppression of insulin receptor activation and inflammation through the impairment 
of the phosphorylation of IRS-1. Moreover, this excessive lipid storage may directly 
contribute to organelle failure including mitochondrial dysfunction, and endoplasmic 
reticulum stress [109, 118]. 
Energy metabolism within the liver is tightly regulated. Two transcription factors, 
sterol regulatory element-binding protein 1 (SREBP-1) and carbohydrate-responsive 
element-binding protein (ChREBP) are intimately involved in hepatic glucose and 
lipid metabolism [118]. Dysfunction of the insulin receptor causes hyperglycemia and 
hyperinsulinemia. On the one hand, hyperinsulinemia leads to increase SREBP-1c 
expression resulting in increased de novo lipogenesis and decreased fatty acid 
oxidation. In the other hand, hyperglycemia induces ChREBP and leads to further 
increase in de novo lipogenesis. Decreased hepatic lipid transport may also occur via 
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altered synthesis of apolipoprotein B, leading to decreased VLDL production [114-
116, 118, 119].  
Although insulin resistance is considered the key factor in developing hepatic 
steatosis further research is needed to determine the cause and effect relationship 
between both, in other words, if NAFLD is a cause or a consequence of insulin 
resistance. In fact, excessive intrahepatic triglycerides content could be both a cause 
and a manifestation of insulin resistance, resulting from a sequence of events 
initiated by adipose tissue insulin resistance and propagated to other tissues [120, 
121]. 
Increased intrahepatic fatty acid content provides a source of inflammation and 
oxidative stress, which may be responsible for the progression from NAFLD to NASH 
and predisposing to the risk for further severe progression. Mitochondria are the 
main cellular source of reactive oxygen species, which may trigger steatohepatitis 
and fibrosis by three different mechanisms: 1) lipid peroxidation and mitochondrial 
dysfunction, 2) the release of inflammatory cytokine and 3) the consequent lobular 
inflammation, hepatocyte necrosis, apoptosis and cell dropout. The final result is a 
necroinflammatory hepatitis that can lead to fibrosis, cirrhosis, hepatocellular 
carcinoma and liver failure [86, 89]. 
2.3 NAFLD and mitochondrial dysfunction 
Mitochondria have a critical role in the regulation of global metabolic homeostasis. 
These organelles supply the cell with ATP through oxidative phosphorylation, 
synthesize key molecules and control calcium homeostasis, among other useful 
processes. However, mitochondria are also a source of free radicals. Thereby, it is 
not surprising that mitochondrial health is tightly regulated and mitochondrial 
dysfunction or damage can greatly perturb metabolic homeostasis impacting 
metabolic diseases [122].  
Cells can manage nutrient supply increasing mitochondrial content. Moreover, 
mitochondria exhibit the ability to adapt to changing metabolic conditions and are 
able to increase fatty acid oxidation in an attempt to counteract fat accumulation. 
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However, persistent nutrient surplus can overwhelmed the mitochondrial system 
and cause its dysfunction. Energy excess overloads and hyperpolarizes mitochondria, 
leading to the accumulation of incompletely oxidized lipid products from the citric 
acid cycle (CAC), also known as tricarboxylic acid cycle (TCA) or Krebs cycle, causing 
fat accumulation and excessive production of reactive oxygen species (ROS) and, 
consequently, oxidative stress. These intermediates also activate stress cascade 
which disrupt the insulin signaling pathway leading to insulin resistance. In addition, 
excessive ROS production causes mutations to the mitochondrial genomic content, 
affecting the respiration system, mitochondrial dynamics, decreasing mitophagy 
leading to aberrant mitochondria and, ultimately cell death (Figure 8) [123].  
Figure 8. Mitochondrial dysfunction. Nutrient surplus promotes the accumulation of lipid metabolite 
intermediates that overload and hyperpolarize mitochondria. Then ROS build-up causing oxidative 
stress, disrupting insulin signaling pathway and impairing mitochondria biogenesis. Adapted from 
Riera et al. [123]. 
Mitochondrial architecture is tightly regulated by the dynamic, antagonistic and 
balanced opposing processes of fusion and fission. Mitochondrial fusion 
counterbalances functional defects and allows genetic compensation while 
mitochondrial fission allows the segregation of damaged mitochondria and their 
recycling through mitophagy, an autophagic process that selectively degrades 
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damaged mitochondria, ensuring mitochondrial turnover and cellular viability. 
Finally, insulin resistance also contributes to the development of an endless vicious 
cycle by impairing CAC, respiratory system and mitochondrial biogenesis inducing 
lipid accumulation in glucose-consuming tissues such as skeletal muscle and liver 
[122-127].  
Thereby, we can conclude that mitochondria play a fundamental role in the 
development and progression of NAFLD. An increased lipid accumulation cause 
severe mitochondrial damage leading to the impairment of mitochondrial activity. 
These events initiate the first steps of NAFLD and, if they persist, hepatocyte 
recuperation could be compromised. Therefore, a careful and intensive investigation 
of molecular mechanism involving mitochondria metabolism and their role in 
NAFLD/NASH may contribute to the development of novel therapeutic strategies for 
the protection of these organelles and consequently, for the treatment of NAFLD. 
A large number of transcription factors and co-regulators are involved in the 
regulation of cellular and mitochondrial metabolism. Therefore, molecular targets 
that can improve mitochondrial function have emerged over the past decade. One of 
the most characterized co-regulator of mitochondrial biogenesis and energy 
metabolism is the transcriptional peroxisome proliferator-activated receptor co-
activator a (PGC1a) [123, 128]. A decrease of the expression of PGC1a has been 
implicated in skeletal muscle insulin resistance in humans and in animal models [129, 
130]. In contrast, increasing PGC1a content preserves oxidative phosphorylation and 
inhibits insulin resistance and fat accumulation. PGC1α also minimizes the build-up 
of ROS through the transcriptional regulation of numerous ROS-detoxifying enzymes 
[131, 132]. AMP-activated protein kinase (AMPK) is another key factor. AMPK, one of 
the key energy sensors of the cell, activates PGC1α in conditions of low cellular 
energy, inhibiting anabolic processes and activating catabolic pathway producing 
energy such as fatty acid oxidation and respiration. AMPK orchestrates a complex 
catabolic response to increase mitochondrial biogenesis, enhances antioxidant 
defense and improve fatty-acid oxidation [133, 134]. For this reason, the 
development of strategies to directly manipulate AMPK to improve mitochondrial 
function is increasing and the use of metformin is an example [135, 136]. 
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2.4 NAFLD management 
Diagnosis 
NAFLD is usually an asymptomatic disease and, consequently, it is often diagnosed 
accidentally following a routine blood tests or an imaging study done for other 
reasons. Clinicians should consider a diagnosis of NAFLD in patients with abnormal 
liver panel tests and the presence of one or more metabolic risk factors (increased 
BMI, elevated blood pressure, insulin resistance, etc.). It is important to exclude 
other common causes of liver injury such as alcohol or drug consumption, viral 
hepatitis, hemochromatosis as well as other coexisting etiologies for chronic liver 
disease [101].  
While serum aspartate transaminase (AST) and alanine transaminase (ALT) levels 
may be abnormal in the presence of hepatic steatosis they are often not, even using 
more stringent cut-offs for the upper limit of normality. Consequently, they are 
considered as poor marker for the diagnosis of NAFLD due to their low specificity, 
sensitivity and prognostic value (50–80% of patients with hepatic steatosis have 
normal transaminase levels) [137-140]. For these reasons, other diagnostic methods 
are needed to confirm the suspected diagnosis of fatty liver. 
Currently, liver biopsy still represents the gold standard for the diagnosis of NAFLD. 
However some physicians and patients are reluctant to carry out this invasive 
method. In addition to the sampling error, diagnosis is dependent on the subjectivity 
and experience of the pathologist and its cost and morbidity contribute to the search 
for additional modalities for diagnosis and staging of disease. In the last decade, 
many non-invasive methods have been developed to reduce the need for liver 
biopsy and to overcome its drawbacks [141-143].  
The imaging technologies are of wide interest as a possible non-invasive method for 
evaluating and diagnosing liver steatosis and NASH. Ultrasonography still represents 
the most common method employed for qualitative assessment of hepatic steatosis. 
It is non-invasive, widely available, cheap and fast. However, it has several 
limitations: it is subjective, shows poor sensitivity for the detection of mild steatosis, 
cannot distinguish NASH from simple steatosis and cirrhosis can only be diagnosed in 
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advances cases. Computed tomography (CT) and magnetic resonance spectroscopy 
(MRS) seem to be more sensitive techniques for the quantification of liver steatosis. 
However CT can only assess moderate steatosis or more, cannot detect early 
cirrhosis or the degree of fibrosis and there is the drawback of radiation exposure. 
Moreover, MRS is still less widely available and much more expensive [144-147]. 
Finally, transient elastography (TE) (Fibroscan®) is another non-invasive imaging tool 
developed in the last decade. It is an accurate and reproducible test of liver fibrosis 
and possibly hepatic steatosis and has been validated in a wide spectrum of liver 
diseases. However one of the limitations of these procedures is its high cost and 
that, nowadays, is not widely available [148-150]. 
A growing number of potential biomarkers have been proposed for the diagnosis of 
NAFLD. Markers of the mechanisms that lead to liver injury and disease progression 
in NAFLD are potential targets. 
Serum cytokeratin-18 (CK18), a major intermediate filament protein in hepatocytes 
related with hepatocyte apoptosis, is one of the most widely investigated 
biomarkers and has shown as the most promise in the diagnosis of NASH [151-153]. 
However, nowadays, this test is not routinely available in many centers and there is 
no established cut-off values [154-156].  Further biomarkers have been evaluated for 
the diagnosis of fatty liver and NASH including various cytokines (TNF-a, IL-6 and the 
chemokines CCL2 and RANTES), acute phase proteins as, for example, C-reactive 
proteins (CRP), and oxidative stress markers [157, 158]. However, only few have 
been independently validated. Hence, more extensive studies are needed to prove 
their overall clinical utility.  
 
Finally, the emergent field of metabolomics is increasingly being applied towards the 
identification of biomarkers for disease diagnosis, prognosis and risk prediction. 
Metabolomics involves the quantification of a large number of low molecular weight 
compounds in plasma and tissue samples. Recent developments in high throughput 
analysis and robust statistical analysis have allowed investigators to detect changes 
in cellular and tissue metabolism related with some diseases such as Parkinson’s and 
type 2 diabetes mellitus and more recently, NAFLD [159-166].  
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Treatment 
Interventions for the treatment of NAFLD target excess body weight and the main 
causes of the pathophysiology of fatty liver: insulin resistance, inflammation and 
oxidative stress among others. 
Obesity is one of the most important risk factor of NAFLD. Accordingly, weight loss is 
the cornerstone in the management of steatosis and NASH in most cases. Weight 
loss can be achieved through healthy habits, in terms of food intake and physical 
activity. For this reason they are the first-line approach to the prevention and 
treatment of NAFLD. It has been demonstrated that lifestyle modifications leading to 
weight reduction and/or increased physical activity consistently reduces fat 
accumulation in the liver [167, 168]. However, these habits are rarely maintained in 
a long-term. Therefore, there are some weight loss medications that can be used in 
some patients in conjunction of lifestyle modifications (Table 2). Some pilot studies 
demonstrated that orlistat, an enteric lipase inhibitor which reduces dietary fat 
absorption, improves liver histology reducing fatty acid infiltration, inflammation and 
fibrosis in obese patients with NAFLD or NASH [169-171]. However, very few studies 
have specially tested drug-induced weight loss in NAFLD context; further studies are 
needed to elucidate its clinical utility. In contrast, the evaluation of potential benefits 
of bariatric surgery for NAFLD among patients with severe obesity is the goal of 
many studies.  
Bariatric surgery has an increasing role in the management of patients with obesity 
and metabolic syndrome and recently, appears to be a promising therapeutic 
approach for NAFLD. Patients experience a high, fast and sustained weight loss. In 
addition, some studies have shown that surgery-induced weight loss is also 
associated with improved hepatic histology including reduced steatosis, 
steatohepatitis and fibrosis by ameliorating some factors that contribute to the 
pathogenesis of NAFLD (improvement of insulin sensitivity and inflammation) [172-
175]. However, the role of bariatric surgery as a primary treatment for NAFLD has to 
be systematically studied. 
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Successful weight loss after lifestyle modifications, anti-obesity medication or as 
result of bariatric surgery has been demonstrated to improve both metabolic 
parameters and liver histology. The beneficial effects are probably mediated by an 
enhanced of adipose tissue function, an improvement of insulin sensitivity and a 
decrease of inflammation and oxidation. All together could modify the course of 
NAFLD [176-181]. 
Another treatment approach in patients with NAFLD is the liver-directed 
pharmacotherapy. As insulin resistance plays an important role in the 
pathophysiology of NAFLD, therapies targeting obesity and insulin resistance were 
widely studied. Thereby, insulin sensitizing agents, such as metformin and 
thiazolidinediones (TDZs) became the most promising drugs in NAFLD management 
[182, 183].  
Metformin is a biguanide widely used for the treatment of type 2 diabetes which 
action is mediated by the activation of AMPK, a key regulator of lipid and glucose 
metabolism. TDZs enhance insulin sensitivity activating peroxisome proliferator-
activated receptor g (PPARg). PPARg is highly expressed in adipose tissue where it 
controls adipocyte differentiation. Its activation plays an important role in increasing 
insulin sensitivity as well as in promoting FFA uptake into adipocytes reducing its 
delivery to the liver or other organs. Thereby, metformin and TDZs have been 
successfully tested and some studies have demonstrated their beneficial effects on 
liver function and liver histology [135, 184-187]. 
Increased oxidative stress and the consequent depletion of antioxidant molecules 
within the hepatocytes are regarded as the initiators of the progression from simple 
hepatic steatosis to NASH [188]. For this reason, an antioxidant supplementation 
could be a potential treatment for NASH. As an example, some studies have showed 
that vitamin E inhibits peroxidation, suppresses inflammatory cytokines, counteracts 
the lower levels of antioxidants enzymes and consequently, ameliorates liver 
steatosis and the progression of the disease [189, 190]. 
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Hypertriglyceridemia is a main component of metabolic syndrome and is strongly 
associated with NAFLD. Different lipid-lowing agents such as fibrates and statins 
(PPARs agonists) have been tested for the treatment of NAFLD, given that 
PPARs regulate transcriptional genes responsible for fatty acid oxidation, and 
showed beneficial effects [191, 192].  
Finally, given the emerging importance of inflammation in fatty liver, cytokines and 
their regulatory molecules can be another therapeutic target in near future. Anti-
TNFa agents have beneficial effects in animal models of NASH and some pilot 
studies in patients reported a significant reduction in liver enzymes levels associated 
with improved steatosis, lobular inflammation and fibrosis stage [193, 194]. In this 
way, our studies have found that the continuous administration of polyphenols in 
animals model reduce weight gain, liver steatosis and insulin resistance probably by 
the combination of anti-inflammatory and anti-oxidant effects provided by these 
bioactive compounds [195-198]. 
Despite considerable research on pharmacotherapy for the treatment of NAFLD its 
efficacy and safety remains inconclusive, and nowadays there are no licensed single 
pharmacological agent. However, there are many late phase clinical trials in 
progress, so the situation will probably change in a near future. Moreover, further 
advances in the understanding of the pathogenesis of NAFLD will also help in the 
developing of reliable therapeutic strategies for this increasingly liver injury. 
Finally, patients with end-stage of NAFLD (with decompensated cirrhosis or 
hepatocellular carcinoma) are candidates for liver transplantation which definitely is 
the only possible treatment [199].  
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3. Inflammation and metabolism: the role of Chemokine (C-C 
motif) Ligand 2 (CCL2) 
Historically, immunity and energy metabolism have been considered to be distinct 
capabilities to the maintenance of homeostasis, supported by different cell-types 
and differentially regulated. However, during the last decades, a wealth of evidence 
has come out demonstrating that immunity and metabolism are closely 
interconnected [200-202].  
The huge search for the discovery of the unifying mechanism responsible of the 
pathogenesis of obesity and its comorbidities has revealed a strong relationship 
between nutrient excess and derangements in immune system. Consequently, the 
classical view of inflammation, described as the principal coordinated response of 
the body to harmful stimuli (infection, tissue stress, injury, etc.) by many complex 
signals in distinct cells and organs [189], needs to be expanded to fully explain the 
inflammatory processes induced by adverse metabolic conditions and the 
accompanying deleterious effects.  
Although the often short-term response of inflammation is a crucial defense 
mechanism, its long-term consequences, mainly caused by a continuous nutritional 
surplus, are not beneficial and leads to the development of metabolic diseases. All 
this resulted in a new concept known as “metainflammation” (metabolically 
triggered inflammation) to describe the low-grade chronic inflammation related to 
metabolic disorders [200, 203]. Consequently, the historical and simple point of view 
of obesity as lipid storage disease has been replaced by the concept that it is an 
inflammatory disease.  
The first discovery of inflammation in obesity was carried out by Dr. Hotamisligil who 
observed increased levels of TNF-a in adipose tissue of obese mice compared with 
lean controls [204-206]. This discovery was then followed by many studies describing 
these inflammatory differences in obese and lean animals as well as in humans. 
Thus, it has been demonstrated that chemokines and their receptors play an 
important role in the pathogenesis of all metabolic disorders which make them and 
their receptors attractive as therapeutic targets. 
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3.1 Chemokine and chemokine receptor family 
 
Chemokines or chemotactic cytokines are a group of small secreted proteins 
consisting of 60 to 100 amino acids of about 8-14 kDa, with a highly variable 
sequence homology (from <20% to 90%) and represent the largest family of 
cytokines. They direct the migration of leukocytes throughout the body under 
physiological and pathological conditions [207-210]. 
Chemokines were first identified in 1977. Since then, approximately 50 chemokines 
and 20 chemokines receptors have been identified [210, 211].  
Chemokines are divided into four families based on the arrangement of the two 
conserved cysteine residues located in the N-terminal region (Figure 9). The two 
largest families are the CXC or a family in which one amino acid separates the first 
two cysteines, and CC or b family, where these two cysteines residues are adjacent. 
The other families are the (X)C or g family, having only one of the first two cysteines, 
and finally, CX3C or d family , which is currently represented by a single member 
named fractalkine (CX3CL1), which has three amino acids between the two cysteines 
residues as well as a transmembrane mucin-like domain [210-212]. 
 
Figure 9. Classification of chemokines based on the position of the two highly conserved cysteines 
residues in N-terminus. Adapted from Rostene et al. [212]. 
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The biological effects of chemokines are mediated by seven-transmembrane-domain 
receptors that represent a subset of the G-protein-coupled receptor superfamily 
(Figure 10). The conventional signaling pathway attributed to chemokines receptors 
involves the mobilization of calcium from intracellular stores and the subsequently 
downstream cascades trigger conformational changes on leukocyte integrins that 
promote cell adhesion and extravasation. More specifically, for its activity the 
bg subunits are released and activate phosphoinositide-specific phospholipase C 
(PLC) isoenzymes leading to the formation of inositol-1,4,5-triphosphate (IP3) and 
increasing the intracellular calcium concentration. The signals mediated by 
chemokine receptors are short and transient [207, 208, 213].  
 
Figure 10. Chemokine receptor. They are found on the surface of certain cells and have a seven-
transmembrane domain coupled to G-protein for signal transduction within the cell. From Camps et 
al. [213]. 
 
Besides these typical chemokine receptors, there are atypical chemokine receptors 
(Duffy antigen receptor for chemokines or DARC, D6, CCX-CKR) which bind their 
ligand with high affinity and specificity but they do not transduce the intracellular 
signal which leads to chemotactic and other cell responses after chemokine binding. 
In some cases, the ligand is transported across the cytoplasm and released on the 
other side of the cell while in other cases the chemokine is internalized and 
degraded. Figure 11 contains the known human chemokines and their receptors 
[207, 208, 213, 214]. 
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Figure 11. The chemokine superfamily consists of a large number of ligands and receptors. In red CC 
family, in green CXC family and in blue a minority of receptors which have only one ligand. Finally, 
atypical receptors and its possible ligands are represented in black. From Lazennec et al. [215]. 
 
The binding between ligands and their receptors seems to be promiscuous. Thus, a 
single chemokine can bind to several receptors and a single receptor may traduce 
signal for several chemokines. This idea could suggest the redundancy of these 
molecules in pathophysiology and it became a controversial issue. However, many 
studies suggest that each chemokine and receptor may have a special position on 
the orchestrated biological response and cannot be fully replaced by another ligand. 
In fact, various chemokines can induce different an even opposite biological effects 
although acting at the same receptor [209, 213].  
Chemokines are also grouped into two main subfamilies; homeostatic and 
inflammatory chemokines based in the expression pattern and function. 
Homeostatic chemokines are generally constitutively expressed and are involved in 
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the recruitment of immune cells under normal conditions, for example, they direct 
the trafficking of lymphocytes to lymphoid tissues. On the other hand, inflammatory 
cytokines are upregulated by pro-inflammatory stimuli such as infection or trauma 
and participate in innate and adaptive immune response; they control the 
recruitment of leukocytes during inflammation and tissue injury. These 
classifications are not mutually exclusive, in other words, some inflammatory 
chemokines can have homeostatic functions and inversely, some homeostatic 
chemokines could be upregulated during pathogenic inflammation [207, 209, 210, 
213, 216].  
Once chemokine secretion is induced, the migration of cells expressing the 
appropriate chemokine receptors takes place by a chemokine gradient which allows 
cells to move in the direction of high local concentration of chemokines. 
In addition to their major biological function, the regulation of cell trafficking, 
subsequent research has elucidated their involvement in other functions of the 
inflammatory processes such as fibrosis, tissue remodeling and angiogenesis, 
development, hematopoiesis, and homing [210, 211]. 
Finally, beside to their roles in the immune system, accumulating evidence suggests 
that, chemokines and their receptors play an important role in the pathophysiology 
of several diseases. Perturbations of chemokines and/or their receptors expression 
or function can lead to the persistence of an inflammatory reaction creating a key 
pathogenic event for the establishment of chronic inflammation which is the 
hallmark of many diseases such arthritis, asthma, HIV infection as well as obesity, 
NAFLD, insulin resistance, atherosclerosis and cancer [216-218]. 
For this reason, chemokines and their receptors have become an important target 
for searching novel biomarkers and specific therapeutic approaches. In this way, 
CCL2 and its receptor (CCR2), the most well studied chemokine-chemokine receptor 
systems, are potential targets for the treatment of various diseases. 
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3.2 Chemokine (C-C motif) Ligand 2 (CCL2) 
Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant 
protein-1 (MCP-1), is the first discovered and the most extensively studied human CC 
chemokine [219]. 
CCL2 was discovered in 1989 at the International Cancer Institute in Maryland (USA), 
identified from the conditioned media of human myelomonocytic cell line THP-1 
based on its in vitro monocyte chemotactic activity [220, 221]. 
Structure 
This protein is a member of the CC or b chemokine family and is typically secreted in 
two predominant forms with molecular weight of 9 and 13 kDa. These two isoforms 
are the result of a differential O-glycosylation with the disaccharide galactose-b-D-N-
acetylgalactosamine, present only in 13kDa isoform. Even this differential 
glycosilation, they have the same capacity to induce monocyte migration [219, 222]. 
In addition, this protein seems to be identical to the murine JE gene product (mouse 
CCL2) [221, 222]. 
Regulation 
CCL2 is encoded by CCl2 gene which is located in chromosome 17 (17q11.2). It is 
expressed, either constitutive or after inflammatory stimuli, by different cell types 
including epithelial, endothelial, smooth muscle cells, fibroblasts and astrocyte but 
the major source of this protein are monocytes and macrophages and, more 
recently, adipocytes have been recognized as another important source of CCL2 
[219, 221-223]. In addition, it has been demonstrated that CCL2 protein and mRNA 
are expressed in the majority of tissues, so there is a systemic production and, at the 
same time, the possibility to respond in situ to inflammatory stimuli [224, 225]. 
Its expression is regulated at transcriptional level by a variety of stimulatory 
mediators such as TNF-a, interferon gamma (INF-g), platelet-derived growth factor 
(PDGF), interleukins IL-1 and IL-4, bacterial lipopolysaccharide and reactive oxygen 
species [219, 222]. The pro-inflammatory NF-kb transcription factor is the key 
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mediator in the transcription of CCL2 due to the promoter region of CCl2 gene 
contains two NF-kb binding sites in the distal part [226-228]. 
Biological function 
CCL2 is a potent chemoattractant which regulates the migration and infiltration of 
monocyte cells to sites of injury and inflammation. It is also important for T cell and 
natural killer cells differentiation [229]. Moreover, CCL2 participates in the first steps 
of inflammation process, for example, in adhesion (upregulating the expression of 
integrin on monocyte cell surface) and extravasation of monocytes through vascular 
endothelium to foci of active inflammation [219].  
As mentioned before, this protein exerts its function through binding to CCR2, an 
heptahelical G-protein-coupled receptor embedded on the lipid bilayer of cells 
targeted for activation and migration. This receptor, once activated, trigger a signal 
transduction cascade that, as described previously, results in IP3 formation, 
intracellular calcium release and protein kinase C (PKC) activation which finally, 
through NF-kb transcription factor and Rho family proteins, regulates cell motion 
and mobility (Figure 12) [219, 230]. 
CCR2 is the receptor for all monocyte chemoattractant proteins: MCP-1, MCP-2 
(CCL8), MCP-3 (CCL7), MCP-4 (CCL13) and MCP-5 (CCL12) [231]. It is expressed 
abundantly in monocytes, basophils, dendritic cells, natural killer cells and activated 
T lymphocytes. In addition, it could appear in two different forms (CCR2A I CCR2B) as 
a result of an alternatively splicing which only differ in carboxy-terminal region. The 
change in the sequence alters the location of the protein in the cell and CCR2B, the 
predominant isoform is mainly localized to the plasma membrane whereas the 
transcript variant A encodes the cytoplasmic isoform [232-235]. 
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Figure 12. CCL2/CCR2 signaling pathway. DAG, diacylglycerol, IP3, inositol triphosphate; PIP2, 
phosphatidylinositol-biphosphate, PLC, phospholipase C. Adapted from Melgarejo et al. [219]. 
 
3.3 CCL2/CCR2 and disease 
 
Recent studies have elucidated the role of chemokines and their receptors in several 
pathological processes. Chemokine receptor activation implicates the regulation of 
pleiotropic signaling pathways influencing a wide number of molecular and cellular 
processes. Hence, an inappropriate inflammatory response leads to numerous 
human diseases [230, 236].  
The involvement of chemokines in disease has mainly been demonstrated using 
genetically modified mice, antibody or inhibitor-mediated neutralization and 
obviously, with epidemiological studies in humans [234]. 
CCL2 and its receptor CCR2 have been related to the pathogenesis of different 
diseases including vascular permeability and attraction of immune cells during 
metastasis, a number of different neurological disorders, autoimmune diseases and 
metabolic diseases such as obesity, insulin resistance, atherosclerosis and NAFLD 
becoming an interesting and highly studied target for novel therapeutic strategies 
[237].  
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CCL2/CCR2 in obesity  
As mentioned before, obesity is associated with a chronic low-grade inflammation 
which implicates adipocyte dysfunction and endocrine activity of adipose tissue. In 
obesity, adipose tissue is characterized by macrophage infiltration and the release of 
multiple inflammatory mediators which lead to metabolic disturbance such as insulin 
resistance and ectopic lipid accumulation [113, 200, 238].  
Evidence that CCL2 is related to obesity is provided by the observation of higher 
CCL2 plasma levels in obese patients than in lean controls [239, 240]. Similarly, high 
levels of circulating CCL2 also have been found in obese mice compared with wild-
type littermates [241-243]. Furthermore, the different depots of adipose tissue, such 
as subcutaneous and visceral, show increased gene expression of CCL2 in obesity, 
both in animal models and in obese patients [244-246]. In contrast, weight loss 
decreases macrophage infiltration in adipose tissue and also the circulating CCL2 
levels demonstrating that beneficial effects of weight loss are mediated by 
ameliorating the inflammatory status of adipose tissue [240, 247]. Similarly, different 
studies with CCL2 or CCR2 deficient mice, or with the use of CCR2 inhibitors in obese 
mice, have demonstrated that CCL2/CCR2 deficiency attenuates the development of 
obesity, adipose tissue macrophage infiltration, inflammation, and systemic insulin 
resistance [248-250]. Hence, CCL2 induces macrophage recruitment and adipose 
tissue inflammation as well as insulin resistance. Accordingly, the inhibition of this 
inflammatory pathway ameliorates metabolic disturbances [251, 252].  
An increase in adipose tissue mass (in number and size of adipocytes) is the main 
feature of obesity. It has been demonstrated that CCL2 contributes to adipocyte 
differentiation and induces adipogenesis by the induction of a zinc-finger protein, 
MCP-1-induced protein (MCPIP) and the following signaling pathway which involves 
ROS, endoplasmic reticulum stress and autophagy. Moreover, CCL2 also contributes 
to the expansion and remodeling of adipose tissue [253-255]. 
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CCL2/CCR2 in NAFLD 
The adipose tissue inflammation caused by CCL2 macrophage recruitment and the 
subsequent insulin resistance results in increased lipolysis. The impaired lipid 
buffering leads to the exposure to an increased efflux of FFA of non-adipose tissues 
such as the liver. This metabolic stress can lead to an imbalance between FFA supply 
and hepatic FFA disposal pathways, causing lipid accumulation within hepatocytes 
[256]. 
Several studies have demonstrated that both, CCL2 circulating levels and gene 
expression are higher in patients with NAFLD [250, 257-259]. Moreover, serum CCL2 
levels in NAFLD patients are positively correlated with the severity of liver damage, 
in other words, increasing levels from healthy control to simple steatosis reaching 
the highest concentration in patients with NASH [260-262]. 
The generation of oxidative stress-related molecules is responsible for the 
progression from simple steatosis to NASH. Some studies have demonstrated that 
ROS and some products of lipid peroxidation such as 4-hydroxynonenal and 
malondialdehyde are significantly lower when CCl2 is deleted. Moreover, the lack of 
CCL2 is associated with a reduced expression of several gens implicated in 
fibrogenesis [263-265]. 
Finally, CCL2/CCR2 deficiency or their pharmacological inhibition in the presence of 
chronic liver damage attenuates the development of NAFLD [266, 267]. 
Taken together, all these data indicate that CCL2 plays an important role in the 
pathogenesis of NAFLD [218, 256]. 
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4. Autophagy: the cellular housekeeper 
The literal translation of autophagy emanates from the Greek roots “auto” (self) and 
“phagy” (eating) “self-eating” and broadly refers to an intracellular catabolic 
pathway that targets cytosolic components to lysosomes to be degraded. This 
process responds to stresses with the ultimate purpose of self-preservation. The 
autophagic process is suited uniquely to the timely identification of surplus, 
unnecessary or dysfunctional proteins and organelles for the maintenance of cellular 
homeostasis and supplying substrates for energy generation [268, 269]. 
The term autophagy was first introduced in 1963 by De Duve et al. Over the past few 
years, the study of this field has witnessed a dramatic growth. This is attributed 
partly to the discovery of the key components of its cellular machinery through 
studies conducted in yeast and Drosophila, but more important, from studies in 
mammalian cells and tissues [269].  
Three primary types of autophagy have been identified: macroautophagy, chaperon-
mediated autophagy (CMA) and microautophagy, depending on its physiological 
function and the mode of cargo delivery to the lysosome (Figure 13).  
 
 
 
 
 
 
 
 
Figure 13. The three types of autophagy. In macroautophagy, an autophagosome is formed and it is 
fused with lysosomes to degrade the cellular constituents or pathogens. Microautophagy involves the 
uptake of cellular components within an invagination of the lysosomal membrane for enzymatic 
degradation. Finally, in chaperone-mediated autophagy, cytosolic proteins containing a pentapeptide 
motif bind to the chaperone Hsc70. This complex binds to the LAMP-2A receptor on the lysosome for 
internalization and degradation. From Oh et al. [270]. 
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As a briefly mention, CMA involves selective translocation of the cytosolic proteins 
which are marked by a pentapeptide motif with a consensus sequence similar to 
KFERQ across the lysosomal membrane. Cytosolic chaperones aid in the target 
recognition and unfolding, and a multimer comprising the lysosomal protein LAMP-
2a (lysosomal-associated membrane protein-2a) subunits is thought to be rate-
limiting for target translocation into lysosomes [271, 272]. On the other hand, in 
microautophagy, a poorly understood phenomenon in mammalian cells, the 
cytosolic contents are engulfed by direct invagination of the lysosomal membranes 
into tubulovesicular structures [273, 274]. However, macroautophagy is considered 
to play the most important role in pathophysiology and has been well studied in 
recent years. For this reason, the term autophagy is usually referred to 
macroautophagy and this thesis is focused on it. 
Macroautophagy is the major regulated catabolic mechanism that eukaryotic cells 
use to degrade proteins and organelles. This form of autophagy involves the 
sequestration of portions of the cytoplasm within a vesicle (autophagosome) which 
fuses to the lysosome (autolysosome) in which the captured material (cargo), 
together with the inner membrane, is degraded. The autophagosome lacks the acidic 
environment and the enzymes required for terminal digestion of the engulfed 
contents; thus, the fusion of the autophagosome with the lysosome supplies the 
acidic environment as well as a battery of hydrolases [275, 276]. 
Autophagosome formation is a complex and highly regulated process that requires 
more than 30 autophagy-related genes (Atg) and the resultant proteins. These 
proteins form functional complexes and can be grouped according to their functions 
in the key stages of this pathway. The main steps are: induction or initiation, 
nucleation, membrane elongation and enclosure and, finally, the fusion with 
lysosomes. As a summary, initiation is controlled by the ULK complex, followed by 
activation of the PI3-kinase complex leading to nucleation of the phagophore, the 
initial de novo formation of a double-membrane that encloses a portion of 
cytoplasm. The origin of the membranes involved in the formation of 
autophagosomes could be the endoplasmic reticulum, mitochondria, and golgi 
apparatus. However, it is still not clear which is the major contributor [275-278].  
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Membrane elongation is governed by two ubiquitin-like conjugation systems. The 
first is the conjugation of Atg12 to Atg5 mediated by two ligases, Atg7 and Atg10. 
Atg5 also associates with Atg16 to form the Atg12-Atg5-Atg16 complex. The second 
involves the cleavage of LC3/Atg8 by Atg4 leading to the soluble form LC3-I 
(microtubule-associated protein light chain 3-I), which is then conjugated to 
phosphatidylethanolamine (PE), via the participation of Atg7 and Atg3. This lipid 
conjugation forms the autophagic double-membrane associated LC3-II protein 
allowing the closure of the autophagic vacuole. Accordingly, LC3-II, is used as a 
marker of autophagosomes due to its important role in the autophagic process. 
Finally, autophagosomes fuse with lysosomes, where the breakdown of the 
autophagic cargo takes place [275-278]. Figure 14 illustrates the molecular 
mechanism underlying autophagy. 
Figure 14. The macroautophagy pathway. Following inhibition of MTOR, the ULK complex is activated 
and initiates autophagosome formation. The class III PI3 kinase complex also regulates the 
autophagosome nucleation step. To expand the autophagosome membrane, two ubiquitin-like 
conjugation systems are required for conjugation of LC3 and Atg12 to phosphatidylethanolamine (PE) 
on the autophagosome membrane and Atg5, respectively. The complete autophagosome fuses with 
the lysosome to form the autolysosome, and cargo molecules engulfed by autophagosomes are 
degraded by lysosomal hydrolases and recycled back to the cytoplasm.  
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Regulation of macroautophagy occurs via mechanistic target of rapamycin (MTOR), a 
nutrient and energy-sensing kinase. A cell with a stable energy source has active 
MTOR signaling through its phosphorylation, leading to inhibition of autophagy 
interacting with autophagy effectors (ULK1, FIP200). Conversely, a nutrient-depleted 
cell has decreased or inhibited MTOR activity, thus autophagy is activated. 
Moreover, an additional level of cross-talk between MTOR and autophagy is 
provided by AMPK, the main sensor of intracellular energy. When cells become 
energy-deprived, AMPK efficiently turns-off the MTOR pathway and also positively 
regulates ULK complex to induce autophagy (Figure 14) [279-284].  
Insufficient or dysfunctional autophagy accumulates abnormal or dysfunctional 
material. Thus, in agreement to this context, a number of diseases are associated 
with impaired autophagy such as neurodegenerative diseases, cancer, aging, 
inflammation, obesity and liver diseases [285-287]. For this reason, an improved 
understanding of autophagic process should provide substantial information for new 
therapeutic manipulations of this endogenous process.  
MTOR, as a master regulator of cellular metabolism, has become an appealing 
pharmacologic target to manipulate autophagy. As implied in its name, rapamycin is 
the most available MTOR inhibitor that has been tested for clinical practice. 
Rapamycin induces autophagy and has demonstrated beneficial effects in cancer and 
some neurodegenerative diseases [288-290].  
Moreover, as mentioned before, the activation of AMPK inhibits MTOR and 
consequently, enhances autophagy. Hence the administration of AMPK activators 
such as metformin stimulates autophagic process and could be considered as 
another possible therapeutic target [291, 292].  
Further evaluations are needed to determine the effectiveness of MTOR inhibitors 
for inducing autophagy with minimal side effects to provide potential candidates for 
developing novel therapeutics for the management of human diseases. 
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4.1 Autophagy and NAFLD 
Autophagy in the liver has been well studied. The features and functions of the liver 
make this organ very dependent on autophagy. Accordingly, impairment of 
autophagy has profound deleterious effects on liver function [293-295].  
The autophagic engulfment of organelles such as mitochondria (mitophagy) or 
discrete molecules such as lipids (lipophagy) serves as integral machinery of 
hepatocellular homeostasis [296].  
Lipophagy, the delivery of cellular lipid droplets to the lysosomes, helps to modulate 
the lipid stores more efficiently to respond to energy demand and to protect cells 
from lipid-mediated damage [297-299]. Therefore, a decrease of autophagy in the 
liver leads to lipid accumulation and subsequent development of NAFLD [300].  
Several studies in cultured hepatocytes with impaired autophagy, generated by 
pharmacologic inhibition or by using RNA interference against Atg5 or Atg7, have 
revealed that inhibition of autophagy leads to higher accumulation of triglycerides 
respect to controls. These results were also obtained in hepatocyte-specific Atg7-
deficient mice [301].  
Moreover, high-fat diet fed mice exhibit an impairment of hepatic autophagy as 
demonstrated by decreased mobilization of lipid into the autophagic compartment. 
Lipid accumulation altered the membrane structure, and a resultant decrease in the 
efficiency of fusion between autophagosomes and lysosomes may explain this 
inhibitory effect. Moreover, the ability of excessive cellular lipid accumulation to 
impair autophagy provides another mechanism for the progression of simple 
steatosis to NASH and its complications [301, 302]. 
Studies conducted in humans also revealed the relationship between autophagy and 
NAFLD. A recent report demonstrated that autophagy was decreased in obese 
patients with steatosis and NASH [303].  
It has been demonstrated that an activation of liver autophagy constitutes a 
promising therapeutic approach against steatosis and hepatic complications. 
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Accordingly, it has been reported that hepatic overexpression of Atg7 in high-fat diet 
fed mice or obese mice improved the condition of the fatty liver and insulin 
resistance [304]. Moreover, enhancers of autophagy such as rapamycin have been 
tested in obese mice and they ameliorated the presence of steatosis and insulin 
resistance [305].  
For this reason, therapeutic efforts to decrease hepatic lipid stores by raising 
autophagic function could prevent the initiation of liver injury or the development of 
NASH complications, such as hepatocellular carcinoma. 
4.2 Autophagy and inflammation  
Growing evidence suggests that autophagy not only regulates cellular homeostasis 
but also plays an important role in protection against pathogens. In this line, 
autophagy has been linked with innate and adaptive immune response in host 
defense by regulation of cytokine production [306-308]. 
Furthermore, autophagy is implicated in cellular development and differentiation 
including adipogenesis, a key feature of obesity. It has been shown that inhibition of 
autophagy reduces accumulation of triglycerides within adipocytes, increases 
transcription factors involved in adipocyte differentiation and also increases 
mitochondrial function [299, 309-311].  
In contrast, other data report that autophagy modulates adipose tissue inflammation 
controlling the production of cytokines. Some studies reveal that the inhibition of 
autophagy is related with the gene expression and the secretion of pro-inflammatory 
cytokines in both animals and murine adipose tissue. Accordingly, autophagy may 
act as a protective mechanism to limit chronic low-grade inflammation of adipose 
tissue related with obesity [311, 312].  
For this reason it is required further exploration to elucidate if autophagy could be a 
potential regulatory mechanism that links inflammation and metabolic disorders. 
Understanding the mechanisms and pathways involved in autophagy could lead to 
future therapeutic strategies against inflammation and related conditions such as 
obesity, insulin resistance, atherosclerosis and liver disease.  
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5. Animal models in scientific research 
  
Animal research plays a crucial role to better understand the pathophysiology of 
several human diseases and, consequently, contributes to the development of 
effective medical treatments. 
Research animals provide scientists with complex living systems consisting of cells, 
tissues and organs. The most important features are their striking similarity to 
humans in anatomy, physiology and genetics. Over 95% of the mouse genome is 
similar to our own, and they are vulnerable of the same health problems, making its 
use particularly applicable to human diseases [313].  
Practically, mice are a cost-effective and efficient tool to speed research and the 
development of drug therapies. Mice are small, have a short generation time and an 
accelerated lifespan, keeping the costs, space, and time required to perform 
research manageable [313]. 
In addition, our ability to directly manipulate its genome provides an incredible 
powerful tool to model specific diseases. Depending on the target in question, there 
are a number of models that can be applied. Perhaps, this is the most important 
advantage to using mouse for biomedical research [314]. Genes can be injected 
directly into the fertilized egg of mouse creating what is known as a transgenic 
animal. This approach allows us to create a new animal model which overexpresses 
CCL2, the chemokine in which we have focused all our efforts and which is involved 
in many pathological processes.  
In the same way, scientists developed techniques that allowed them to target genes 
within mouse genome (so-called knockouts). These knockout mice are a resource to 
understand the genetic basis of different metabolic diseases such as obesity, 
atherosclerosis and fatty liver among others.  
Thus, with these kind of animal studies scientist will expand their ability to model 
human diseases more accurately, as well as directly test their theories and novel 
therapeutic approaches. 
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Hypothesis 
 
Excessive energy intake alters metabolic homeostasis and leads to a state of low-
grade inflammation which has an important role in the development of non-
communicable diseases such as obesity and NAFLD. These metabolic disturbances 
might be detected in plasma revealing new biomarkers. Moreover, the assessment 
of the role of chronic inflammation in animal models fed an energy surplus could 
suggest novel therapeutic strategies for the management of these prevalent 
diseases. 
 
 
 
Aims 
 
ü To better understand the pathogenesis of NAFLD in obesity. 
 
ü To identify a non-invasive metabolite biomarker of NAFLD. 
 
ü To determine the effects of a continuous and ubiquitous overexpression of 
CCL2 combined with excessive energy intake. 
 
ü To evaluate the absence of CCR2 receptor in this genetic and environmental 
background for the development of novel therapeutic strategies. 
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STUDY 1 
 
Mapping of the circulating metabolome 
reveals α-ketoglutarate as a predictor of 
morbid obesity-associated non-alcoholic fatty 
liver disease 
Int J Obes (Lond) 2015; 39(2):279-87 
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Abstract 
Background: Obesity severely affects human health, and the accompanying non-
alcoholic fatty liver disease (NAFLD) is associated with high morbidity and mortality. 
Rapid and non-invasive methods to detect this condition may substantially improve 
clinical care. 
Methods: We used liquid and gas chromatography–quadruple time-of-flight–mass 
spectrometry (LC/GC-QTOF-MS) analysis in a non-targeted metabolomics approach 
on the plasma from morbidly obese patients undergoing bariatric surgery to gain a 
comprehensive measure of metabolite levels. On the basis of these findings, we 
developed a method (GC-QTOF-MS) for the accurate quantification of plasma α-
ketoglutarate to explore its potential as a novel biomarker for the detection of 
NAFLD. 
Results: Plasma biochemical differences were observed between patients with and 
without NAFLD indicating that the accumulation of lipids in hepatocytes decreased 
β-oxidation energy production, reduced liver function and altered glucose 
metabolism. The results obtained from the plasma analysis suggest 
pathophysiological insights that link lipid and glucose disturbances with α-
ketoglutarate. Plasma α-ketoglutarate levels are significantly increased in obese 
patients compared with lean controls. Among obese patients, the measurement of 
this metabolite differentiates between those with or without NAFLD. Data from the 
liver were consistent with data from plasma. Clinical utility was assessed, and the 
results revealed that plasma α-ketoglutarate is a fair-to-good biomarker in patients 
(n=230). Other common laboratory liver tests used in routine application did not 
favourably compare. 
Conclusion: Plasma α-ketoglutarate is superior to common liver function tests in 
obese patients as a surrogate biomarker of NAFLD. The measurement of this 
biomarker may potentiate the search for a therapeutic approach, may decrease the 
need for liver biopsy and may be useful in the assessment of disease progression.
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Introduction 
Obesity severely affects human health. The number of adults with morbid obesity 
(that is, a body mass index (BMI) ൒40 kg/m2) is increasing, and the prevalence of 
obesity (>30% in some countries) is unacceptably high. Moreover, the incidence of 
obesity is increasing among children, and obesity-associated premature mortality 
rivals that of smoking [1–4]. Morbidly obese patients undergoing bariatric surgery 
share a common metabolic background and similar environmental factors. We 
assume that possible genetic differences among these particular obese patients are 
likely negligible. Non-alcoholic fatty liver disease (NAFLD) is no longer a benign 
condition and is now considered an important co-morbidity in these patients [5–7]. 
The prognosis is pessimistic because of the risk of progressive liver disease (for 
example, non-alcoholic steatohepatitis, fibrosis, cirrhosis, liver failure and 
hepatocarcinoma) [8]. There is a great need for NAFLD biomarker discovery because 
it is often difficult to determine when a liver biopsy is appropriate. A significant 
number of individuals are asymptomatic until their liver begins to fail, at which point 
conventional treatments are useless. 
Current laboratory tests are insufficient and unreliable for the determination of 
NAFLD presence. Previous estimates using common liver function tests in the 
plasma, such as the determination of alanine aminotransferase levels, suggest that 
the prevalence of NAFLD should be nearly 100% in obese patients [9]. Evaluation by 
proton magnetic resonance spectroscopy is expensive and is currently being refined 
[10], and patients of this size did not typically fit into the apparatus. However, the 
use of liver biopsy revealed in our patients that a significant portion did not display 
fatty infiltration of hepatocytes. In this study, we aimed to better understand NAFLD 
pathogenesis in obesity and to identify a non-invasive metabolite biomarker.  
We hypothesised that the excess in energy intake alters anabolic and catabolic 
functions, especially in the liver, which may be detected in a plasma metabolomic 
profile. We used non-targeted metabolomics to compare obese patients without 
steatosis with their affected counterparts to identify differences between these 
groups. We expected numerous and low differences among the measured 
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metabolites, which may explain the lack of previous metabolomics-based testing for 
these diseases [11]. However, post hoc analysis and further quantification resulted in 
the qualification and verification of the plasma α-ketoglutarate concentration as a 
good indicator of NAFLD in obese patients. 
Material and methods 
Participants 
Our local ethics committee approved the study protocol, and written informed 
consent was obtained from the participants (EPINOLS/12-03-29/3proj6). Patients 
fulfilling the criteria established for morbid obesity (BMI ൒40 kg/m2), for which 
bariatric surgery was indicated after numerous failed attempts to lose weight using 
non-surgical means, were recruited from the outpatient clinic between 2006 and 
2012. We first conducted a non-targeted metabolomic analysis in a limited group of 
patients with or without steatosis (n=15 in each group). Steatohepatitis, fibrosis and 
hepatocyte injury in these patients were histologically ruled out. These samples were 
sent to Metabolon Inc. (Durham, NC, USA) for analyses. No differences in the quality 
of life were observed between the groups, and the selected patients did not 
consume alcohol or any prescribed medication that could alter liver function, 
including vitamin supplements. The results of these non-targeted preliminary 
analyses prompted us to qualify and verify plasma α-ketoglutarate as a candidate 
biomarker to identify NAFLD in obese patients. For this purpose, we recruited 230 
patients in which the only inclusion criterion was application for bariatric surgery, 
thus including a wide variety of conditions likely to be encountered in clinical 
practise. Blood was obtained immediately before surgery and after clinical nutrition 
evaluation. Portions of the liver were obtained during the surgical procedure after 
patient consultation to minimise risks and to limit the variability based on location of 
biopsy [12]. Bio-banked samples (n=54) from a group of age- and sex-matched lean, 
healthy controls (BMI <24 kg/m
2
) [13] were used to assess differences in plasma α-
ketoglutarate levels between lean and obese patients. Dietary advice and 
standardised overnight fasting were implemented to ensure uniformity and 
consistency. Plasma aliquots were anticoagulated with EDTA and were frozen at 
−80°C within 2 h after collection. 
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Clinical data and analytic measurements 
Relevant data were extracted from clinical records or were obtained using 
standardised guidelines and routine laboratory methods [14]. The BMI was 
calculated as the weight in kilograms divided by the height in metres squared. 
Histological alterations in the liver biopsies were evaluated in sections stained with 
haematoxylin and eosin. The degree of steatosis was evaluated using image analysis 
software and was expressed as percentages (AnalySIS image software system, Soft 
Imaging System, Munster, Germany). Patients were considered free of steatosis 
when values were ൑5%. Patients with steatosis were arbitrarily classified as mild: 6-
30%; moderate: 31–60%; and severe: >61% [8, 15]. Portions of the liver biopsies 
were also used to measure α-ketoglutarate in tissues from patients with or without 
steatosis (n=6 in each group). The shape and size of mitochondria were determined 
in portions of the liver using standard transmission electronic microscopy (n=3 in 
each group). 
Non-targeted metabolomic platform 
Specimens. Samples outsourced to Metabolon’s laboratory were extracted upon 
arrival. The instrument and overall process variability was 4% and 9%, respectively. 
Chromatography. Chromatographic conditions have been previously described [16]. 
In brief, the liquid chromatography–mass spectrometry (LC–MS, LC–MS
2
) platform 
was based on a Waters ACQUITY UPLC (Waters Technologies, Milford, MA, USA) and 
a Thermo-Finnigan (San Jose, CA, USA) LTQ mass spectrometer, which consisted of 
an electrospray ionisation source and a linear ion-trap mass analyser. The MS 
analysis alternated between MS and data-dependent MS
2 
scans using dynamic 
exclusion. The samples for gas chromatography/mass spectrometry (MS) analysis 
were derivatised and analysed on a Thermo-Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer using electron impact ionisation. Metabolites were 
identified using a reference library of ~2800 standard chemical entries that included 
retention times, mass (m/z) and MS or MS
2
 spectra. 
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Quantitative measurement of plasma α-ketoglutarate using gas 
chromatography–quadrupole time-of-flight mass spectrometry analysis 
Sample pre-treatment. This method was developed in our laboratory. A surrogate 
standard was added to maximise technical precision during the injection and 
recovery during the extraction procedure. We used deuterated succinic acid (Isotec 
Stable Isotopes, Miamisburg, OH, USA) rather than deuterated α-ketoglutarate, 
which readily exchanges deuterium [17]. A solution of deuterated succinic acid (25μl, 
2 mg/l) was added to aliquots of plasma that were thawed on ice at 4 °C (50 μl), 
deproteinised with 400 μl of methanol, mixed using a vortex (2 min) and centrifuged 
(15000 g, 15 min, 4 °C). The supernatant was dried and stored at −80 °C. Samples 
were derivatised using 30 μl of methoxyamine hydrochloride in pyridine (30 mg/ml) 
and incubated 1.5 h at 37 °C with agitation. Then, 30 μl of N-methyl-N-(trimethylsilyl) 
trifluoroacetamide (Sigma-Aldrich, Steinheim, Germany) was added with shaking and 
further incubated in darkness for 1 h before analysis. We found this derivatisation 
step to be a reproducible and robust method, independent of the matrix and 
without appreciable losses in yield that minimised the loss of α-ketoacids to 
decarboxylation [18]. A calibration curve of α-ketoglutaric acid (Fluka, St Gallen, 
Switzerland) was prepared (0–82.5 μM) immediately before each assay. 
Chromatographic analysis. Samples (1 μl) were automatically injected onto a 7890A 
gas chromatograph coupled to a 7200 quadrupole time-of-flight mass spectrometer 
(Agilent Technologies, Santa Clara, USA) equipped with a J&W Scientific (Folsom, CA, 
USA) HP5-MS column (19091S-433). Helium was used as a carrier gas at a flow rate 
of 1.5 ml min
−1
 in constant-flow mode. The oven programme was set at an initial 
temperature of 70 °C that was increased to 190 °C at a rate of 12 °C/min followed by 
an increase to 325 °C at a rate of 20 °C/min and a final hold at 325 °C for 3.25 min. 
Ionisation was performed using electronic impact with an electron energy of 70 eV 
and an emission intensity of 35 μA. Raw data were processed using MassHunter 
B.05.00 (Agilent Technologies). Plasma α-ketoglutaric acid was quantified using a 
target ion and was identified using qualifier ions and the retention time. The 
molecular weight of the derivatised molecule, retention time, quantifier and qualifier 
ions, relative abundance, recovery, accuracy, precision and additional pertinent 
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results are provided in Supplementary Figure S1. The limit of detection was 
0.001μM. Instrumental reproducibility was 2.2%. Standard curves for the analysis 
were reproducible and displayed R2 values of ൒0.99, which indicated linearity over 
the measured concentration range; we did not detect carryover. 
Statistical analysis 
Significantly altered metabolites, which were corrected for multiple testing, were 
defined using a P-value <0.05 and a predesigned false discovery rate [19]. We 
performed Welch’s t-tests and/or Wilcoxon’s rank sum tests for pairwise 
comparisons. A repeated measurement analysis of variance was used in some 
instances. We used multivariate statistics to improve the refining and distilling of 
complex raw data and for pattern recognition. Random Forests is a supervised 
classification technique based on an ensemble of decision trees [20]. This method 
provides an unbiased estimate of how well one can predict sample classes in a new 
data set (prediction accuracy) and a selection of variables that make the largest 
contributions to the classification. We also used linear discriminant analysis as a 
classical method of classification and principal component analysis as an 
unsupervised data analysis, which measures the innate variation in data sets. 
Ingenuity pathway analysis, which is a web-based functional analysis, was used to 
explore biomolecular interaction networks to identify the signalling and metabolic 
pathways and to compare the affected pathways. Fisher’s exact test was used to 
calculate a P-value to determine the probability of the association between the 
metabolites and the canonical pathway. The network score was based on the 
hypergeometric distribution and was calculated using the right-tailed Fisher’s exact 
test. Logistic regression analysis and receiver operator characteristic curves 
described and assessed the binary classification [11, 21]. The employed statistical 
software included the program ‘R’ (http://cran.r-project.org) and the SPSS 18.0 
package (IBM, Madrid, Spain). 
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Results 
Plasma metabolites and obesity-related liver steatosis  
Raw data. The baseline characteristics of the selected patients, raw data and an 
exhaustive list of the measured metabolites in untargeted metabolomic analyses are 
shown in Supplementary Tables S1 and S2. Most patients were female (73%) and 
BMI values ranged between 43.1 and 52.1 kg/m
2
. Patients with steatosis showed 
significantly higher plasma cholesterol and triglyceride concentrations than those 
without steatosis. Common liver function tests revealed higher values in patients 
with steatosis, but significance was only reached for γ-glutamyl transpeptidase 
(Supplementary Table S1). We identified 316 metabolites of which 38 were 
significantly different between groups. Finally, 19 metabolites with the highest 
statistical difference were chosen using more stringent conditions for further 
consideration (Supplementary Figure S2). The relative abundance of perturbations 
in amino acids and lipid metabolism are shown in Figure 1a.  
Figure 1. (a) Heat map of the relative plasma concentration of selected metabolites that may 
distinguish obese patients with or without steatosis (green, lower; red, greater). (b) Random 
(decision) Forest analysis was used as implemented in the R package software as a framework to 
create a large number of particular models built around the presence or absence of steatosis. 
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Interpretation. The citric acid cycle is the most important metabolic pathway for the 
energy supply and connects most metabolic pathways. The following alterations 
support the idea of defective liver function: 1) the levels of all three branched-chain 
amino acids (leucine, isoleucine and valine) were significantly increased in patients 
with steatosis; and 2) the levels of branched-chain keto acids (3-methyl-2-
oxobutyrate, 3-methyl-2-oxovalerate and 4-methyl-2-oxopentanoate) were slightly 
elevated in the plasma from patients with steatosis.  
Steatosis may also sequester fatty acids from β-oxidation in liver cells using an 
alternative energy source, as shown by significant decreased levels of 3-
hydroxybutyrate and a significant increase in the concentration of plasma α-
ketoglutarate and succinylcarnitine in patients with steatosis. The mechanisms of 
lipolysis and gluconeogenesis appear to be affected (Supplementary Figure S3). 
Glucose metabolism is also altered in patients with steatosis. The significant 
decrease in the concentration of plasma 1,5-anhydroglucitol in these patients 
probably indicates long-term higher hyperglycaemia. In addition, hyperglycaemia-
induced oxidative stress is likely in patients with steatosis, as indicated by the 
increased plasma levels of bradykinin and des-Arg9-bradykinin. The plasma level of 
the dicarboxylic acid 2-hydroxybutyrate (α–hydroxybutyrate), which is an early 
marker for impaired glucose regulation, was also significantly increased.  
Plasma glycocholate and taurocholate concentrations were higher in patients with 
steatosis, which indicates that the damaged livers were not functioning properly in 
the uptake of these compounds. The excretion of steroids is also limited in liver 
steatosis because these compounds are not effectively sulphated, which was 
indicated by significantly lower plasma levels of sulphated steroids (that is, 4-
androsten-3β, 17-β-diol disulphate 1, 4-androsten-3β, 17-β-diol disulphate 2, 5α-
androstan-3β, 17β-diol disulphate, 5α-pregnan-3β, 20α-diol disulphate, pregnen-diol 
disulphate, pregnen steroid monosulphate, andro steroid monosulphate 2 and 21-
hydroxypregnenolone disulphate). 
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Pattern recognition 
Random Forest analysis resulted in a predictive accuracy of >80% to distinguish 
patients with or without steatosis and revealed plasma α-ketoglutarate as the 
primary differentiator in a ranked list of metabolites in order of their importance in 
the classification scheme (Figure 1b). The application of linear discriminant analysis 
and principal component analysis yielded similar results for group clustering and 
pattern recognition (Figure 2), and logistic regression and receiver operator 
characteristic analyses produced a list of possible biomarkers.  
Figure 2. Model plots constructed using principal component analysis (a and b) and linear 
discrimination analysis (e and f). Logistic regression analysis and receiver operator characteristic 
curves indicated the presence of a pattern for the selection of candidate biomarkers and group 
clustering. As shown in the calculations (c, d, g and h), plasma α-ketoglutarate was the most qualiﬁed 
for this purpose. 
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Metabolite interaction networks  
We uploaded the metabolite lists (with kyoto encyclopedia of genes and genomes 
IDs) onto an ingenuity pathway analysis server to identify the biological pathways 
and functions of the biomolecules of interest. The top-associated network functions 
were limited to scores of >24.  
Figure 3. Interaction and regulatory networks associated with steatosis in morbidly obese patients as 
identiﬁed using the ingenuity pathway analysis. Plots are depicted for the top-associated network 
functions (score >24, a and b) and top canonical pathway (c). 
We highlighted networks that were similar and that shared identical functions, that 
is, lipid metabolism, amino-acid metabolism, molecular transport and small molecule 
biochemistry. Only tRNA charging (P=0.0007) and isoleucine degradation (P=0.0009) 
were significantly different among the top canonical pathways. Interactions and 
regulatory networks are depicted in Figure 3, which integrates most of the altered 
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metabolites based on their biochemical relationships in obese patients with 
steatosis.  
These plots indicate that L-glutamic acid upregulates α-ketoglutarate (2-oxoglutaric 
acid) and suggest a role of branched-chain amino-acid transaminase. Predicted 
disturbances, which probably result in α-ketoglutarate accumulation in the plasma, 
are depicted in Supplementary Figure S4.  
These results indicate a role for mitochondrial dysfunction. Our preliminary findings 
also indicate that in patients without steatosis the mean diameter of the 
mitochondria was slightly lower, the matrix was more electron dense and the crests 
were more visible compared with patients with steatosis. More importantly, toroidal 
mitochondria were abundant and only observed in non-steatotic patients and there 
was a significantly higher accumulation of autophagosomes in patients with 
steatosis. It is therefore plausible that the detection of perturbations in the citric acid 
cycle (CAC) may facilitate the evaluation of mitochondrial functions in physiology 
and disease [22].  
Plasma α-ketoglutarate as a biomarker 
The obtained results identified and qualified plasma α-ketoglutarate as a diagnostic 
biomarker [23]. We calculated, with 95% confidence, that the true area under the 
curve of the reported receiver operator characteristic curve for plasma α-
ketoglutarate ranged from 0.90 to 0.96 with a specificity of 0.93 at a fixed sensitivity 
of 0.8 (Figure 2). However, these results were calculated using a low number of 
carefully selected patients. To decrease uncertainty or margin of error in the 
relevance of these measurements, we extended the analysis to a broad range of 
morbidly obese patients (Table 1) in which the degree of steatosis was widely 
distributed. 
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Notably, steatosis was predominantly mild, and the other liver alterations were 
primarily benign (Supplementary Figure S5). Approximately 25% of our patients 
were insulin sensitive, but this condition was unrelated to the presence of NAFLD. 
Plasma α-ketoglutarate was slightly but significantly associated with homoeostasis 
model assessment values (ρ=0.25, P=0.01).  
We calculated that at least 115 cases would be required to determine whether 
plasma α-ketoglutarate outperforms other commonly used biomarkers using an 
inferential approach [24]. These minimum requirements were increased to 230 cases 
to ensure validity in a target group in which positive and negative outcomes are not 
equally distributed and in which the addition of fibrosis and/or inflammation may 
complicate the interpretation.  
A significant association between circulating triglycerides and steatosis was observed 
in these patients (ρ=0.42, P<0.001; see also Table 1), which is similar to the 
association observed with plasma α-ketoglutarate levels (ρ=0.49, P<0.001). Lean 
controls exhibited significantly (P<0.001) lower (1.1 μM (0.82–1.37)) plasma α-
ketoglutarate levels than obese patients (7.5 μM (5.5–10.8) without overlap (median 
(interquartile range)). The values were also significantly higher in obese patients with 
steatosis than in those without steatosis, indicating the potential to discriminate 
between the different stages in the progression of these conditions (Figure 4). These 
differences were also observed in liver tissue; in samples without steatosis, α-
ketoglutarate concentration was significantly (P=0.017) lower (22.1 μM per 100mg 
dry weight (11.3–31.3)) than in those with steatosis (57.8 μM per 100 mg dry weight 
(32.8–63.1)).  
Among the measured variables, only the plasma α-ketoglutarate concentration 
exhibited significant agreement with the degree of steatosis, which may differentiate 
between mild, moderate and severe steatosis. Although comparisons were 
significant, data are not shown for severe steatosis because the number of patients 
was considered too low to yield relevance. The area under the curve of the receiver 
operator characteristic curves exhibited a fair-to-good clinical utility (Figure 4).  
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Other common laboratory liver function tests failed to discriminate between 
patients with or without NAFLD. Interestingly, the clinically considered ‘gold 
standard’, alanine aminotransferase, exhibited the worst performance. In contrast, 
γ-glutamyl transpeptidase performed relatively well (Supplementary Figures S6 and 
S7).  
Figure 4. The mean plasma α-ketoglutarate concentration was signiﬁcantly lower in lean controls and 
patients without steatosis (a) and displayed signiﬁcant agreement with the degree of steatosis (b and 
c). The area under the curve of the receiver operator characteristic curves were signiﬁcant, and 
clinical utility was approximately fair to good; for this purpose, the number of patients with severe 
steatosis was considered too low to yield relevance (d). 
We subsequently constructed multivariate models that combined the values of the 
available biomarkers, but the performance was lower than plasma α- ketoglutarate 
alone. Conversely, the addition of plasma α-ketoglutarate to any of these models 
improved the performance (Figure 5). The optimal clinically useful threshold (that is, 
the plasma concentration) rather than the mathematically optimal threshold is 
difficult to assign.  
The choice is highly dependent on the intended use. Ideally, all patients with 
steatosis should be correctly classified, but this may come at the cost that some 
patients may be incorrectly classified as free of steatosis. For example, 8 or 4 μM 
(which represent two mathematically possible candidates) yield a similar positive 
predictive value (>80%), but 8 μM provides high specificity (>85%) and 4 μM 
provides high sensitivity (>97%).  
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Figure 5. Multimetabolite biomarker models should provide more information than a single 
biochemical measurement, as assessed using receiver operator characteristic curves. However, 
predictive scores from multivariate models that combined several variables were not superior to 
plasma α–ketoglutarate alone, as exempliﬁed by the combination with plasma γ-glutamyl 
transpeptidase (GGT), which displayed the best performance of commonly used laboratory 
biomarkers. 
 
Discussion 
There is currently no clinically useful plasma surrogate for the assessment of hepatic 
steatosis in obesity. Multivariate metabolomics analyses provide meaningful 
information owing to the simultaneous global assessment of hundreds of 
endogenous metabolites in a biological sample. To perform studies in this context, it 
is important to ensure the maintenance of pre-analytical aspects. Similar nutritional 
status and similar food intake are necessary because dietary factors have an 
important role as a causative factor of NAFLD [25–27]. As we predicted, 
inflammation does not appear to be a prominent factor, [28, 29] but neither obesity 
nor NAFLD are simple, monogenic disorders. Therefore, we chose clinically 
controlled bariatric patients who exhibited a similarly high BMI.  
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The accumulation of lipids in hepatocytes induced a relative energy deficit, reduced 
liver function and disturbed insulin resistance, which is apparently accompanied by 
an acquired and reversible mitochondrial dysfunction [30]. Our data also partially 
support the importance of a newly described mechanism (lipophagy) that links 
lipolysis and regulation of intracellular lipid stores [31]. Notably, the deficit in 
sulphonation that we have observed in NAFLD patients may be clinically relevant. 
This is because phase II drug-metabolising enzymes maintain cellular homoeostasis 
via the metabolism of several endogenous molecules that may facilitate metabolic 
disorders and may result in the improper management of xenobiotics and 
endobiotics [32, 33]. Therefore, the search for NAFLD diagnostics in obesity should 
focus on mechanisms of energy homoeostasis, mitochondrial biogenesis, fatty acid 
oxidation and glucose metabolism, which may require new strategies [34]. The 
results obtained from the plasma analysis are consistent with those obtained in the 
livers of different animal models and human studies, which demonstrate that 
steatosis is the cause or consequence of disturbances in hepatic lipid and glucose 
metabolism that decreases the ability to obtain energy [8, 25, 35, 36]. The metabolic 
imbalance caused by obesity and NAFLD affects mitochondrial metabolism and 
metabolic pathways, which are important for recycling α-ketoglutarate into and out 
of the mitochondrion and allow for the continuous production of intracellular 
messengers [37]. Finally, it has been recently described in a model of mitochondrial 
dysfunction (PINK1 deficiency) that increased expression of α-ketoglutarate is the 
most prominent and early effect, probably representing a compensatory mechanism 
[38]. Monitoring mitochondrial function via the quantitative evaluation of 
mitochondrial metabolite abundances may be an important new avenue of research 
in obesity-associated NAFLD. This is mainly because CAC metabolites have a central 
role in catabolic and anabolic functions (that is, it is amphibolic in nature). As in 
other non-communicable diseases, it is most likely adequate to adopt the view that 
steatosis is governed by a pivotal regulatory role of metabolic reprogramming in cell 
fate decisions [39, 40].  
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Plasma α-ketoglutarate levels may distinguish lean controls from obese patients with 
a “predictive accuracy” of 100% and predict obese patients with or without NAFLD 
better than commonly used biomarkers. This result supports the potential clinical 
utility of plasma α-ketoglutarate levels. However, additional validation in other 
patients from an identical target population is required. Preliminary results in 
ongoing validation studies suggest that this novel biomarker deserves further 
evaluation and development and that this biomarker should be added to clinical 
practise. In addition, pilot studies indicate the usefulness of performing serial 
measurements in the same patient, which do not require high specificity or 
sensitivity, to monitor disease progression and/or the response to treatment. The 
major limitation of our results is the confinement to morbid obesity. We believe this 
is a blood test that provides a solution for a major unmet clinical need but 
implementation of a new biomarker is difficult and requires validation. Regardless of 
the attractiveness of plasma α-ketoglutarate as a biomarker, the high costs of 
validation hamper the introduction of new biomarkers and therefore commercial 
considerations may ultimately determine the clinical use [41]. However, commonly 
used laboratory tests do not appropriately guide clinical decisions. Imaging studies 
are also not possible for patients of this size, and patients do not readily accept more 
invasive studies. 
We also confirmed the potential of metabolomics to influence patient care. 
Metabolomics is designed to delineate biological processes, and the selection of 
metabolites for development as clinical biomarkers should be performed a priori 
rather than post hoc. Our results indicate that this approach is not necessarily true if 
compound quantification follows metabolomics, which is a strategy that is currently 
feasible and is not time consuming. This study successfully utilised a metabolomics 
approach to provide new insights into the consequences of NAFLD in obese patients 
and supports the possible translational relevance of plasma α-ketoglutarate as a 
biomarker of a condition that carries an enormous burden of disease. 
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Abstract 
Excessive energy management leads to low-grade, chronic inflammation, which is a 
significant factor predicting non-communicable diseases. In turn, inflammation, 
oxidation, and metabolism are associated with the course of these diseases; 
mitochondrial dysfunction seems to be at the crossroads of mutual relationships. 
The migration of immune cells during inflammation is governed by the interaction 
between chemokines and chemokine receptors. Chemokines, especially C-C-
chemokine ligand 2 (CCL2), have a variety of additional functions that are involved in 
the maintenance of normal metabolism. It is our hypothesis that a ubiquitous and 
continuous secretion of CCL2 may represent an animal model of low-grade chronic 
inflammation that, in the presence of an energy surplus, could help to ascertain the 
afore-mentioned relationships and/or to search for specific therapeutic approaches. 
Here, we present preliminary data on a mouse model created by using targeted gene 
knock-in technology to integrate an additional copy of the CCl2 gene in the 
Gt(ROSA)26Sor locus of the mouse genome via homologous recombination in 
embryonic stem cells. Short- term dietary manipulations were assessed and the 
findings include metabolic disturbances, premature death, and the manipulation of 
macrophage plasticity and autophagy. These results raise a number of mechanistic 
questions for future study. 
Introduction 
Excessive energy intake is a part of the current human lifestyle that leads to a state 
of chronic systemic low-grade inflammation, which is thought to play a role in the 
development of atherosclerosis, cancer, and other non-communicable diseases. At 
the same time, it is also plausible that the long- term consequences of prolonged 
inflammation exacerbate the deleterious effects of continuous nutrient surplus [1–
3]. The immune system and metabolism are closely interconnected [4, 5]. During 
inflammation, the whole body is under metabolic stress, and energy excess 
management could compromise the relationships among metabolism, oxidation, and 
inflammation. We reasoned that searching for an adequate animal model [6] might 
allow us to better understand disease pathogenesis.  
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Chemokines are promising candidates for the design of such a model. Some of the 
functions of chemokines are associated with the migration of immune cells, and 
chemokines are important for the correct functioning of metabolism. In humans, C-C 
chemokine ligand 2 (CCL2; formerly referred as MCP-1 or monocyte chemoattractant 
protein-1) could be a marker of inflammation; it is overexpressed in non-
communicable diseases and is involved in a variety of metabolic functions [7]. 
Actually, CCL2 modifies lipid and glucose metabolism and contributes to insulin 
resistance and hepatic steatosis [8–11]. Of note, circulating chemokines cause and 
maintain metabolic disturbances that may be reversed by anti-inflammatory drugs, 
and the role of chemokines is likely a causal and predisposing factor [12, 13]. Rather 
than local overexpression [14–17], it is now recognized that CCL2 protein and mRNA 
are expressed in the vast majority of tissues, suggesting both a systemic production 
and the ability to respond in situ to inflammatory stimuli [18, 19].  
Therefore, we hypothesized that challenging an animal model that systemically 
overexpresses CCL2 with diets rich in fat and cholesterol could help to assess the role 
of chronic inflammation in response to excessive energy intake. We then proceeded 
to integrate a copy of the Ccl2 gene in the Gt(ROSA)26Sor (commonly referred to as 
ROSA26) locus of the mouse genome via homologous recombination in embryonic 
stem cells (ES) to generate targeted transgenic mice [20-22] that overexpress CCL2 in 
all tissues. Preliminary data are promising and suggest a number of mechanistic 
questions for future study. 
Material and methods 
Animal Handling 
All procedures and experimental protocols were examined and approved by the 
Ethics Review Committee for Animal Experimentation of the Universitat Rovira i 
Virgili. Basic protocols for tissue collection, diets, allocation concealment and 
metabolic assessment of the mice have been already described in detail [6, 18, 23]. 
Strains were backcrossed >10 generations to C57BL/6J mice and maintained 
homozygously. Littermates without mutations were used as controls (WT). We also 
provide data from knockouts (KO) of CCL2 (conveniently backcrossed), which were 
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purchased from the Jackson Laboratory (Sacramento, CA). Dietary experiments 
began at 10 weeks of age, when all strains display similar phenotypes. To avoid 
possible effects of immature adipocyte modelling, most results were obtained in 
different groups after 6 or 14 weeks of treatment (16 and 24 weeks old, resp.). To 
explore dietary effects, mice from each group were fed either chow (Teklad rodent 
diet; Harlan, Barcelona, Spain) or a high-fat diet (FuttermittelfürMaüse; SSniff spezial 
diäten, Soest, Deutschland) and caged indefinitely under supervision. The breeding 
of all experimental populations was performed in our own facilities, and the 
progenies were maintained under close surveillance. The animals were not kept 
under germ-free conditions.  
Targeted Transgenic (TG) Mice  
The transgenic model was generated via a gene targeted inducible knock-in (KI), that 
is, a line with a duplicated gene, approach using standard methods and proprietary 
technology from Ozgene (Bentley, WA, Australia). The mRNA sequence 
corresponding to the mouse Ccl2 gene (NM_011333 and ENSMUSG00000035385) is 
located on chromosome 11. The gene has 3 exons spread over approximately 3 Kb. 
The gene fragment was obtained from C57BL/6 genomic DNA (PCR primers 
AGCAAGATGATCCCAATGAGTAGGC and GAGGTGGTTGTGGAAAAGGTAGTGG) to be 
inserted by gene targeting into the ROSA26 locus. Upstream regulatory elements are 
important in the transcriptional regulation of Ccl2 gene. Human ubiquitin promoter 
(Ubic) was chosen for the transgene to produce a high-level of expression. A loxP-
flanked STOP cassette prevents the transcription of the gene following the UbiC 
promoter (See Figure 1 and Supplementary Materials S1 and S2 available online at 
http://dx.doi.org/10.1155/2013/953841). The STOP cassette can be removed using 
Cre recombinase. PGK-Neo-SD-IS, a selection cassette, is inserted downstream of the 
Ccl2 gene to enrich homologous recombination events. The ROSA26 locus is 
conserved between mice and humans. The location is autosomal (chromosome 6) 
and is actively transcribed in most tissues (Figure 1). Moreover, epigenetic 
inactivation is unlikely [21, 24–26].  
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The combination of gene targeting and ES cell technology exploiting homologous 
recombination provides advantages over other techniques [27–31] (Supplementary 
Material S3). Mice are available upon request.  
 
Figure 1. A STOP sequence flanked by loxP sites was inserted between the Ubiquitin promoter and 
the mouse Ccl2 gene (a). The sequences of both the STOP cassette (bold) and the loxP sites 
(underlined) are shown later (b). The wild-type allele for Ccl2 gene is located in the region 11 C-E1 of 
chromosome 11 and the transgenic vector (bottom) is inserted in the ROSA26 locus of chromosome 6 
(c). The procedure is designed to avoid chromosomal instabilities. 
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Immunopathology Studies and Assessment of Liver Steatosis 
Portions of organs and tissues were either frozen in nitrogen or fixed in 4% 
phosphate-buffered formalin for 24 h at room temperature, washed twice with 
water, stored in 70% ethanol at 4 ºC, and embedded in paraffin for histological 
analyses. Primary and secondary antibodies were obtained from Santa Cruz 
Biotechnology (Heidelberg, Germany) and Serotec (Oxford, UK) [18, 32]. Detection 
was performed with the ABC peroxidase system (Vector, Burlingame, CA) using DAB 
(Dako, Glostrup, Denmark) as the substrate. To assess specificity, primary antibodies 
were omitted in the controls. Liver steatosis was assessed as previously described 
[6]. 
Laboratory Measurements  
We measured murine CCL2 in plasma, serum, and tissues by ELISA (Peprotech, 
London, UK), according to the instructions of the manufacturer. Recombinant human 
CCL2 antigen was used as the calibrator for assay standardisation, and we found 
weak cross-reactivity with other chemokines, especially CCL7. The intraassay 
coefficients of variation were <3.2%, and the interassay of variation was <9.1%. 
Other biochemical measurements were performed in automated analysers using 
commercially available reagents as described [6, 33]. Selected tissues were 
homogenised using the Precellys 24 system (Izasa, Barcelona, Spain) with prefilled 
bead tubes in the buffer of choice. Fractions of the homogenised liver were 
immunoblotted as described [34], using antibodies and reagents from Santa Cruz 
Biotechnology (Heidelberg, Germany). 
Transmission Electron Microscopy 
Small pieces of the liver were immediately fixed in a 2% glutaraldehyde solution in 
0.1 M cacodylate buffer, pH 7.4. Samples were then post-fixed in 1% osmium 
tetroxide (OsO4) for 2 h and dehydrated in sequential steps of acetone prior to 
impregnation in increasing concentrations of the resin in acetone over a 24 h period. 
Semithin sections (500nm) were stained with 1% toluidine blue. Ultrathin sections 
(70 nm) were subsequently cut using a diamond knife, double-stained with uranyl 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
Results 
 
106 
 
acetate and lead citrate, and examined using a transmission electron microscope 
(Hitachi, Tokyo, Japan).  
Characterisation of Mouse Bone Marrow-Derived Macrophages  
The methods were performed as previously described [35]. Bone marrow cells were 
isolated by removing leg bones from WT and TG mice (aged 10 weeks) and were 
cultured for 24 hours. Floating cells were removed, and the remaining attached cells 
were analysed. Cells were further cultured in DMEM supplemented with 10% 
inactivated foetal calf serum, 50 mM beta-mercaptoethanol, and 1000 U/mL murine 
granulocyte-macrophage colony-stimulating factor (GM-CSF) or 25 ng/mL human 
macrophage colony- stimulating factor (M-CSF) (ImmunoTools, Friesoythe, Germany) 
to provide polarised activation of cells into M1 and M2 as a simplified descriptor of 
their functional plasticity. To assess the effect of activation, macrophages were 
treated with 100 ng/mL E. coli 055:B5 lipopolysaccharide (LPS) for 24 hours and were 
compared with the respective untreated controls. After this treatment, supernatants 
from M1 (GM-CSF) and M2 (M-CSF) macrophages were tested for the presence of 
CCL2, tumour necrosis factor-a (TNFa), and interleukin 10 (IL-10) using ELISA 
(BioLegend, Inc., Madrid, Spain). Total RNA was extracted using the RNeasy kit 
(Qiagen, Barcelona, Spain) and was retrotranscribed using the Reverse Transcription 
System kit (Applied Biosystems; Invitrogen, Barcelona, Spain). Oligonucleotides for 
selected genes were designed according to the Roche so ware for quantitative real-
time PCR (Universal Probe Roche library), which was performed using a LightCycler 
480 (Roche Diagnostics, Barcelona, Spain). The assays were performed in triplicate, 
and the results normalised according to the expression level of TATA-binding protein 
mRNA. C-C chemokine receptor type 2 (CCR2 or CD192), TNFa, inhibin beta A 
(INHBA), inducible nitric oxide synthase (iNOS), C-C chemokine receptor type 7 
(CCR7), and Egl nine homolog 3 (EGLN3) were chosen as M1 markers. Arginase 
(ARG), EMR1/F4/80, insulin growth factor-1 (IGF1), IL-10, the mannose receptor 
CD206, and growth arrest-specific 6 (GAS6) were chosen as M2 markers. 
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Statistical Analyses  
The normality of the distributions was assessed using the Kolmogorov-Smirnov 
method. Variables were compared using Mann-Whitney tests or Kruskal-Wallis one-
way analysis adjusted for multiple testing. Unless otherwise indicated, the values in 
the figures represent the mean and SEM obtained in groups of 8 mice. The c
2
 test 
was used to compare categorical variables. For all measurements, we used either 
SPSS (SSPS Inc., Chicago, IL) or GraphPad Prism software 
(http://www.graphpad.com/scientic-soware/prism/).  
Results 
Targeted Transgenic Mice Do Not Display Physical Abnormalities 
The resulting mice for the targeted mutation are viable, fertile, and normal in size 
and weight. The animals do not display apparent behavioural or reproductive 
defects. The transgene insertion of a single copy occurs at a defined site, which 
allows for easy genotyping (Figure 2) and eliminates possible instabilities, 
independent segregation during breeding, and unpredictable positions in the 
chromosomes. An additional advantage of this strategy is the Cre/lox recombination 
system that facilitates tissue-specific overexpression. The Ubic is conditioned by an 
Lox-Stop-Lox (LSL) element that is activated by Cre-mediated excision using the 
appropriate, tissue-specific Cre strain.  
Transgenic Mice Overexpress CCL2 in Selected Tissues, and Circulating 
Protein Is Increased with respect to Controls 
Consistently, transgenic mice displayed more CCL2 protein in all tissues examined 
with respect to WT animals. The differences increased with age, and there were 
minor relative differences among tissues (Figure 3). We confirm that CCL2 was 
immunologically detected in all selected tissues of the transgenic mice. The CCL2 
mRNA expression in the transgenic mice was also higher in different types of cells 
with respect to WT mice. The amount of CCL2 was higher after the designed period 
of exposure to a diet with a high fat content. Of note, the serum and plasma CCL2 
were also higher in transgenic mice than in WT mice, which is most likely caused by 
CCL2 secretion by multiple tissues. In accordance with previous observations, the 
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plasma concentrations differed from the serum concentration. The differences are 
likely caused by coagulation and handling, but the differences were not statistically 
significant in transgenic mice. Notably, CCL2 was also detected in KO mice, but with 
less intensity. This is most likely due to quantitatively minor cross reactivity, as 
described in the methods.  
Figure 2. Simplified strategy for genotyping that includes the sequence of each primer (a), the 
reaction proposed for each primer (b), and the expected PCR products for each strain (c). The method 
is designed for the concomitant use of all primers and a representative gel is shown in (d). 
Dietary Factors Influence Body Weight and Adipocyte Size  
When mice were fed a regular chow diet, we did not observe significant differences 
in body weight increase among groups. The cumulative food intake was identical for 
the three strains examined. In contrast, when fed a high fat diet, both transgenic 
animals and WT animals developed obesity. Of note, the C57BL/6J male mouse is a 
commonly used model of diet-induced obesity [36]. The effect of CCL2 
overexpression was apparent immediately after the ingestion of the high calorie 
diet, and the weight increased more rapidly than in WT mice. The absence of CCL2, 
however, protected the KO mice from excessive weight gain. The lack of significant 
differences in the food intake excluded any effect of CCL2 on appetite (Figure 4). 
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Overexpression of CCL2 also increased the size of the adipocytes. Data are presented 
for epididymal adipose tissue (Figure 5), but the effect was similar in other adipose 
tissues. The adipocyte size was significantly higher in CCL2 transgenic animals 
compared with WT and KO animals fed with both diets, but the difference was 
higher when mice were fed a diet with a high caloric content. When different types 
of adipose tissue were weighed, we found that the mice fed a chow diet showed no 
significant differences between the strains, with the possible exception of inguinal 
tissue. Conversely, the addition of fat to the diet resulted in a significant increase in 
the weight of white adipose tissue from other depots in mice with CCL2 
overexpression. Notably, there was no effect on the weight of brown adipose tissue 
(Figure 6 and Supplementary Material S4). However, these differences among 
groups in adipose tissues weight disappeared when mice were fed with a high fat 
diet for 14 weeks. These results are probably indicating an already reported effect of 
adipose tissue remodelling on the consequences of high-fat dietary intake [37] 
(Supplementary Material S5). 
Figure 3. Overexpression of CCL2 with respect to wild type and knockout was observed in all selected 
tissues (extracts) in the transgenic mice as measured by ELISA. Differences were also observed in 
plasma and serum and there was cross-reactivity with similar chemokines that could explain the 
detection of CCL2 in KO mice (a). CCL2 was also detected by immunochemistry in different types of 
cells (b). 
*
P<0.005; Micrographs in the left column are representative for liver, pancreas, and kidney. 
Those in the right column were for brain, intestine, and stomach. 
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Figure 4. The effect of high-fat diet in body weight increase was evident in transgenic and wild-type 
mice ((a), (b)), but the different increase was immediate after dietary manipulation in transgenic. This 
effect was negligible in knockout mice (c). The combination of these effects with high-fat diet (d) 
shows similar results to facilitate comparison. These findings are not due to differences in the 
cumulative food intake ((e), (f)) indicating that CCL2 probably has no effect on appetite. 
*
P<0.05. 
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Figure 5. The size of the adipocytes was significantly higher in transgenic mice than in wild-type and 
knockout mice and the effect was observed with both dietary interventions regardless of the duration 
of the dietary treatment (6 or 14 weeks) (a) but it was more intense when mice were fed a high-fat 
diet. For clarity, values are indicated only for adipocytes in epididymal white adipose tissue. 
Representative micrographs are shown for transgenic, wild-type, and knockout animals ((b), (c) and 
(d), resp.) when fed a chow diet and for the corresponding animals fed a high-fat diet ((e), (f), (g)) at 
16 and 24 weeks’ old. 
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Figure 6. The effect of CCL2 expression in the weight of adipose tissue ((a)–(d)) of animals fed either 
chow (left column) or high-fat diet (right column). Of note, differences among strains were more 
evident during energy surplus and no change was observed in brown adipose tissue. 
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Diet-Induced Disturbances in Glucose and Lipid Metabolism  
Glucose tolerance tests (a proxy for insulin resistance) were unaffected in strains fed 
the chow diet during the experimental period of 6 weeks. However, WT littermates, 
KO, and transgenic mice displayed abnormal values when fed a high-fat diet, con 
firming the effect of diet in the pathogenesis of insulin resistance and suggesting 
that this short-term intervention is not adequate to investigate a possible 
disturbances. Moreover, there were no differences among the strains in the plasma 
glucose levels after 6 hours of fasting, and after 3 hours in the fasting state, we 
found that the plasma glucose baseline concentrations were significantly higher in 
CCL2 overexpressing mice with respect to CCL2 deficient animals. This effect was 
more evident in the transgenic mice (Supplementary Material S6) but differences in 
plasma glucose disappeared after 14 weeks of dietary treatment suggesting 
immature adipose tissue remodelling [38]. When these tests were performed in 
animals fed a high-fat diet for a longer experimental period of 14 weeks in which 
adipose tissue is already well modelled, the lack of differences in insulin tolerance 
was maintained, probably indicating that the effect of CCL2 overexpression in the 
pathogenesis of insulin resistance is negligible. However, results in the absence of 
CCL2 indicate that this chemokine may modify glucose metabolism and therefore we 
cannot discard the effects under a more intense metabolic stress [9]. Variations in 
plasma cholesterol and triglycerides concentrations were minimal among the strains 
at 16 weeks old. A high-fat diet significantly increased the amount of circulating 
cholesterol, an effect that was higher in CCL2 overexpressing mice. Conversely, there 
were unexpected and most likely not representative, changes in the plasma 
triglycerides concentration of these mice as a consequence of dietary manipulations 
(data not shown). 
The Influence of CCL2 and Dietary Manipulations in the Liver 
When fed the chow diet, mice did not display significant differences among strains in 
the appearance of their liver tissue. The steatosis scores did not detect significant 
differences among strains, although some minor variations were detected (Figure 7) 
that did not correlate with the hepatic lipid content (data not shown). When mice 
were fed a high-fat diet, we found a certain amount of lipid accumulation in WT 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
Results 
 
114 
 
mice, but this lipid accumulation was significantly more evident in transgenic mice. 
Conversely, there was no accumulation of lipids in KO mice (Figure 7). Therefore, the 
effect of CCL2 under these conditions is directly related to the amount of tissue CCL2 
disposal; the absence of CCL2 prevents liver steatosis, and overexpression of CCL2 
predisposes the liver to steatosis. We also found that the expression of fatty acid 
synthase in the liver increased significantly in all strains when fed a high-fat diet, but 
there were no significant differences in the comparisons between transgenic and KO 
mice. We also explored the activating phosphorylation of AMP-activated protein 
kinase (AMPK), and values did not change as a result of high-fat diet in transgenic 
mice and were significantly higher in KO mice compared with transgenic mice 
(Supplementary Material S7). When the livers were examined for the presence of 
F4/80 antigen, a widely accepted marker of macrophages, we found that both 
dietary fat and overexpression of CCL2 modify the size, number and morphology of 
liver macrophages (Figure 8 and Supplementary Material S8). Of note, F4/80 stained 
cells were more frequent in KO mice, a finding that merits further study because 
these results could represent a change in function and could be responsible for the 
differential effects of CCL2 in liver steatosis. We then explored the influence of both 
CCL2 and diet in mitochondrial biogenesis. Based on the appearance of the matrix, 
the mitochondria are healthier in mice fed a chow diet than in those fed a high-fat 
diet. The matrix was also consistently less electron-dense in transgenic mice. We also 
found altered fusion dynamics. In transgenic mice fed a chow diet, the process was 
unbalanced towards mitochondrial fusion, but the dietary manipulation significantly 
elicited a shift towards fission. The changes were similar in WT mice, but the effect 
of diet was quantitatively less evident than in transgenic mice. In KO mice, however, 
there were more mitochondria per cell, and fusion and fission were correctly 
balanced and apparently not altered by differences in diet. These findings strongly 
support further mechanistic studies, which may link the expression of CCL2 with 
mitochondrial biogenesis, inflammation, and energy management. According to our 
results, these putative mechanisms are related to the autophagic response, which 
was clearly enhanced in transgenic mice. Conversely, most liver cells in WT and KO 
displayed no evidence of autophagy (Figure 9). 
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Figure 7. We found no significant differences among strains in the appearance of liver tissue when 
mice were fed a chow diet (left column (a), (c), (e); transgenic, wild-type, and knockout mice resp.). 
Representative micrographs show in the right column that a high fat diet produces steatosis in 
transgenic mice (b), dispersed lipid droplets in the liver of wild type mice (d), and no change in 
knockout mice (f). 
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Figure 8. Dietary fat (right column) and CCL2 expression modify the size, number, and morphology of 
liver macrophages with respect to those fed a chow diet (left column) as assessed with F4/80 staining. 
Values for stained area and length of macrophages ((a)–(d)) are illustrated with representative 
microphotographs from transgenic ((e), (f)), WT ((g), (h)) and KO mice ((i), (j)).  
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Figure 9. The appearance of mitochondria was affected by the dietary manipulation and the 
expression of CCL2 as shown in representative microphotographs (a) and these changes were 
accompanied by a significant effect in fusion-fission balance (b). The number of autophagosomes per 
cell was counted and was significantly higher in transgenic mice. Further, these were rare in both WT 
and KO and independent of diet (c). The heterogeneous nature of autophagic elements is illustrated 
in (d) (photographs obtained in transgenic mice). 
Transgenic Mice at Overexpress CCL2 Die Prematurely When Fed High-
Fat Diet 
The transgenic mice fed a high-fat diet died prematurely between 10 and 14 months. 
The mice progressively decreased activity, reduced food intake and the appearance 
of frailty became evident. There was also a casualty in the transgenic mice fed chow 
diet, but it was sudden, unexpected, and without a prior decrease in weight or 
activity. Among the casualties, one was also observed in the WT group fed a high-fat 
diet (Supplementary Material S9). A full autopsy was performed, and the cause of 
death was uncertain. There was neither cancer nor arteriosclerosis in these animals, 
but there were some cutaneous, superficial, and localised lesions in the skin 
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accompanied with local loss of hair. There was also no evidence of sepsis. The only 
remarkable findings were limited to the spleen and the liver. The size and weight of 
the spleen was consistently higher in the transgenic mice fed high-fat diet. The 
presence of splenomegaly in these transgenic mice was consistent with the presence 
of giant cells that were identified as megakaryocytes (Factor VIII positive staining) 
and other proliferative signs. The weight of the liver was also higher in the transgenic 
mice, which is most likely due to the higher presence of steatosis. In the liver, there 
were signs of regenerative cells and increased apoptosis. Ongoing studies with 
higher sample sizes and the inclusion of females have been designed to further 
ascertain this point. 
Bone Marrow Macrophages of Transgenic Mice: Expression of Selected 
Cytokines and mRNA 
The CCL2 mRNA expression in the bone marrow macrophages was higher in 
transgenic than in WT mice, irrespective of stimulation with either GM-CSF (M1, pro-
inflammatory) or M-CSF (M2, phagocytic). The mRNA expression of the selected M2 
markers was similar, with either low or undetectable expression in the GM-CSF 
macrophages without differences between transgenic and WT mice. The expression 
of the selected M1 markers was practically identical in the GM-CSF macrophages 
from TG and WT mice, with the notable exception of CCR7. Surprisingly, the 
expression of this chemokine receptor was significantly lower in TG mice, indicating 
lower pro-inflammatory activity. The expression of the M1 markers in M-CSF 
macrophages showed a unique and significant decrease in CCR2 mRNA expression; 
however, some M2 markers, including CD206, GAS6, and IGF1, were also 
underexpressed. IL-10 expression also decreased, but the differences were not 
statistically significant. The results suggest that CCL2 overexpression may alter 
macrophage polarisation. Consequently, the secretion of selected cytokines was 
examined in macrophages that were treated with LPS and were compared with the 
relevant controls. The CCL2 secretion was higher in TG mice with both treatments 
compared with the WT mice and was 2–4 fold higher (2–4-fold change) in M-CSF 
macrophages. The IL-10 secretion was clearly detectable only in LPS-treated animals. 
The concentration in the supernatant was higher in TG than in WT mice, and the 
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differences were statistically significant in GM-CSF macrophages. Finally, TNFa 
secretion was ostensibly higher in LPS-treated animals and significantly higher in TG 
mice with respect to the relevant controls (Figures 10 and 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Relative mRNA expression in transgenic mice with respect to WT mice of selected markers 
for M1 and M2 macrophages in cells treated in vitro with either GC-MSF or M-CSF. Acronyms used 
were C-C chemokine receptor type 2 (CCR2), TNFa, Inhibin, beta A (INHBA), inducible nitric oxide 
synthase (iNOS), C-C chemokine receptor type 7 (CCR7), Egl nine homolog 3 (EGLN3), Arginase (ARG), 
EGF module-containing mucin-like hormone receptor EMR1 (F4/80), insulin growth factor-1 (IGF1), IL-
10, the mannose receptor CD206, and Growth arrest-specific 6 (GAS6).   
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Figure 11. The relative CCL2 mRNA expression (a) and the secretion in supernatants of selected 
cytokines in bone marrow-derived macrophages of transgenic and WT cells treated in vitro with 
either GC-MSF (b) or M-CSF (c). 
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Discussion 
The transgenic mice developed in this study systemically overexpress CCL2. These 
animals were created to assess the combined effect of the recruitment of circulating 
monocytes in all tissues and the response to the stimuli of high dietary fat and 
energy ingestion. The hypothesis was that the continuous overexpression of this 
chemokine could promote or worsen common pathological conditions, and as 
animal model could be useful for assessing the pathogenic mechanisms and 
therapeutic approaches [39].  
Fertility, growth, and physical appearance were identical to the controls. CCL2 
overexpression did not result in abnormalities in the mice that were fed a regular 
chow diet. However, adding fat to the diet during a short period of time caused 
differences in body weight, adipocyte size, disturbances in glucose and lipid 
metabolism, premature death, and liver alterations that included a higher 
predisposition to fatty liver disease and significant changes in mitochondrial 
biogenesis and autophagy. Additionally, we explored bone marrow macrophages 
under different in vitro conditions, and we found that CCL2 overexpression affects 
functional plasticity.  
In previous studies, CCL2 has been considered a chemokine secreted by adipose 
tissue (adipokine), but systemic CCL2 overexpression regulates white adipose tissue 
(WAT) mass and size without apparent effects in brown adipose tissue (BAT). WAT 
serves primarily as lipid storage, and BAT is used for heat generation. The balance 
between the two adipose tissues affects the whole-body energy homeostasis, and 
the development and severity of obesity [40]. A higher production of CCL2 is not only 
a consequence of obesity but is most likely an exacerbating factor of diet-induced 
alterations. The roles of CCL2 in the aetiology of obesity and diabetes, the regulatory 
mechanisms, and the effect of therapies that inhibit CCL2 production have been 
recently reviewed [4, 41]. We have also found differences between fat cells in 
different adipose tissue depots and the heterogeneity of adipocytes within the same 
depots. Further examination of this issue is necessary because a different pattern of 
gene expression could explain the differential development of various types of 
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adipose tissue [42, 43]. Moreover, this is closely associated with the pattern of fat 
distribution, the extent of obesity, and consequently the impact of different fat 
depots on the severity of metabolic complications [44, 45].  
The size and number of hepatic macrophages significantly differs between transgenic 
and KO mice when detected with antibodies directed against F4/80. Curiously, this is 
an extracellular antigen of unknown function that belongs to a subgroup of the G-
protein-coupled receptors [46]. The changes in macrophages morphology could 
represent concomitant changes in function and whether the macrophages are 
resident or recruited. This is further substantiated by the fact that these transgenic 
mice were prone to develop fatty liver disease and the KO mice were protected. The 
role of increased CCL2 is not yet understood, but the recruitment of macrophages 
seems to be important in different animal models. In KO mice there is an increased 
expression of peroxisome proliferator-activated receptors accompanied by the 
induction of fatty acid metabolism-related genes and the inhibition of pro-
inflammatory cytokine production [47–49]. We confirmed that the effect of fat in the 
pathogenesis of fatty liver disease [49, 50] is influenced by the amount of available 
CCL2 and that the linkage between chemokines and hepatic lipid metabolism is 
plausible.  
The characterisation of bone marrow-derived cells in the transgenic mice indicates 
that CCL2 overexpression affects the transition in the secretory function of 
macrophages (or the M1-M2 paradigm as a simplified descriptor of functional 
plasticity). This is illustrated by differences in GM-CSF and M-CSF, which are 
cytokines that differentiate macrophages in vitro with distinct morphology and 
inflammatory function [51, 52]. The modulation of the phenotypic and functional 
differences in macrophage polarisation by CCL2 overexpression denotes a shift 
towards lower pro-inflammatory activity [53]. CCL2 decreased the expression of 
CCR7 in M1 and decreased the expression of CCR2, IGF1, CD206, IL-10, and GAS6 in 
M2. In cells under LPS treatment, however, CCL2 overexpression increased the 
secretion of IL-10 and TNFa with respect to WT controls. These changes could 
represent a quantitatively determinant factor in the development of macrophage-
induced metabolic alterations. It should be highlighted that a high percentage of 
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total body resident macrophages are present in the liver and that adipose tissue is a 
major site for the accumulation of recruited macrophages [54, 55].  
Notably, CCL2 is involved, directly and/or through the induced metabolic alterations, 
in mitochondrial biogenesis and autophagy. We add CCL2 to the growing list of 
nonessential regulators of mechanisms that divide and fuse mitochondria [56]. The 
balance between rejuvenation and elimination of damaged mitochondria via 
autophagy is affected by both the presence of CCL2 overexpression and the 
increased availability of energy. The antagonistic and balanced activities of the fusion 
and fission machineries are constantly providing responses to inflammation to tightly 
regulate homeostasis of the organism [57, 58]. This is expected because 
mitochondrial diseases are associated with metabolic alterations. Apparently, there 
is a shift towards fusion in CCL2 overexpression to maximise ATP synthesis. 
Contrarily, morphological findings in CCL2 deficient mice, which are independent of 
high-fat diet, suggest a perfect balance [59, 60]. A certain unbalance is expected in 
inflammatory conditions and other energy-dependent disturbances via 
mitochondrial dysfunction [61, 62]. This is important because mitochondria and the 
access to energy (calorie restriction or increased dietary fat) play a pivotal role 
mediated by the mechanistic target of Rapamycin (MTOR) in deciding whether liver 
cells live or die [63]. 
In transgenic mice, autophagy was increased with respect to WT and KO mice, which 
is particularly important because autophagy affects immune responses as a result of 
degradative, biogenetic, and secretory activities that respond to various inputs via 
MTOR [64, 65]. Autophagy might control the infection of certain pathogens but also 
prevents excessive inflammatory reactions in the host [66]. As shown in autophagy-
deficient macrophages, autophagy removes a number of pro-inflammatory stimuli 
[67–69]. Therefore, increased liver autophagy during CCL2 overexpression could be 
interpreted as an e ort from the host to avoid the deleterious action of continuous 
inflammation. Links between autophagy and inflammation have also been found in 
immune functions affecting several diseases, opening a new dimension in the 
understanding of the multifactorial basis of non-communicable diseases. For 
example, increasing macrophage autophagy protects patients with advanced 
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atherosclerosis [70]. It has also been reported that CCL2 controls the extent of 
autophagy in human prostate cancer [71], and autophagy is pivotal for the survival 
and differentiation of monocytes [72].  
Finally, CCL2 overexpression resulted in premature death when combined with a 
high-energy intake. These findings require more extensive examination, and the 
cause of death remains obscure. Mice progressively lost interest in the environment, 
reduced activity, and their intake of food decreased. No chronic disease was evident, 
and there were no signs of sepsis or major infection. It is tempting to consider the 
possibility of premature aging, and future investigations will include the 
characterisation of a senescence-associated secretory phenotype, particularly in pro-
inflammatory cytokine enrichment [73] and the pro-inflammatory phenotype that 
accompanies aging [74, 75]. 
Conclusions, perspectives, and limitations  
This animal model raises a number of questions about the prevalent diseases 
responsible for limiting the quality of modern life. Additionally, this model provides a 
link between inflammation and metabolism and suggests targets for the 
management of diseases in which there is a clear CCL2 over- expression. Specifically, 
this model can help to uncover the role of CCL2 in mitochondrial dysfunction, 
autophagy, and functionality of macrophages and aging in combination with 
excessive energy intake. Information gained could be useful for designing new 
mechanism-based therapeutic strategies. None of the described effects appear in 
mice that are fed a regular diet, and this fact highlights the importance of calorie 
restriction for health. Therefore, the nutrient-sensing MTOR pathway seems to be 
crucial for the management of non-communicable diseases. Consequently, drugs 
modulating MTOR are obvious candidates for assessment. For example, experiments 
on cancer, aging, and viral infections strongly suggest that this is the case for 
metformin [76-78]. This anti-diabetic drug activates AMPK and inhibits MTOR with 
potent anti-inflammatory actions. The usefulness of rapamycin, an MTOR inhibitor, 
and similar drugs in cancer prevention has been assayed [79]. Aspirin decreases 
inflammation, inhibits the MTOR pathway, decreases cancer incidence, and may 
reduce the burden of atherosclerosis [13, 80]. Lastly, although studies are scarce, 
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angiotensin-II-blockers and beta-blockers, widely used in hypertensive patients, can 
also prevent the activation of the MTOR pathway and the incidence of chronic 
diseases [81]. The potential indications for these drugs are mostly related to chronic 
diseases in which inflammation plays a crucial role. This animal model could be used 
to further select candidates and suggests a number of mechanistic questions for 
future study. Particularly, we consider this model as a valuable contribution to our 
evolving comprehension of the interphase between autophagy and inflammation. 
However, we acknowledge that care must be taken in analysing the results of studies 
performed in animal models and that further research e ort is necessary to fully 
characterize our observations. To name a few, possible effects of sex should be 
studied and metabolic alterations should be confirmed with the use of metabolic 
cages and more specific methods to detect significant differences. Particularly, CCL2 
may have a higher influence if there is a relative contribution from different type of 
cells, particularly from immune cells [72]. 
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Background and aims 
There is a strong relationship between metabolism and immune system. Low-grade 
chronic inflammation is a consequence of a compromised management of excessive 
energy intake and represents a significant factor in the development of prevalent 
metabolic diseases such as obesity and NAFLD. Chemokines and its receptors are 
important factors for the interconnection between nutrient excess and derangements 
in immune system. These molecules play a crucial role in the inflammatory process 
through the recruitment of macrophages to metabolically compromised tissues and, 
consequently participate in the course of disease such as obesity, insulin resistance, in 
which inflammation is a key factor of its pathogenesis. For this reason, nowadays, 
chemokines and chemokines receptors have become attractive therapeutic targets. 
Accordingly, the aim of this study was to determine if the metabolic effects of a 
continuous and ubiquitous expression and secretion of CCL2 combined with energy 
surplus can be counteract by the absence of CCR2 (CCL2 receptor). 
Material and Methods 
Animal experimental models 
We carried out this study using the CCL2 transgenic model previously described, and 
designed by our group using standard methods and proprietary technology from 
Ozgene (Bentley, WA, Australia). We also provide data from a novel animal model, a 
double genetically modified mouse, CCL2 overexpressor and CCR2 knockout mice. 
This strain was obtained by inbreeding CCL2 transgenic and CCR2 knockout mice. 
Finally, as controls, we used CCL2 knockout mouse conveniently backcrossed and 
purchased from Jackson Laboratory (Sacramento, CA, USA). They were housed under 
standard conditions and given a regular chow diet and water ad libitum until 
experiments began. To explore dietary effects, at 10 weeks of age, littermates for 
each model were equally and randomly assigned to two dietary groups (n=8); one fed 
with the regular chow diet (Teklad rodent diet; Harlan, Barcelona, Spain) and the 
other fed with a high-fat diet (FuttermittelfurMaüse; SSniff spezial diaten, Soest, 
Deutschland).  
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Sample collection  
Blood was also obtained at the moment of sacrifice and collected into tubes 
containing EDTA. The relevant tissues were removed, flash-frozen and stored at 80°C 
until further analysis. 
Histology 
Microscopic examination was performed on the liver and epididymal adipose tissue. 
Tissues were removed, fixed for 24h in 4% phosphate-buffered formalin at room 
temperature, processed and embedded in paraffin for histological analyses. The area 
of adipocytes was quantified using AnaliSYS software (Soft Imaging System, Munster. 
Germany). The corresponding fractions of the liver were sectioned and stained with 
hematoxylin and eosin and steatosis was evaluated by estimating the percentage of 
area covered by fat droplets. Finally, sections of liver were used to detect F4/80 (rat 
anti-mouse macrophages/monocytes; Serotec, Oxford, UK). Images were acquired, 
and results were analysed with AnaliSYS software.  
Western Blot analysis 
Liver samples were weighted and homogenized in 5 ml/g of lysis buffer (20 mM Tris–
HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% CHAPS, 1 mM Pefabloc and 1% 
phosphatase inhibitor cocktail no. 2, all from Sigma–Aldrich Inc., Steinheim, Germany) 
using the Precellys 24 system (Bertin Technologies, France). Protein concentration 
was determined by 2D Quant kit (GE Healthcare, Piscataway, NJ, USA). After SDS-
PAGE, gels were transferred to nitrocellulose membranes using the iBlot transfer 
system (Invitrogen, Barcelona, Spain). Detection antibodies were rabbit anti-AMPK 
(2532, Cell Signaling Tech., Danvers, MA, USA) and rabbit anti-pAMPK (2531, Cell 
Signaling Tech.) The secondary antibody was goat anti-rabbit-HRP (Dako, Glostrup, 
Denmark). Chemiluminescent detection was performed using the ECL Advance 
Western Blotting Detection kit (Amersham, GE Healthcare, Barcelona, Spain), and 
membranes were analysed in Chemidoc system (Bio-Rad, Madrid, Spain). 
Densitometric quantification of the immunoblotted membranes was performed with 
Image Lab software (Version 2.0 build11, Bio-Rad Laboratories).  
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Statistical analysis 
Data were compared using Mann-Whitney tests. GraphPad Prism 5.03 software 
(GraphPad, San Diego, CA) was used to perform all statistical analyses. Unless 
otherwise indicated, values are expressed in mean ± SEM. A p-value <0.05 was 
considered statistically significant. 
Results 
Effects on body weight, food intake and on adipose tissue 
When mice were fed a regular chow diet we did not observe significant differences in 
body weight increase neither in cumulative food intake among groups. In contrast, 
when fed a high fat diet, CCL2 overexpression induced weight gain and the absence of 
CCR2 in transgenic mice as well as the lack of CCL2 in control mice protects them from 
the development of obesity. There were not any significant differences in food intake; 
hence differences can be attributed to the presence of CCL2 (Figure 1).  
 
 
Figure 1. Body weight gain and cumulative food intake in mice fed either chow diet or high-fat diet. 
*p<0.05 for differences between groups.  
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Overexpression of CCL2 increased the size of epididymal adipose tissue adipocytes, 
independently of the caloric content of the diet. The adipocyte size was higher in 
CCL2 transgenic mice compared with knockout mice. The differences are higher when 
mice were fed a high-fat diet (Figure 2). 
Moreover, at the moment of sacrifice, selected types of adipose tissue depots were 
weighed. When mice were fed the regular diet we did not observe significant 
difference between the strains. However, high caloric intake combined with CCL2 
overexpression resulted in a significant increase of all adipose tissue depots. Knockout 
mice fed a high-fat diet also showed higher adipose tissue weight compared to chow 
diet fed mice but this increase was significantly higher in transgenic animals (Figure 
3).  
The influence of CCR2 absence in dietary manipulations in the liver 
We found no significant differences among strains in the appearance of liver tissue 
when mice were fed a chow diet. However, when mice where fed a high-fat diet, the 
hepatic lipid content correlated with the expression of CCL2, in other words, we 
found significantly high amount of lipid accumulation in the liver of transgenic mice, 
conversely, the absence of CCR2 or CCL2 prevented liver steatosis (Figure 4). 
In addition, we also explored the activating phosphorylation of AMP-activated protein 
kinase (AMPK) (Figure 5). We did not find differences among strains when they were 
fed a regular diet. However, interestingly, the lack of CCR2 or CCL2 combined with a 
high-fat diet induced the activation of this protein. In transgenic mice, values did not 
change as a result of high-fat diet intake. 
Finally, when F4/80 immunostaining was assessed (Figure 6), the number of F4/80 
stained cells was higher in knockout mice than in the transgenic model in both dietary 
interventions. This could represent that the overexpression of CCL2 could affect 
macrophage function and could be related with the differences in the presence of 
liver steatosis. 
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Figure 2. Epidydimal adipose tissue adipocyte size. Representative micrographs are shown for 
transgenic and knockouts animals (A, B and C, respectively) when fed a chow diet (left column) or high-
fat diet (left column). Adipocyte area quantification (D) revealed that CCL2 overexpression increased 
adipocyte size independently of the administered diet. 
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Figure 3. Adipose tissue depots weight in animals fed either chow diet (left column) or high-fat diet 
(right column). Of note, differences among strains were significantly evident with an energy surplus. 
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Figure 4. Appearance of liver tissue. Representative micrographs are shown for transgenic and 
knockouts animals (A, B and C, respectively) when fed a chow diet (left column) or high-fat diet (left 
column). 
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Figure 5. Activation of AMPK in the liver. We did not observe any difference when mice fed chow diet 
(A, C). However, the absence of CCR2 or CCL2 combined with energy surplus activated AMPK by 
increasing pAMPK expression in the liver (B, D).  
 
 
Figure 6. Quantification of macrophage infiltration in the liver. The lack of CCR2 or CCL2 increases the 
number of liver macrophages in both dietary groups. 
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Obesity, described by the WHO as the “epidemic of the XXI”, has become the 
greatest worldwide public health concern [3]. The demographic, economic and 
epidemiological changes, resulting in unfavorable diets and in the decrease of 
physical activity, have driven to globally and alarming increase of its prevalence in 
both adults and children [19].  
The consequences of obesity are many and diverge from higher risk of premature 
death to numerous health disorders such as T2DM, cardiovascular disease, NAFLD, 
some types of cancer, and a number of psychiatric disorders [25, 39]. 
NAFLD is an important comorbidity of obesity and is recognized worldwide as the 
most common cause of chronic liver disease in adults and children and its incidence 
and prevalence are constantly increasing [96, 101]. Furthermore, NAFLD is not a 
simple disease; it includes a spectrum of hepatic abnormalities which extends from 
simple steatosis without inflammation to NASH, a pathological entity associated with 
an increased risk for developing more serious diseases such as cirrhosis, liver failure 
and hepatocellular carcinoma [99]. 
Traditionally, obesity has been associated with NAFLD prevalence. Many studies 
claim that NAFLD prevalence may be greater than 90% in the presence of morbid 
obesity (BMI above 40) [87, 315]. However, this relationship between liver steatosis 
and obesity is not an absolute one. Some studies have shown that, although less 
prevalent than in obese patients, both NAFLD and NASH could be observed in 
individuals with a BMI in a normal range [316, 317]. Moreover, in our morbidly obese 
cohort the degree of steatosis was widely distributed and notably, steatosis was 
predominantly mild. More interestingly, a significant number of patients with 
extreme obesity never developed NAFLD and other liver alterations such as portal 
and/or lobular inflammation and fibrosis were primarily benign. For this reason, we 
aimed to better understand the pathogenesis of NAFLD searching for metabolic 
differences between these two groups, morbidly obese patients with and without 
steatosis.  
The results showed that patients with steatosis presented alterations in the 
metabolism of carbohydrates and lipids and liver damage compared to the group of 
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individuals without steatosis. Accordingly, understanding the pathogenesis of NAFLD 
could be useful to identify biomarkers of disease progression and to clarify the 
effects and limitations of therapeutic regimes. Furthermore, new findings regarding 
the involvement of specific metabolic pathways could provide important potential 
targets for future therapeutic interventions. However, more studies are needed to 
achieve a reduction in morbidity and mortality from this disease. 
Given the risk of progressive liver disease in obese patients, the significant number 
of individuals which are asymptomatic until their liver begins to fail and also the 
association between NAFLD with an increase of all-cause mortality, an early 
prognosis and an accurate diagnosis and staging of the disease has become an 
important health challenge [88].  
Nowadays, although there are no clear recommendations whether liver biopsy is 
necessary to confirm the diagnosis of NAFLD, it still represents the gold standard to 
distinguish the different stages of fatty liver disease. However, it has several 
drawbacks because it is invasive, painful and a costly procedure associated with 
sampling error and variability. Moreover, the high prevalence of NAFLD in the 
general population make liver biopsy unsuitable as a diagnostic procedure, in other 
words, it is not practical to perform liver biopsy in all patients to screen for NAFLD or 
NASH. These shortcomings and limitations of liver biopsy highlight the great need to 
find a non-invasive method for the assessment of NAFLD [142]. 
Some data indicated that the use of some non-invasive imaging technologies such as 
proton magnetic resonance spectroscopy can be useful in the assessment of hepatic 
steatosis and could help to minimize the frequency of liver biopsy. However, the 
uses of these methods are limited by high costs, restricted availability, and morbidly 
obese patients usually did not fit into the apparatus [143, 145, 146].  
On the other hand, liver enzymes, including alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT), are well 
recognized as liver injury markers and these liver biochemistries are performed 
widely. However, in regard to NAFLD these laboratory data remain controversial 
[318-320]. As an example, serum ALT is generally used as the population-wide 
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screening test to diagnose NAFLD. In contrast, Chalasani et al. elucidated that this 
measure is not accurate as patients with NAFLD or even advanced NASH and 
cirrhosis can exhibit ALT levels within the normal ranges [154]. In our study, we also 
corroborated these results; ALT could not differentiate between the different grades 
of steatosis and exhibited the worst performance when it was tested to discriminate 
between patients with or without steatosis. Moreover, despite several years of 
research, there is no clear evidence in the literature that any sophisticated 
algorithms of available biomarker are good enough to avoid liver biopsy [321, 322]. 
For these reasons, a great effort is now being made toward the identification and 
validation of novel biomarkers to assess NAFLD and NASH. 
Metabolomics, the study of part or the entire set of small molecules in a biological 
sample, has emerged as a powerful tool for discovering novel biomarkers. One of the 
most important advantages of metabolomics technologies is that they can be used 
to identify a unique “metabolic signature” of disease through the detection of the 
changes in metabolite levels [160, 323].  
Metabolomics has already identified new biomarkers for prostate cancer [324], 
Parkinson’s disease [325] and type 2 diabetes mellitus among other important 
chronic diseases [326, 327]. Moreover, metabolomics technologies have recently 
provided some important insights into the pathogenesis of NAFLD [328-330]. 
However, these studies had some limitations such as a small sample size and not 
detailed models. 
 
Accordingly, to address the urgent need for identification of novel diagnostic 
biomarkers which could facilitate the diagnosis and the treatment of NAFLD, we 
performed a metabolomics analysis of the plasma comparing obese patients without 
steatosis with their affected counterparts to obtain a comprehensive view of 
changes in several metabolic pathways and to identify disease-related patterns and 
biochemical perturbations.  
Mechanisms responsible for fatty liver are still not fully elucidated but decreased 
capacity to oxidize fatty acids, increased delivery and transport of FFAs into the liver  
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and augmented hepatic fatty acid synthesis are likely to play a significant role in the 
pathogenesis of NAFLD and resulted in acquired mitochondrial dysfunction. 
Mitochondrion plays an important role in hepatocyte metabolism, being the primary 
site for the oxidation of fatty acids and oxidative phosphorylation. NAFLD affects 
mitochondrial metabolism and metabolic pathways which can lead to perturbations 
in citric acid cycle [122]. Our exploratory study showed that lean controls exhibited 
significantly lower a-ketoglutarate plasma levels than obese patients and also the 
values were significantly higher in patients with steatosis compared with those 
without this lipid accumulation. Thus, we proposed plasma a-ketoglutarate as a 
potential diagnostic biomarker with higher predicted accuracy than commonly used 
laboratory tests which resulted not appropriate for clinical decisions. Thereby, 
monitoring mitochondrial function by the quantification of mitochondrial metabolite 
levels provided new insights into NAFLD pathophysiology. 
The handling of fat and/or excessive energy intake not only leads to mitochondrial 
dysfunction but also encompasses the linkage of inflammation to the deleterious 
effects of the continuous excessive food consumption.  
During the last decades, a high number of studies have come out demonstrating that 
immunity and metabolism are closely interconnected owing to inflammation is a key 
factor of the pathogenesis of several metabolic disorders such as obesity, insulin 
resistance and NAFLD [200]. 
Chemokine and their receptors, key mediators of inflammatory and immune cell 
trafficking, are involved in the maintenance of metabolic homeostasis and, 
consequently, have made a name for themselves as pleiotropic molecules involved in 
a range of physiological as well as pathological processes [230]. The importance of 
chemokines and their receptors has been appreciated in the research from multi-
disciplinary backgrounds and the development of new therapeutic agents directed 
against chemokines or their receptors with proven effectiveness in the treatment of 
prevalent diseases [248, 331]. Thus, chemokines and their receptors are poised to 
make substantive impacts as both biomarkers and the basis for novel pharmaceutical 
strategies for human disease. 
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Accordingly, to better understand the pathogenesis of metabolic diseases and to 
propose novel therapeutic approaches, we created a novel animal model which 
overexpresses CCL2 in all tissues to assess the low-grade chronic inflammation in 
response to an excessive energy intake.  
Many studies have demonstrated the role of CCL2 in obesity, diabetes and fatty liver 
due to its influence in the regulation of energy metabolism [252, 267]. Moreover, it 
has been reported the involvement of inflammation in mitochondrial function and 
autophagy [237, 261]. 
Using this model we could corroborate that the overexpression of CCL2 combined 
with a high fat diet predisposes to obesity and causes differences in adipocyte size, 
disturbance in glucose and lipid metabolism, premature death and liver alterations 
such as fatty liver and changes in mitochondria biogenesis and autophagy. 
Moreover, this overexpression affects macrophages function and plasticity. Thus, 
these preliminary data contribute to the knowledge about the relationship between 
inflammation and metabolism and suggested some mechanistic questions for future 
studies as well as possible therapeutic targets such as AMPK and MTOR. These two 
proteins play an important role in energy homeostasis through several pathways and 
could be crucial in the management of prevalent metabolic disorders. 
As stated above, the modulation of the chemokine system arises as an attractive 
target for the treatment of inflammatory diseases. Moreover, studies with mice 
lacking specific chemokine ligand or receptor and/or pharmacological inhibitions of 
them have begun to provide new insights into the consequences of the management 
of diseases with an inflammatory background [231, 266].  
CCL2 or CCR2 deficient mice are less predisposed to develop obesity and its related 
comorbidities; they display an improvement of insulin sensitivity, glucose tolerance, 
adiponectin expression and an attenuated expression of pro-inflammatory markers 
in different tissues. Moreover, the lack of these proteins ameliorated the presence of 
hepatic steatosis although fed a high-fat diet [248, 249]. All these results have driven 
to the development of CCR2 antagonists. 
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Hence, in order to determine if the deleterious metabolic effects caused by a 
continuous and ubiquitous overexpression of CCL2 combined with energy surplus 
could be counteract by the absence of CCR2, we created another animal model. In 
that case mice overexpressed CCL2 but, at the same time, they were CCR2 deficient.  
This novel animal model showed less body weight gain, lower adipocyte size as well 
as less weight of adipose tissue depots. So, the absence of CCR2 prevented the 
development of obesity observed in the CCL2 overexpressor mice. Moreover, the 
absence of CCR2 also ameliorated hepatic steatosis probably by the activation of key 
proteins in energy metabolism such as AMPK and modulating macrophage function. 
So we could conclude that, as expected, all metabolic disturbances observed in the 
overexpressor model could be reverted by the inhibition of CCL2/CCR2 axis biologic 
function.  
All this information could be really important to establish CCR2 modulators as a new 
class of therapeutic agents for the management of prevalent metabolic disease such 
as obesity, diabetes, insulin resistance and NAFLD. Actually, some CCR2 antagonists 
such as INCB-3344, RS-504393, TEI-KO3134 among others, have been patented by 
many companies and many of them are in the last stages of clinical trials with 
promising results [332, 333].  
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ü The metabolic imbalance caused by obesity and NAFLD affects mitochondrial 
function and it can be detected in plasma metabolomics profile. Hence, 
monitoring mitochondrial function via the quantitative evaluation on 
mitochondrial metabolite abundances may be an important new avenue of 
research in obesity-related NAFLD. 
 
ü Plasma a-ketoglutarate as a surrogate biomarker of NAFLD is superior to common 
liver function tests in obese patients. Therefore, the measurement of this 
biomarker may potentiate the search for a therapeutic approach, may decrease 
the need for liver biopsy and may be useful in the assessment of disease 
progression.  
 
ü Overexpression of CCL2 in combination with excessive energy intake leads to a 
wide spectrum of metabolic disorders such as obesity, hepatic steatosis and 
mitochondrial dysfunction and also the manipulation of macrophage plasticity 
and autophagy.  
 
ü CCL2 or CCR2 inhibition could counteract these metabolic abnormalities 
becoming an interesting target for the design of new therapeutic strategies. 
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ORIGINAL ARTICLE
Mapping of the circulating metabolome reveals
α-ketoglutarate as a predictor of morbid obesity-associated
non-alcoholic fatty liver disease
E Rodríguez-Gallego1, M Guirro1, M Riera-Borrull1, A Hernández-Aguilera1, R Mariné-Casadó1, S Fernández-Arroyo1, R Beltrán-Debón1,
F Sabench2, M Hernández2, D del Castillo2, JA Menendez3, J Camps1, R Ras4, L Arola5,6 and J Joven1,6
BACKGROUND: Obesity severely affects human health, and the accompanying non-alcoholic fatty liver disease (NAFLD) is
associated with high morbidity and mortality. Rapid and non-invasive methods to detect this condition may substantially improve
clinical care.
METHODS: We used liquid and gas chromatography–quadruple time-of-ﬂight–mass spectrometry (LC/GC-QTOF-MS) analysis
in a non-targeted metabolomics approach on the plasma from morbidly obese patients undergoing bariatric surgery to gain
a comprehensive measure of metabolite levels. On the basis of these ﬁndings, we developed a method (GC-QTOF-MS) for the
accurate quantiﬁcation of plasma α-ketoglutarate to explore its potential as a novel biomarker for the detection of NAFLD.
RESULTS: Plasma biochemical differences were observed between patients with and without NAFLD indicating that the
accumulation of lipids in hepatocytes decreased β-oxidation energy production, reduced liver function and altered glucose
metabolism. The results obtained from the plasma analysis suggest pathophysiological insights that link lipid and glucose
disturbances with α-ketoglutarate. Plasma α-ketoglutarate levels are signiﬁcantly increased in obese patients compared with
lean controls. Among obese patients, the measurement of this metabolite differentiates between those with or without NAFLD.
Data from the liver were consistent with data from plasma. Clinical utility was assessed, and the results revealed that plasma
α-ketoglutarate is a fair-to-good biomarker in patients (n= 230). Other common laboratory liver tests used in routine application
did not favourably compare.
CONCLUSION: Plasma α-ketoglutarate is superior to common liver function tests in obese patients as a surrogate biomarker
of NAFLD. The measurement of this biomarker may potentiate the search for a therapeutic approach, may decrease the need
for liver biopsy and may be useful in the assessment of disease progression.
International Journal of Obesity advance online publication, 22 April 2014; doi:10.1038/ijo.2014.53
Keywords: biomarker; citric acid cycle; energy; oxoglutaric acid; mitochondria; steatosis
INTRODUCTION
Obesity severely affects human health. The number of adults with
morbid obesity (that is, a body mass index (BMI)⩾ 40 kgm− 2) is
increasing, and the prevalence of obesity (>30% in some
countries) is unacceptably high. Moreover, the incidence of
obesity is increasing among children, and obesity-associated
premature mortality rivals that of smoking.1–4
Morbidly obese patients undergoing bariatric surgery share a
common metabolic background and similar environmental
factors. We assume that possible genetic differences among these
particular obese patients are likely negligible. Non-alcoholic fatty
liver disease (NAFLD) is no longer a benign condition and is now
considered an important co-morbidity in these patients.5–7 The
prognosis is pessimistic because of the risk of progressive liver
disease (for example, non-alcoholic steatohepatitis, ﬁbrosis,
cirrhosis, liver failure and hepatocarcinoma).8 There is a great
need for NAFLD biomarker discovery because it is often difﬁcult to
determine when a liver biopsy is appropriate. A signiﬁcant number
of individuals are asymptomatic until their liver begins to fail, at
which point conventional treatments are useless.
Current laboratory tests are insufﬁcient and unreliable for the
determination of NAFLD presence. Previous estimates using
common liver function tests in the plasma, such as the
determination of alanine aminotransferase levels, suggest that
the prevalence of NAFLD should be nearly 100% in obese
patients.9 Evaluation by proton magnetic resonance spectroscopy
is expensive and is currently being reﬁned,10 and patients of this
size did not typically ﬁt into the apparatus. However, the use of
liver biopsy revealed in our patients that a signiﬁcant portion did
not display fatty inﬁltration of hepatocytes. In this study, we aimed
to better understand NAFLD pathogenesis in obesity and to
identify a non-invasive metabolite biomarker.
We hypothesised that the excess in energy intake alters
anabolic and catabolic functions, especially in the liver, which
may be detected in a plasma metabolomic proﬁle. We used non-
targeted metabolomics to compare obese patients without
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steatosis with their affected counterparts to identify differences
between these groups. We expected numerous and low
differences among the measured metabolites, which may explain
the lack of previous metabolomics-based testing for these
diseases.11 However, post hoc analysis and further quantiﬁcation
resulted in the qualiﬁcation and veriﬁcation of the plasma
α-ketoglutarate concentration as a good indicator of NAFLD in
obese patients.
MATERIALS AND METHODS
Participants
Our local ethics committee approved the study protocol, and written
informed consent was obtained from the participants (EPINOLS/12-03-
29/3proj6). Patients fulﬁlling the criteria established for morbid obesity
(BMI⩾ 40 kgm− 2), for which bariatric surgery was indicated after
numerous failed attempts to lose weight using non-surgical means, were
recruited from the outpatient clinic between 2006 and 2012. We ﬁrst
conducted a non-targeted metabolomic analysis in a limited group of
patients with or without steatosis (n=15 in each group). Steatohepatitis,
ﬁbrosis and hepatocyte injury in these patients were histologically ruled
out. These samples were sent to Metabolon Inc. (Durham, NC, USA) for
analyses. No differences in the quality of life were observed between the
groups, and the selected patients did not consume alcohol or any
prescribed medication that could alter liver function, including vitamin
supplements. The results of these non-targeted preliminary analyses
prompted us to qualify and verify plasma α-ketoglutarate as a candidate
biomarker to identify NAFLD in obese patients. For this purpose, we
recruited 230 patients in which the only inclusion criterion was application
for bariatric surgery, thus including a wide variety of conditions likely to be
encountered in clinical practise. Blood was obtained immediately before
surgery and after clinical nutrition evaluation. Portions of the liver were
obtained during the surgical procedure after patient consultation to
minimise risks and to limit the variability based on location of biopsy.12
Bio-banked samples (n=54) from a group of age- and sex-matched lean,
healthy controls (BMIo24 kgm− 2)13 were used to assess differences in
plasma α-ketoglutarate levels between lean and obese patients. Dietary
advice and standardised overnight fasting were implemented to ensure
uniformity and consistency. Plasma aliquots were anticoagulated with
EDTA and were frozen at − 80 °C within 2 h after collection.
Clinical data and analytic measurements
Relevant data were extracted from clinical records or were obtained using
standardised guidelines and routine laboratory methods.14 The BMI was
calculated as the weight in kilograms divided by the height in metres
squared. Histological alterations in the liver biopsies were evaluated in
sections stained with haematoxylin and eosin. The degree of steatosis was
evaluated using image analysis software and was expressed as percen-
tages (AnalySIS image software system, Soft Imaging System, Munster,
Germany). Patients were considered free of steatosis when values were
⩽ 5%. Patients with steatosis were arbitrarily classiﬁed as mild: 6–30%;
moderate: 31–60%; and severe: >61%.8,15 Portions of the liver biopsies
were also used to measure α-ketoglutarate in tissues from patients with or
without steatosis (n= 6 in each group). The shape and size of mitochondria
were determined in portions of the liver using standard transmission
electronic microscopy (n= 3 in each group).
Non-targeted metabolomic platform
Specimens. Samples outsourced to Metabolon’s laboratory were
extracted upon arrival. The instrument and overall process variability was
4% and 9%, respectively.
Chromatography. Chromatographic conditions have been previously
described.16 In brief, the liquid chromatography–mass spectrometry
(LC–MS, LC–MS2) platform was based on a Waters ACQUITY UPLC (Waters
Technologies, Milford, MA, USA) and a Thermo-Finnigan (San Jose, CA,
USA) LTQ mass spectrometer, which consisted of an electrospray ionisation
source and a linear ion-trap mass analyser. The MS analysis alternated
between MS and data-dependent MS2 scans using dynamic exclusion. The
samples for gas chromatography/mass spectrometry (MS) analysis were
derivatised and analysed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole mass spectrometer using electron impact ionisation.
Metabolites were identiﬁed using a reference library of ~ 2800 standard
chemical entries that included retention times, mass (m/z) and MS or MS2
spectra.
Quantitative measurement of plasma α-ketoglutarate using gas
chromatography–quadrupole time-of-ﬂight mass spectrometry
analysis
Sample pre-treatment. This method was developed in our laboratory.
A surrogate standard was added to maximise technical precision during
the injection and recovery during the extraction procedure. We used
deuterated succinic acid (Isotec Stable Isotopes, Miamisburg, OH, USA)
rather than deuterated α-ketoglutarate, which readily exchanges
deuterium.17 A solution of deuterated succinic acid (25 μl, 2 mg l− 1) was
added to aliquots of plasma that were thawed on ice at 4 °C (50 μl),
deproteinised with 400 μl of methanol, mixed using a vortex (2 min) and
centrifuged (15 000 g, 15 min, 4 °C). The supernatant was dried and stored
at − 80 °C. Samples were derivatised using 30 μl of methoxyamine
hydrochloride in pyridine (30 mg ml− 1) and incubated 1.5 h at 37 °C with
agitation. Then, 30 μl of N-methyl-N-(trimethylsilyl) triﬂuoroacetamide
(Sigma-Aldrich, Steinheim, Germany) was added with shaking and further
incubated in darkness for 1 h before analysis. We found this derivatisation
step to be a reproducible and robust method, independent of the matrix
and without appreciable losses in yield that minimised the loss of
α-ketoacids to decarboxylation.18 A calibration curve of α-ketoglutaric acid
(Fluka, St Gallen, Switzerland) was prepared (0–82.5 μM) immediately
before each assay.
Chromatographic analysis. Samples (1 μl) were automatically injected onto
a 7890A gas chromatograph coupled to a 7200 quadrupole time-of-ﬂight
mass spectrometer (Agilent Technologies, Santa Clara, USA) equipped with a
J&W Scientiﬁc (Folsom, CA, USA) HP5-MS column (19091S-433). Helium was
used as a carrier gas at a ﬂow rate of 1.5 ml min−1 in constant-ﬂow mode.
The oven programme was set at an initial temperature of 70 °C that was
increased to 190 °C at a rate of 12 °C min−1 followed by an increase to 325 °
C at a rate of 20 °C min− 1 and a ﬁnal hold at 325 °C for 3.25 min. Ionisation
was performed using electronic impact with an electron energy of 70 eV and
an emission intensity of 35 μA. Raw data were processed using MassHunter
B.05.00 (Agilent Technologies). Plasma α-ketoglutaric acid was quantiﬁed
using a target ion and was identiﬁed using qualiﬁer ions and the retention
time. The molecular weight of the derivatised molecule, retention time,
quantiﬁer and qualiﬁer ions, relative abundance, recovery, accuracy,
precision and additional pertinent results are provided in Supplementary
Figure S1. The limit of detection was 0.001 μM. Instrumental reproducibility
was 2.2%. Standard curves for the analysis were reproducible and displayed
R2 values of ⩾ 0.99, which indicated linearity over the measured
concentration range; we did not detect carryover.
Statistical analysis
Signiﬁcantly altered metabolites, which were corrected for multiple testing,
were deﬁned using a P-value o0.05 and a predesigned false discovery
rate.19 We performed Welch’s t-tests and/or Wilcoxon’s rank sum tests for
pairwise comparisons. A repeated measurement analysis of variance was
used in some instances. We used multivariate statistics to improve the
reﬁning and distilling of complex raw data and for pattern recognition.
Random Forests is a supervised classiﬁcation technique based on an
ensemble of decision trees.20 This method provides an unbiased estimate
of how well one can predict sample classes in a new data set (prediction
accuracy) and a selection of variables that make the largest contributions
to the classiﬁcation. We also used linear discriminant analysis as a classical
method of classiﬁcation and principal component analysis as an
unsupervised data analysis, which measures the innate variation in data
sets. Ingenuity pathway analysis, which is a web-based functional analysis,
was used to explore biomolecular interaction networks to identify the
signalling and metabolic pathways and to compare the affected pathways.
Fisher’s exact test was used to calculate a P-value to determine the
probability of the association between the metabolites and the canonical
pathway. The network score was based on the hypergeometric distribution
and was calculated using the right-tailed Fisher’s exact test. Logistic
regression analysis and receiver operator characteristic curves described
and assessed the binary classiﬁcation.11,21 The employed statistical
software included the program ‘R’ (http://cran.r-project.org) and the SPSS
18.0 package (IBM, Madrid, Spain).
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RESULTS
Plasma metabolites and obesity-related liver steatosis
Raw data. The baseline characteristics of the selected patients,
raw data and an exhaustive list of the measured metabolites in
untargeted metabolomic analyses are shown in Supplementary
Tables S1 and S2. Most patients were female (73%) and BMI
values ranged between 43.1 and 52.1 kg m− 2. Patients with
steatosis showed signiﬁcantly higher plasma cholesterol and
triglyceride concentrations than those without steatosis. Com-
mon liver function tests revealed higher values in patients with
steatosis, but signiﬁcance was only reached for γ-glutamyl
transpeptidase (Supplementary Table S1). We identiﬁed 316
metabolites of which 38 were signiﬁcantly different between
groups. Finally, 19 metabolites with the highest statistical
difference were chosen using more stringent conditions for
further consideration (Supplementary Figure S2). The relative
abundance of perturbations in amino acids and lipid metabolism
are shown in Figure 1a.
Interpretation. The citric acid cycle is the most important
metabolic pathway for the energy supply and connects most
metabolic pathways. The following alterations support the idea
of defective liver function: (1) the levels of all three branched-
chain amino acids (leucine, isoleucine and valine) were
signiﬁcantly increased in patients with steatosis; and (2) the
levels of branched-chain keto acids (3-methyl-2-oxobutyrate,
3-methyl-2-oxovalerate and 4-methyl-2-oxopentanoate) were
slightly elevated in the plasma from patients with steatosis.
Steatosis may also sequester fatty acids from β-oxidation in liver
cells using an alternative energy source, as shown by signiﬁcant
decreased levels of 3-hydroxybutyrate and a signiﬁcant increase
in the concentration of plasma α-ketoglutarate and succinylcar-
nitine in patients with steatosis. The mechanisms of lipolysis and
gluconeogenesis appear to be affected (Supplementary Figure S3).
Glucose metabolism is also altered in patients with steatosis. The
signiﬁcant decrease in the concentration of plasma 1,5-anhydro-
glucitol in these patients probably indicates long-term higher
hyperglycaemia. In addition, hyperglycaemia-induced oxidative
stress is likely in patients with steatosis, as indicated by the
increased plasma levels of bradykinin and des-Arg9-bradykinin.
The plasma level of the dicarboxylic acid 2-hydroxybutyrate
(α–hydroxybutyrate), which is an early marker for impaired
glucose regulation, was also signiﬁcantly increased. Plasma
glycocholate and taurocholate concentrations were higher in
patients with steatosis, which indicates that the damaged
livers were not functioning properly in the uptake of these
compounds. The excretion of steroids is also limited in liver
steatosis because these compounds are not effectively
sulphated, which was indicated by signiﬁcantly lower plasma
levels of sulphated steroids (that is, 4-androsten-3β, 17-β-diol
disulphate 1, 4-androsten-3β, 17-β-diol disulphate 2, 5α-andro-
stan-3β, 17β-diol disulphate, 5α-pregnan-3β, 20α-diol disulphate,
pregnen-diol disulphate, pregnen steroid monosulphate,
andro steroid monosulphate 2 and 21-hydroxypregnenolone
disulphate).
Figure 1. (a) Heat map of the relative plasma concentration of selected metabolites that may distinguish obese patients with or without
steatosis (green, lower; red, greater). (b) Random (decision) Forest analysis was used as implemented in the R package software as a
framework to create a large number of particular models built around the presence or absence of steatosis.
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Pattern recognition
Random Forest analysis resulted in a predictive accuracy of >80%
to distinguish patients with or without steatosis and revealed
plasma α-ketoglutarate as the primary differentiator in a ranked
list of metabolites in order of their importance in the classiﬁcation
scheme (Figure 1b). The application of linear discriminant analysis
and principal component analysis yielded similar results for
group clustering and pattern recognition (Figure 2), and logistic
regression and receiver operator characteristic analyses produced
a list of possible biomarkers.
Metabolite interaction networks
We uploaded the metabolite lists (with kyoto encyclopedia of
genes and genomes IDs) onto an ingenuity pathway analysis
server to identify the biological pathways and functions of the
biomolecules of interest. The top-associated network functions
were limited to scores of >24. We highlighted networks that were
similar and that shared identical functions, that is, lipid
metabolism, amino-acid metabolism, molecular transport and
small molecule biochemistry. Only tRNA charging (P= 0.0007) and
isoleucine degradation (P= 0.0009) were signiﬁcantly different
among the top canonical pathways. Interactions and regulatory
networks are depicted in Figure 3, which integrates most of the
altered metabolites based on their biochemical relationships in
obese patients with steatosis. These plots indicate that L-glutamic
acid upregulates α-ketoglutarate (2-oxoglutaric acid) and suggest
a role of branched-chain amino-acid transaminase. Predicted
disturbances, which probably result in α-ketoglutarate accumula-
tion in the plasma, are depicted in Supplementary Figure S4.
Figure 2. Model plots constructed using principal component analysis (a and b) and linear discrimination analysis (e and f). Logistic regression
analysis and receiver operator characteristic curves indicated the presence of a pattern for the selection of candidate biomarkers and group
clustering. As shown in the calculations (c, d, g and h), plasma α-ketoglutarate was the most qualiﬁed for this purpose.
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These results indicate a role for mitochondrial dysfunction. Our
preliminary ﬁndings also indicate that in patients without steatosis
the mean diameter of the mitochondria was slightly lower, the
matrix was more electron dense and the crests were more visible
compared with patients with steatosis. More importantly, toroidal
mitochondria were abundant and only observed in non-steatotic
patients and there was a signiﬁcantly higher accumulation of
autophagosomes in patients with steatosis. It is therefore plausible
that the detection of perturbations in the citric acid cycle (CAC)
may facilitate the evaluation of mitochondrial functions in
physiology and disease.22
Plasma α-ketoglutarate as a biomarker
The obtained results identiﬁed and qualiﬁed plasma α-ketoglutarate
as a diagnostic biomarker.23 We calculated, with 95% conﬁdence,
that the true area under the curve of the reported receiver operator
characteristic curve for plasma α-ketoglutarate ranged from 0.90 to
0.96 with a speciﬁcity of 0.93 at a ﬁxed sensitivity of 0.8 (Figure 2).
However, these results were calculated using a low number of
carefully selected patients. To decrease uncertainty or margin of
error in the relevance of these measurements, we extended the
analysis to a broad range of morbidly obese patients (Table 1) in
which the degree of steatosis was widely distributed. Notably,
steatosis was predominantly mild, and the other liver alterations
were primarily benign (Supplementary Figure S5). Approximately
25% of our patients were insulin sensitive, but this condition was
unrelated to the presence of NAFLD. Plasma α-ketoglutarate was
slightly but signiﬁcantly associated with homoeostasis model
assessment values (ρ= 0.25, P= 0.01). We calculated that at least
115 cases would be required to determine whether plasma
α-ketoglutarate outperforms other commonly used biomarkers
using an inferential approach.24 These minimum requirements were
increased to 230 cases to ensure validity in a target group in which
Figure 3. Interaction and regulatory networks associated with steatosis in morbidly obese patients as identiﬁed using the ingenuity pathway
analysis. Plots are depicted for the top-associated network functions (score >24, a and b) and top canonical pathway (c).
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positive and negative outcomes are not equally distributed and in
which the addition of ﬁbrosis and/or inﬂammation may complicate
the interpretation. A signiﬁcant association between circulating
triglycerides and steatosis was observed in these patients (ρ= 0.42,
Po0.001; see also Table 1), which is similar to the association
observed with plasma α-ketoglutarate levels (ρ= 0.49, Po0.001).
Lean controls exhibited signiﬁcantly (Po0.001) lower (1.1 μM
(0.82–1.37)) plasma α-ketoglutarate levels than obese patients
(7.5 μM (5.5–10.8)) without overlap (median (interquartile range)).
The values were also signiﬁcantly higher in obese patients with
steatosis than in those without steatosis, indicating the potential to
discriminate between the different stages in the progression of
these conditions (Figure 4). These differences were also observed in
liver tissue; in samples without steatosis, α-ketoglutarate concentra-
tion was signiﬁcantly (P= 0.017) lower (22.1 μM per 100 mg dry
weight (11.3–31.3)) than in those with steatosis (57.8 μM per 100 mg
dry weight (32.8–63.1)). Among the measured variables, only the
plasma α-ketoglutarate concentration exhibited signiﬁcant agree-
ment with the degree of steatosis, which may differentiate between
mild, moderate and severe steatosis. Although comparisons were
signiﬁcant, data are not shown for severe steatosis because the
number of patients was considered too low to yield relevance. The
area under the curve of the receiver operator characteristic curves
exhibited a fair-to-good clinical utility (Figure 4). Other common
laboratory liver function tests failed to discriminate between patients
with or without NAFLD. Interestingly, the clinically considered ‘gold
standard’, alanine aminotransferase, exhibited the worst perfor-
mance. In contrast, γ-glutamyl transpeptidase performed relatively
well (Supplementary Figures S6 and S7). We subsequently
constructed multivariate models that combined the values of the
available biomarkers, but the performance was lower than plasma α-
ketoglutarate alone. Conversely, the addition of plasma α-ketoglu-
tarate to any of these models improved the performance (Figure 5).
The optimal clinically useful threshold (that is, the plasma
concentration) rather than the mathematically optimal threshold is
difﬁcult to assign. The choice is highly dependent on the intended
use. Ideally, all patients with steatosis should be correctly classiﬁed,
but this may come at the cost that some patients may be incorrectly
classiﬁed as free of steatosis. For example, 8 or 4 μM (which represent
two mathematically possible candidates) yield a similar positive
predictive value (>80%), but 8 μM provides high speciﬁcity (>85%)
and 4 μM provides high sensitivity (>97%).
DISCUSSION
There is currently no clinically useful plasma surrogate for the
assessment of hepatic steatosis in obesity. Multivariate metabolomics
analyses provide meaningful information owing to the simultaneous
global assessment of hundreds of endogenous metabolites in a
biological sample. To perform studies in this context, it is important
to ensure the maintenance of preanalytical aspects. Similar
nutritional status and similar food intake are necessary because
dietary factors have an important role as a causative factor of
NAFLD.25–27 As we predicted, inﬂammation does not appear to be a
prominent factor,28,29 but neither obesity nor NAFLD are simple,
monogenic disorders. Therefore, we chose clinically controlled
bariatric patients who exhibited a similarly high BMI.
The accumulation of lipids in hepatocytes induced a relative
energy deﬁcit, reduced liver function and disturbed insulin
resistance, which is apparently accompanied by an acquired and
reversible mitochondrial dysfunction.30 Our data also partially
support the importance of a newly described mechanism
(lipophagy) that links lipolysis and regulation of intracellular lipid
stores.31 Notably, the deﬁcit in sulphonation that we have
observed in NAFLD patients may be clinically relevant. This is
because phase II drug-metabolising enzymes maintain cellular
homoeostasis via the metabolism of several endogenous mole-
cules that may facilitate metabolic disorders and may result in the
improper management of xenobiotics and endobiotics.32,33 There-
fore, the search for NAFLD diagnostics in obesity should focus on
mechanisms of energy homoeostasis, mitochondrial biogenesis,
fatty acid oxidation and glucose metabolism, which may require
new strategies.34 The results obtained from the plasma analysis
are consistent with those obtained in the livers of different animal
models and human studies, which demonstrate that steatosis is
the cause or consequence of disturbances in hepatic lipid and
glucose metabolism that decreases the ability to obtain
energy.8,25,35,36 The metabolic imbalance caused by obesity and
Table 1. Selected clinical characteristics and laboratory variables in obese patients segregated by the degree of steatosis
Without steatosis (n= 76) Mild steatosis (n=86) Moderate steatosis (n= 52) Severe steatosis (n= 16)
Clinical characteristics
Male, n (%) 8 (10.5) 12 (13.9) 10 (19.2) 4(25.0)
BMI, kgm− 2 47.0 (44.1–51.0) 45.9 (43.2–49.5) 48.1 (44.1–51.1) 44.5 (42.9–47.8)
Laboratory variablesa
Total cholesterol, mmol l− 1 4.0 (3.4–4.9) 4.5 (3.9–5.4) 4.9 (4.2–5.5)b 4.2 (3.5–5.6)
HDL cholesterol, mmol l− 1 0.9 (0.7–1.1) 0.9 (0.7–1.0) 0.9 (0.8–3.4) 0.8 (0.5–1.1)
LDL cholesterol, mmol l− 1 2.4 (1.9–3.0) 2.7 (2.6–3.3) 3.0 (2.3–3.4) 2.6 (1.9–3.0)
Triglycerides, mmol l− 1 1.6 (1.2–1.9) 2.2 (1.6–2.7)c 2.0 (1.7–3.0)b 2.5 (1.6–3.0)
NEFAs, mEq l− 1 1.1 (1.0–1.4) 1.2 (1.0–1.5) 1.1 (0.8–1.6) 1.0 (0.9–1.7)
Glucose, mmol l− 1 7.1 (5.9–8.4) 7.4 (6.2–10.0) 7.9 (7.0–9.8)b 7.6 (6.7–13.4)
Insulin, pmol l− 1 74.6 (41.9–117.6) 79.3 (42.5–122.3) 82.7 (56.8–137.3) 91.5 (40.8–172.2)
HOMA-IR 3.3 (1.9–6.1) 3.9 (2.6–6.1) 3.9 (2.7–8.0) 3.61 (2.02–11.6)
AST, μKat l− 1 0.5 (0.3–0.8) 0.5 (0.4–0.7) 0.9 (0.6–1.1)b,d 1.1 (0.6–2.0)e,f
ALT, μKat l− 1 0.5 (0.4–0.6) 0.4 (0.4–0.7) 0.9 (0.5–1.2)b,d 0.6 (0.4–1.9)
GGT, μKat l− 1 0.2 (0.2–0.3) 0.3 (0.2–0.8) 0.4 (0.3–0.6)b 0.4 (0.3–0.8)e
LDH, μKat l− 1 2.5 (2.2–2.9) 2.7 (2.3–3.3) 3.2 (2.6–4.0)b,d 4.0 (2.8–6.7)e,f
Total bilirubin, mmol l− 1 7.0 (5.0–10.0) 8.0 (5.3–11.8) 8.5 (4.5–11.0) 9.5 (5.8–20.8)
Leptin, ngml− 1 68.5 (55.4–97.5) 73.7 (51.9–97.5) 83.2 (59.5–114.1) 87.8 (75.2–185.4)
Adiponectin, μgml− 1 3.6 (2.4–4.3) 2.6 (1.8–4.2) 2.4 (1.8–3.9) 2.2 (1.6–3.4)
CRP, mg l− 1 6.6 (5.0–10.9) 9.2 (6.7–13.2) 12.7 (8.1–18.5)b 11.4 (5.9–14.4)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, γ-glutamyl transpeptidase;
HOMA-IR, homoeostasis model assessment-estimated insulin resistance; LDH, lactate dehydrogenase; NEFAs, non-esteriﬁed fatty acids. Signiﬁcant differences
(at least Po0.05) in comparisons. aValues are given as median (interquartile range). bWithout steatosis vs moderate steatosis. cWithout steatosis vs mild
steatosis. dMild steatosis vs moderate steatosis. eWithout steatosis vs severe steatosis. fMild steatosis vs severe steatosis.
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NAFLD affects mitochondrial metabolism and metabolic path-
ways, which are important for recycling α-ketoglutarate into and
out of the mitochondrion and allow for the continuous production
of intracellular messengers.37 Finally, it has been recently
described in a model of mitochondrial dysfunction (PINK1
deﬁciency) that increased expression of α-ketoglutarate is the
most prominent and early effect, probably representing a
compensatory mechanism.38
Monitoring mitochondrial function via the quantitative evaluation
of mitochondrial metabolite abundances may be an important new
avenue of research in obesity-associated NAFLD. This is mainly
because CAC metabolites have a central role in catabolic and
anabolic functions (that is, it is amphibolic in nature). As in other
non-communicable diseases, it is most likely adequate to adopt the
view that steatosis is governed by a pivotal regulatory role of
metabolic reprogramming in cell fate decisions.39,40
Plasma α-ketoglutarate levels may distinguish lean controls
from obese patients with a ‘predictive accuracy’ of 100% and
predict obese patients with or without NAFLD better than
commonly used biomarkers. This result supports the potential
clinical utility of plasma α-ketoglutarate levels. However, addi-
tional validation in other patients from an identical target
population is required. Preliminary results in ongoing validation
studies suggest that this novel biomarker deserves further
evaluation and development and that this biomarker should be
added to clinical practise. In addition, pilot studies indicate the
usefulness of performing serial measurements in the same patient,
which do not require high speciﬁcity or sensitivity, to monitor
disease progression and/or the response to treatment. The major
limitation of our results is the conﬁnement to morbid obesity. We
believe this is a blood test that provides a solution for a major
unmet clinical need but implementation of a new biomarker is
difﬁcult and requires validation. Regardless of the attractiveness of
plasma α-ketoglutarate as a biomarker, the high costs of validation
hamper the introduction of new biomarkers and therefore
commercial considerations may ultimately determine the clinical
use.41 However, commonly used laboratory tests do not appro-
priately guide clinical decisions. Imaging studies are also not
possible for patients of this size, and patients do not readily accept
more invasive studies.
Figure 4. The mean plasma α-ketoglutarate concentration was signiﬁcantly lower in lean controls and patients without steatosis (a) and
displayed signiﬁcant agreement with the degree of steatosis (b and c). The area under the curve of the receiver operator characteristic curves
were signiﬁcant, and clinical utility was approximately fair to good; for this purpose, the number of patients with severe steatosis was
considered too low to yield relevance (d).
Figure 5. Multimetabolite biomarker models should provide more
information than a single biochemical measurement, as assessed using
receiver operator characteristic curves. However, predictive scores from
multivariate models that combined several variables were not superior
to plasma α–ketoglutarate alone, as exempliﬁed by the combination
with plasma γ-glutamyl transpeptidase (GGT), which displayed the best
performance of commonly used laboratory biomarkers.
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We also conﬁrmed the potential of metabolomics to inﬂuence
patient care. Metabolomics is designed to delineate biological
processes, and the selection of metabolites for development as
clinical biomarkers should be performed a priori rather than post
hoc. Our results indicate that this approach is not necessarily true
if compound quantiﬁcation follows metabolomics, which is a
strategy that is currently feasible and is not time consuming. This
study successfully utilised a metabolomics approach to provide
new insights into the consequences of NAFLD in obese patients
and supports the possible translational relevance of plasma
α-ketoglutarate as a biomarker of a condition that carries an
enormous burden of disease.
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Table S1. Baseline clinical characteristics and laboratory variables of obese patients with 
or without liver steatosis used for the first nontargeted metabolomics approach.  
 
Values are given as median (interquartile range). ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BMI, body mass index; CRP, C-reactive protein; GGT, γ-glutamyl transpeptidase; LDH, 
lactate dehydrogenase; NEFAs, nonesterified fatty acids.  
  
 Without steatosis 
(n=15) 
With Steatosis 
(n=15) 
p-value 
    
Clinical characteristics    
Male, n (%) 4 (26.7) 4 (26.7) 1.000 
BMI, kg/m
2 
48.2 (44.6-52.1) 44.5 (43.1-46.2) 0.058 
Laboratory variables    
Total cholesterol, mmol/L 3.9 (3.4-4.9) 4.8 (4.3-5.8) 0.013 
HDL-cholesterol, mmol/L 0.9 (0.8-1.0) 0.9 (0.7-1.0) 0.624 
LDL-cholesterol, mmol/L 2.4 (1.7-2.9) 2.8 (2.6-3.4) 0.031 
Triglycerides, mmol/L 1.2 (1.0-1.6) 2.1 (1.6-2.7) 0.019 
NEFAs, mEq/L 1.2 (1.0-1.7) 1.1 (0.8-1.5) 0.296 
Glucose, mmol/L 7.0 (5.6-8.4) 9.2 (7.0-10.7) 0.077 
Insulin, pmol/L 80.2 (67.2-119.2) 58.3 (35.0-152.8) 0.694 
HOMA-IR 4.3 (2.8-7.1) 5.5 (1.8-9.6) 0.963 
Albumin, g/L 35.0 (32.1-38.3) 36.4 (32.4-40.6) 0.457 
AST, mKat/L 0.5 (0.3-0.8) 1.1 (0.6-1.1) 0.064 
ALT, mKat/L 0.5 (0.3-0.6) 0.8 (0.5-1.3) 0.057 
GGT, mKat/L 0.3 (0.2-0.5) 0.8 (0.3-1.1) 0.009 
LDH, mKat/L 2.5 (1.8-2.8) 3.3 (2.6-4.5) 0.064 
Total bilirubin, mmol/L 7.0 (6.0-7.8) 8.0 (6.0-10.8) 0.321 
Leptin, ng/mL 80.2 (53.2-111.3) 78.7 (52.6-90.4) 0.485 
Adiponectin, mg/mL  2.3 (1.6-3.3) 1.8 (1.5-4.1) 0.983 
CRP, mg/L 6.0 (5.0-10.3) 9.3 (5.0-18.3) 0.297 
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Figure S1. Relevant analytical data obtained during the chromatographic analysis of 
plasma a-ketoglutarate, which was quantified using a target ion and identified using 
qualifier ions and the retention time (A). Extracted ion chromatogram of both, 
deuterated succinic acid (as internal standard) and α-ketoglutaric acid (B). Subtracted 
accurate mass spectra of derivatized succinic and a-ketoglutaric acid are also provided 
(C, D). The values for the recovery, accuracy, and imprecision (E) were considered 
acceptable. 
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Figure S4. Predicted disturbances that likely result in the accumulation of α-ketoglutarate in 
the plasma. (A) The isocitrate dehydrogenase (IDH) reaction is carefully regulated to avoid 
the depletion of isocitrate, and, therefore, an accumulation of a-ketoglutarate. The 2-
oxoglutarate or a-ketoglutaratedehydrogenase (ODGH) complex catalyzes the overall 
conversion of α-ketoglutarate to succinyl-CoA and CO2 during the citric acid cycle. 
Succinate-CoA ligase (SUCL) facilitates the flux of molecules into other metabolic pathways 
by controlling the interconversion between succinyl-CoA and succinate. This control is 
important because succinyl-CoA is a necessary intermediate for many biosynthetic 
reactions. The substrates of glutamate synthase (GLS) that are required to produce L-
glutamate are L-glutamine, a-ketoglutarate, NADPH, and H+. Glutathione synthetase (GSS) 
and glutamate-cysteine ligase are responsible for glutathione biosynthesis. Among the 
glutamate sources for glutathione synthesis (B), the transamination of a-ketoglutarate to 
glutamate via alanine aminotransferase is relevant in the presence of liver disease. In this 
reaction, the amino group from alanine is transferred to pyridoxal phosphate to form 
pyridoxamine phosphate and pyruvate. In turn, the pyridoxamine phosphate provides the 
amino group that results in the formation of glutamate from a-ketoglutarate. However, 
glutathione malfunction is unlikely because the circulating amount of associated metabolites 
was similar in both groups of patients (C). Accordingly, we found changes in mitochondrial 
shape and size (n=3), which indicates a higher degree of autophagy in livers with steatosis, 
and the exclusive and frequent appearance of toroidal mitochondria, i.e., the so-called 
“holes”, in patients without steatosis (D). 
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Figure S5. Histological examination of patient livers revealed significant differences among 
obese patients (A). The distribution of steatosis was represented as a percentage of 
patients with a given value of fatty infiltration. The amount of patients without steatosis was 
grouped in one point (≤5; B). The distribution of fibrosis and inflammation is shown in C. 
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Figure S6. The plasma concentrations of selected metabolites from routine laboratory 
measurements in the study population depict differences between patients with and without 
steatosis and differences in arbitrarily considered degrees of steatosis. 
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Excessive energymanagement leads to low-grade, chronic in7ammation, which is a signi^cant factor predicting noncommunicable
diseases. In turn, in7ammation, oxidation, and metabolism are associated with the course of these diseases; mitochondrial
dysfunction seems to be at the crossroads of mutual relationships.[emigration of immune cells during in7ammation is governed
by the interaction between chemokines and chemokine receptors. Chemokines, especially C-C-chemokine ligand 2 (CCL2), have a
variety of additional functions that are involved in themaintenance of normalmetabolism. It is our hypothesis that a ubiquitous and
continuous secretion of CCL2may represent an animal model of low-grade chronic in7ammation that, in the presence of an energy
surplus, could help to ascertain the afore-mentioned relationships and/or to search for speci^c therapeutic approaches. Here, we
present preliminary data on a mouse model created by using targeted gene knock-in technology to integrate an additional copy of
the CCl2 gene in the Gt(ROSA)26Sor locus of the mouse genome via homologous recombination in embryonic stem cells. Short-
term dietary manipulations were assessed and the ^ndings include metabolic disturbances, premature death, and the manipulation
of macrophage plasticity and autophagy. [ese results raise a number of mechanistic questions for future study.
1. Introduction
Excessive energy intake is a part of the current human
lifestyle that leads to a state of chronic systemic low-grade
in7ammation, which is thought to play a role in the develop-
ment of atherosclerosis, cancer, and other noncommunicable
diseases. At the same time, it is also plausible that the long-
term consequences of prolonged in7ammation exacerbate
the deleterious eUects of continuous nutrient surplus [1–3].
[e immune system and metabolism are closely inter-
connected [4, 5]. During in7ammation, the whole body is
undermetabolic stress, and energy excess management could
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compromise the relationships among metabolism, oxidation,
and in7ammation. We reasoned that searching for an ade-
quate animal model [6] might allow us to better understand
disease pathogenesis.
Chemokines are promising candidates for the design
of such a model. Some of the functions of chemokines
are associated with the migration of immune cells, and
chemokines are important for the correct functioning of
metabolism. In humans, C-C chemokine ligand 2 (CCL2;
formerly referred as MCP-1 or monocyte chemoattractant
protein-1) could be a marker of in7ammation; it is overex-
pressed in noncommunicable diseases and is involved in a
variety of metabolic functions [7]. Actually, CCL2 modi^es
lipid and glucose metabolism and contributes to insulin
resistance and hepatic steatosis [8–11]. Of note, circulating
chemokines cause and maintain metabolic disturbances that
may be reversed by anti-in7ammatory drugs, and the role of
chemokines is likely a causal and predisposing factor [12, 13].
Rather than local overexpression [14–17], it is now recognised
that CCL2 protein and mRNA are expressed in the vast
majority of tissues, suggesting both a systemic production
and the ability to respond in situ to in7ammatory stimuli
[18, 19].
[erefore, we hypothesised that challenging an animal
model that systemically overexpresses CCL2 with diets rich
in fat and cholesterol could help to assess the role of chronic
in7ammation in response to excessive energy intake. We
then proceeded to integrate a copy of the Ccl2 gene in the
Gt(ROSA)26Sor (commonly referred to as ROSA26) locus of
themouse genome via homologous recombination in embry-
onic stem cells (ES) to generate targeted transgenic mice [20–
22] that overexpress CCL2 in all tissues. Preliminary data are
promising and suggest a number ofmechanistic questions for
future study.
2. Material and Methods
2.1. Animal Handling. All procedures and experimental pro-
tocols were examined and approved by the Ethics Review
Committee for Animal Experimentation of the Universitat
Rovira i Virgili. Basic protocols for tissue collection, diets,
allocation concealment andmetabolic assessment of themice
have been already described in detail [6, 18, 23]. Strains
were backcrossed >10 generations to C57BL/6J mice and
maintained homozygously. Littermates without mutations
were used as controls (WT). We also provide data from
knockouts (KO) of CCL2 (conveniently backcrossed), which
were purchased from the Jackson Laboratory (Sacramento,
CA). Dietary experiments began at 10 weeks of age, when all
strains display similar phenotypes. To avoid possible eUects of
immature adipocyte modelling, most results were obtained
in diUerent groups amer 6 or 14 weeks of treatment (16 and
24 weeksold, resp.). To explore dietary eUects, mice from
each group were fed either chow (Teklad rodent diet; Harlan,
Barcelona, Spain) or a high-fat diet (Futtermittelfu¨rMau¨se;
SSniU spezial dia¨ten, Soest, Deutschland) and caged indef-
initely under supervision. [e breeding of all experimental
populations was performed in our own facilities, and the
progenies were maintained under close surveillance. [e
animals were not kept under germ-free conditions.
2.2. Targeted Transgenic (TG) Mice. [e transgenic model
was generated via a gene targeted inducible knock-in
(KI), that is, a line with a duplicated gene, approach
using standard methods and proprietary technology from
Ozgene (Bentley, WA, Australia). [e mRNA sequence
corresponding to the mouse Ccl2 gene (NM 011333 and
ENSMUSG00000035385) is located on chromosome 11. [e
gene has 3 exons spread over approximately 3 Kb. [e
gene fragment was obtained from C57BL/6 genomic DNA
(PCR primers AGCAAGATGATCCCAATGAGTAGGC and
GAGGTGGTTGTGGAAAAGGTAGTGG) to be inserted by
gene targeting into the ROSA26 locus. Upstream regulatory
elements are important in the transcriptional regulation of
Ccl2 gene. Human ubiquitin promoter (Ubic) was chosen
for the transgene to produce a high-level of expression.
A loxP-7anked STOP cassette prevents the transcription
of the gene following the UbiC promoter (See Figure 1
and Supplementary Materials S1 and S2 available online
at http://dx.doi.org/10.1155/2013/953841). [e STOP cassette
can be removed using Crerecombinase. PGK-Neo-SD-IS, a
selection cassette, is inserted downstream of the Ccl2 gene
to enrich homologous recombination events. [e ROSA26
locus is conserved between mice and humans. [e location
is autosomal (chromosome 6) and is actively transcribed in
most tissues (Figure 1). Moreover, epigenetic inactivation is
unlikely [21, 24–26].
[e combination of gene targeting and ES cell technology
exploiting homologous recombination provides advantages
over other techniques [27–31] (Supplementary Material S3).
Mice are available upon request.
2.3. Immunopathology Studies and Assessment of Liver Steato-
sis. Portions of organs and tissues were either frozen in
nitrogen or ^xed in 4% phosphate-buUered formalin for 24 h
at room temperature, washed twice with water, stored in 70%
ethanol at 4∘C, and embedded in paraqn for histological
analyses. Primary and secondary antibodies were obtained
from Santa Cruz Biotechnology (Heidelberg, Germany) and
Serotec (Oxford, UK) [18, 32]. Detection was performed with
the ABC peroxidase system (Vector, Burlingame, CA) using
DAB (Dako, Glostrup, Denmark) as the substrate. To assess
speci^city, primary antibodies were omitted in the controls.
Liver steatosis was assessed as previously described [6].
2.4. Laboratory Measurements. We measured murine CCL2
in plasma, serum, and tissues by ELISA (Peprotech, London,
UK), according to the instructions of the manufacturer.
Recombinant humanCCL2 antigenwas used as the calibrator
for assay standardisation, and we found weak cross-reactivity
with other chemokines, especially CCL7. [e intraassay
coeqcients of variation were <3.2%, and the interassay
of variation was <9.1%. Other biochemical measurements
were performed in automated analysers using commercially
available reagents as described [6, 33]. Selected tissues were
homogenised using the Precellys 24 system (Izasa, Barcelona,
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Figure 1: A STOP sequence 7anked by loxP sites was inserted between the Ubiquitin promoter and themouseCcl2 gene (a).[e sequences of
both the STOP cassette (bold) and the loxP sites (underlined) are shown later (b).[e wild-type allele for Ccl2 gene is located in the region 11
C-E1 of chromosome 11 and the transgenic vector (bottom) is inserted in the ROSA26 locus of chromosome 6 (c). [e procedure is designed
to avoid chromosomal instabilities.
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Spain) with pre^lled bead tubes in the buUer of choice.
Fractions of the homogenised liver were immunoblotted as
described [34], using antibodies and reagents from Santa
Cruz Biotechnology (Heidelberg, Germany).
2.5. Transmission Electron Microscopy. Small pieces of the
liver were immediately ^xed in a 2% glutaraldehyde solution
in 0.1M cacodylate buUer, pH 7.4. Samples were then post-
^xed in 1% osmium tetroxide (OsO4) for 2 h and dehydrated
in sequential steps of acetone prior to impregnation in
increasing concentrations of the resin in acetone over a 24 h
period. Semithin sections (500 nm) were stained with 1%
toluidine blue. Ultrathin sections (70 nm) were subsequently
cut using a diamond knife, double-stainedwith uranyl acetate
and lead citrate, and examined using a transmission electron
microscope (Hitachi, Tokyo, Japan).
2.6. Characterisation of Mouse Bone Marrow-Derived
Macrophages. [e methods were performed as previously
described [35]. Bone marrow cells were isolated by removing
leg bones from WT and TG mice (aged 10 weeks) and were
cultured for 24 hours. Floating cells were removed, and the
remaining attached cells were analysed. Cells were further
cultured inDMEM supplemented with 10% inactivated foetal
calf serum, 50 휇M beta-mercaptoethanol, and 1000U/mL
murine granulocyte-macrophage colony-stimulating factor
(GM-CSF) or 25 ng/mL human macrophage colony-
stimulating factor (M-CSF) (ImmunoTools, Friesoythe,
Germany) to provide polarised activation of cells into
M1 and M2 as a simpli^ed descriptor of their functional
plasticity. To assess the eUect of activation, macrophages were
treated with 100 ng/mL E. coli 055:B5 lipopolysaccharide
(LPS) for 24 hours and were compared with the respective
untreated controls. Amer this treatment, supernatants from
M1 (GM-CSF) andM2 (M-CSF)macrophages were tested for
the presence of CCL2, tumour necrosis factor-훼 (TNF훼), and
interleukin 10 (IL-10) using ELISA (BioLegend, Inc., Madrid,
Spain). Total RNA was extracted using the RNeasy kit
(Qiagen, Barcelona, Spain) and was retrotranscribed using
the Reverse Transcription System kit (Applied Biosystems;
Invitrogen, Barcelona, Spain). Oligonucleotides for selected
genes were designed according to the Roche somware for
quantitative real-time PCR (Universal Probe Roche library),
which was performed using a LightCycler 480 (Roche
Diagnostics, Barcelona, Spain). [e assays were performed
in triplicate, and the results normalised according to the
expression level of TATA-binding protein mRNA. C-C
chemokine receptor type 2 (CCR2 or CD192), TNF훼, inhibin
beta A (INHBA), inducible nitric oxide synthase (iNOS),
C-C chemokine receptor type 7 (CCR7), and Egl nine
homolog 3 (EGLN3) were chosen as M1 markers. Arginase
(ARG), EMR1/F4/80, insulin growth factor-1 (IGF1), IL-10,
the mannose receptor CD206, and growth arrest-speci^c 6
(GAS6) were chosen as M2 markers.
2.7. Statistical Analyses. [e normality of the distribu-
tions was assessed using the Kolmogorov-Smirnov method.
Variables were compared using Mann-Whitney tests or
Kruskal-Wallis one-way analysis adjusted for multiple test-
ing. Unless otherwise indicated, the values in the ^g-
ures represent the mean and SEM obtained in groups
of 8 mice. [e 휒2 test was used to compare categori-
cal variables. For all measurements, we used either SPSS
(SPSS Inc., Chicago, IL) or GraphPad Prism somware
(http://www.graphpad.com/scienti^c-somware/prism/).
3. Results
3.1. Targeted Transgenic Mice Do Not Display Physical Abnor-
malities. [e resulting mice for the targeted mutation are
viable, fertile, and normal in size and weight. [e animals do
not display apparent behavioural or reproductive defects.[e
transgene insertion of a single copy occurs at a de^ned site,
which allows for easy genotyping (Figure 2) and eliminates
possible instabilities, independent segregation during breed-
ing, and unpredictable positions in the chromosomes.
An additional advantage of this strategy is the Cre/lox
recombination system that facilitates tissue-speci^c overex-
pression. [e Ubic is conditioned by an Lox-Stop-Lox (LSL)
element that is activated by Cre-mediated excision using the
appropriate, tissue-speci^c Cre strain.
3.2. Transgenic Mice Overexpress CCL2 in Selected Tissues,
and Circulating Protein Is Increased with respect to Controls.
Consistently, transgenic mice displayed more CCL2 protein
in all tissues examined with respect to WT animals. [e
diUerences increased with age, and there were minor rela-
tive diUerences among tissues (Figure 3). We con^rm that
CCL2 was immunologically detected in all selected tissues
of the transgenic mice. [e CCL2 mRNA expression in the
transgenic mice was also higher in diUerent types of cells
with respect to WT mice. [e amount of CCL2 expression
was higher amer the designed period of exposure to a diet
with a high fat content. Of note, the serum and plasma
CCL2 were also higher in transgenic mice than in WT mice,
which is most likely caused by CCL2 secretion by multiple
tissues. In accordance with previous observations, the plasma
concentrations diUered from the serum concentration. [e
diUerences are likely caused by coagulation and handling, but
the diUerences were not statistically signi^cant in transgenic
mice. Notably, CCL2 was also detected in KO mice, but with
less intensity. [is is most likely due to quantitatively minor
cross reactivity, as described in the methods.
3.3. Dietary Factors Induence Body Weight and Adipocyte
Size. When mice were fed a regular chow diet, we did
not observe signi^cant diUerences in body weight increase
among groups. [e cumulative food intake was identical for
the three strains examined. In contrast, when fed a high fat
diet, both transgenic animals and WT animals developed
obesity. Of note, the C57BL/6J male mouse is a commonly
used model of diet-induced obesity [36]. [e eUect of CCL2
overexpression was apparent immediately amer the ingestion
of the high calorie diet, and the weight increased more
rapidly than in WT mice. [e absence of CCL2, however,
protected theKOmice from excessiveweight gain.[e lack of
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Figure 2: Simpli^ed strategy for genotyping that includes the sequence of each primer (a), the reaction proposed for each primer (b), and the
expected PCR products for each strain (c). [e method is designed for the concomitant use of all primers and a representative gel is shown
in (d).
signi^cant diUerences in the food intake excluded any eUect
of CCL2 on appetite (Figure 4).
Overexpression of CCL2 also increased the size of the
adipocytes. Data are presented for epididymal adipose tissue
(Figure 5), but the eUect was similar in other adipose tissues.
[e adipocyte size was signi^cantly higher in CCL2 trans-
genic animals compared with WT and KO animals fed with
both diets, but the diUerence was higher when mice were
fed a diet with a high caloric content. When diUerent types
of adipose tissue were weighed, we found that the mice fed
a chow diet showed no signi^cant diUerences between the
strains, with the possible exception of inguinal tissue. Con-
versely, the addition of fat to the diet resulted in a signi^cant
increase in the weight of white adipose tissue from other
depots inmice with CCL2 overexpression. Notably, there was
no eUect on the weight of brown adipose tissue (Figure 6
and Supplementary Material S4). However, these diUerences
among groups in adipose tissues weight disappeared when
mice were fed with a high fat diet for 14 weeks. [ese results
are probably indicating an already reported eUect of adipose
tissue remodelling on the consequences of high-fat dietary
intake [37] (Supplementary Material S5).
3.4. Diet-Induced Disturbances in Glucose and Lipid Metabo-
lism. Glucose tolerance tests (a proxy for insulin resistance)
were unaUected in strains fed the chow diet during the
experimental period of 6 weeks. However, WT littermates,
KO, and transgenic mice displayed abnormal values when
fed a high-fat diet, con^rming the eUect of diet in the patho-
genesis of insulin resistance and suggesting that this short-
term intervention is not adequate to investigate a possible
role, if any, of CCL2 in the generation of glucose and lipid
disturbances. Moreover, there were no diUerences among the
strains in the plasma glucose levels amer 6 hours of fasting,
and amer 3 hours in the fasting state, we found that the plasma
glucose baseline concentrations were signi^cantly higher in
CCL2 overexpressing mice with respect to CCL2 de^cient
animals. [is eUect was more evident in the transgenic
mice (Supplementary Material S6) but diUerences in plasma
glucose disappeared amer 14 weeks of dietary treatment
suggesting immature adipose tissue remodelling [38].
When these tests were performed in animals fed a high-
fat diet for a longer experimental period of 14 weeks in which
adipose tissue is already well modelled, the lack of diUerences
in insulin tolerance was maintained, probably indicating that
the eUect of CCL2 overexpression in the pathogenesis of
insulin resistance is negligible.
However, results in the absence of CCL2 indicate that this
chemokinemaymodify glucosemetabolism and therefore we
cannot discard the eUects under a more intense metabolic
stress [9]. Variations in plasma cholesterol and triglycerides
concentrations were minimal among the strains at 16 weeks
old. A high-fat diet signi^cantly increased the amount of
circulating cholesterol, an eUect that was higher in CCL2
overexpressing mice. Conversely, there were unexpected,
and most likely not representative, changes in the plasma
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Figure 3: Overexpression of CCL2 with respect to wild type and knockout was observed in all selected tissues (extracts) in the transgenic
mice as measured by ELISA. DiUerences were also observed in plasma and serum and there was cross-reactivity with similar chemokines that
could explain the detection of CCL2 in KOmice (a). CCL2 was also detected by immunochemistry in diUerent types of cells (b). ∗푃 < 0.005;
Micrographs in the lem column are representative for liver, pancreas, and kidney. [ose in the right column were for brain, intestine, and
stomach.
triglycerides concentration of these mice as a consequence of
dietary manipulations (data not shown).
3.5. fe Induence of CCL2 and Dietary Manipulations in
the Liver. When fed the chow diet, mice did not display
signi^cant diUerences among strains in the appearance of
their liver tissue.[e steatosis scores did not detect signi^cant
diUerences among strains, although some minor variations
were detected (Figure 7) that did not correlate with the
hepatic lipid content (data not shown). When mice were
fed a high-fat diet, we found a certain amount of lipid
accumulation in WT mice, but this lipid accumulation was
signi^cantly more evident in transgenic mice. Conversely,
there was no accumulation of lipids in KO mice (Figure 7).
[erefore, the eUect of CCL2 under these conditions is
directly related to the amount of tissue CCL2 disposal; the
absence of CCL2 prevents liver steatosis, and overexpression
of CCL2 predisposes the liver to steatosis. We also found that
the expression of fatty acid synthase in the liver increased
signi^cantly in all strains when fed a high-fat diet, but there
were no signi^cant diUerences in the comparisons between
transgenic and KO mice. We also explored the activating
phosphorylation of AMP-activated protein kinase (AMPK),
and values did not change as a result of high-fat diet in
transgenic mice and were signi^cantly higher in KO mice
comparedwith transgenicmice (SupplementaryMaterial S7).
When the livers were examined for the presence of F4/80
antigen, a widely accepted marker of macrophages, we found
that both dietary fat and overexpression of CCL2 modify the
size, number andmorphology of liver macrophages (Figure 8
and Supplementary Material S8). Of note, F4/80 stained
cells were more frequent in KO mice, a ^nding that merits
further study because these results could represent a change
in function and could be responsible for the diUerential
eUects of CCL2 in liver steatosis. We then explored the
in7uence of both CCL2 and diet inmitochondrial biogenesis.
Based on the appearance of the matrix, the mitochondria
are healthier in mice fed a chow diet than in those fed a
high-fat diet. [e matrix was also consistently less electron-
dense in transgenic mice. We also found altered fusion
dynamics. In transgenicmice fed a chow diet, the process was
unbalanced towards mitochondrial fusion, but the dietary
manipulation signi^cantly elicited a shim towards ^ssion.[e
changes were similar in WT mice, but the eUect of diet was
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Figure 4:[e eUect of high-fat diet in body weight increase was evident in transgenic and wild-type mice ((a), (b)), but the diUerent increase
was immediate amer dietary manipulation in transgenic.[is eUect was negligible in knockout mice (c).[e combination of these eUects with
high-fat diet (d) shows similar results to facilitate comparison. [ese ^ndings are not due to diUerences in the cumulative food intake ((e),
(f)) indicating that CCL2 probably has no eUect on appetite. ∗푃 < 0.05.
quantitatively less evident than in transgenic mice. In KO
mice, however, there were more mitochondria per cell, and
fusion and ^ssion were correctly balanced and apparently not
altered by diUerences in diet. [ese ^ndings strongly support
further mechanistic studies, which may link the expression
of CCL2 with mitochondrial biogenesis, in7ammation, and
energy management. According to our results, these putative
mechanisms are related to the autophagic response, which
was clearly enhanced in transgenic mice. Conversely, most
liver cells inWT and KO displayed no evidence of autophagy
(Figure 9).
3.6. Transgenic Mice fat Overexpress CCL2 Die Prematurely
When Fed High-Fat Diet. [e transgenic mice fed a high-
fat diet died prematurely between 10 and 14 months. [e
mice progressively decreased activity, reduced food intake
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Figure 5: [e size of the adipocytes was signi^cantly higher in transgenic mice than in wild-type and knockout mice and the eUect was
observed with both dietary interventions regardless of the duration of the dietary treatment (6 or 14 weeks) (a) but it was more intense
when mice were fed a high-fat diet. For clarity, values are indicated only for adipocytes in epididymal white adipose tissue. Representative
micrographs are shown for transgenic, wild-type, and knockout animals ((b), (c) and (d), resp.)when fed a chowdiet and for the corresponding
animals fed a high-fat diet ((e), (f), (g)) at 16 and 24 weeks’ old.
and the appearance of frailty became evident. [ere was also
a casualty in the transgenic mice fed chow diet, but it was
sudden, unexpected, and without a prior decrease in weight
or activity. Among the casualties, one was also observed in
the WT group fed a high-fat diet (Supplementary Material
S9). A full autopsy was performed, and the cause of death
was uncertain. [ere was neither cancer nor arteriosclerosis
in these animals, but there were some cutaneous, super^cial,
and localised lesions in the skin accompanied with local
loss of hair. [ere was also no evidence of sepsis. [e only
remarkable ^ndings were limited to the spleen and the liver.
[e size and weight of the spleen was consistently higher
in the transgenic mice fed high-fat diet. [e presence of
splenomegaly in these transgenic mice was consistent with
the presence of giant cells that were identi^ed as megakary-
ocytes (Factor VIII positive staining) and other proliferative
signs.[eweight of the liver was also higher in the transgenic
mice, which is most likely due to the higher presence of
steatosis. In the liver, there were signs of regenerative cells
and increased apoptosis. Ongoing studies with higher sample
sizes and the inclusion of females have been designed to
further ascertain this point.
3.7. Bone Marrow Macrophages of Transgenic Mice: Expres-
sion of Selected Cytokines and mRNA. [e CCL2 mRNA
expression in the bone marrow macrophages was higher
in transgenic than in WT mice, irrespective of stimulation
with either GM-CSF (M1, pro-in7ammatory) or M-CSF
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Figure 6: [e eUect of CCL2 expression in the weight of adipose tissue ((a)–(d)) of animals fed either chow (lem column) or high-fat diet
(right column). Of note, diUerences among strains were more evident during energy surplus and no change was observed in brown adipose
tissue.
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Figure 7:We found no signi^cant diUerences among strains in the appearance of liver tissue whenmice were fed a chow diet (lem column (a),
(c), (e); transgenic, wild-type, and knockout mice resp.). Representative micrographs show in the right column that a high fat diet produces
steatosis in transgenic mice (b), dispersed lipid droplets in the liver of wild type mice (d), and no change in knockout mice (f).
(M2, phagocytic). [e mRNA expression of the selected
M2 markers was similar, with either low or undetectable
expression in the GM-CSF macrophages without diUerences
between transgenic and WT mice. [e expression of the
selected M1 markers was practically identical in the GM-CSF
macrophages fromTG andWTmice, with the notable excep-
tion of CCR7. Surprisingly, the expression of this chemokine
receptor was signi^cantly lower in TGmice, indicating lower
pro-in7ammatory activity. [e expression of the M1 markers
in M-CSF macrophages showed a unique and signi^cant
decrease in CCR2 mRNA expression; however, some M2
markers, including CD 206, GAS6, and IGF1, were also
underexpressed. IL-10 expression also decreased, but the dif-
ferences were not statistically signi^cant. [e results suggest
that CCL2 overexpression may alter macrophage polarisa-
tion. Consequently, the secretion of selected cytokines was
examined in macrophages that were treated with LPS and
were compared with the relevant controls. [e CCL2 secre-
tion was higher in TG mice with both treatments compared
with theWTmice and was 2–4 fold higher (2–4-fold change)
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Figure 8: Dietary fat (right column) and CCL2 expression modify the size, number, and morphology of liver macrophages with respect to
those fed a chow diet (lem column) as assessed with F4/80 staining. Values for stained area and length of macrophages ((a)–(d)) are illustrated
with representative microphotographs from transgenic ((e), (f)), WT ((g), (h)) and KO mice ((i), (j)).
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Figure 9: [e appearance of mitochondria was aUected by the dietary manipulation and the expression of CCL2 as shown in
representative microphotographs (a) and these changes were accompanied by a signi^cant eUect in fusion-^ssion balance (b). [e number
of autophagosomes per cell was counted and was signi^cantly higher in transgenic mice. Further, these were rare in both WT and KO and
independent of diet (c). [e heterogeneous nature of autophagic elements is illustrated in (d) (photographs obtained in transgenic mice).
in M-CSF macrophages. [e IL-10 secretion was clearly
detectable only in LPS-treated animals. [e concentration
in the supernatant was higher in TG than in WT mice,
and the diUerences were statistically signi^cant in GM-CSF
macrophages. Finally, TNF훼 secretion was ostensibly higher
in LPS-treated animals and signi^cantly higher in TG mice
with respect to the relevant controls (Figures 10 and 11).
4. Discussion
[e transgenic mice developed in this study systemically
overexpress CCL2. [ese animals were created to assess the
combined eUect of the recruitment of circulating monocytes
in all tissues and the response to the stimuli of high dietary fat
and energy ingestion.[e hypothesis was that the continuous
overexpression of this chemokine could promote or worsen
common pathological conditions, and as animal model could
be useful for assessing the pathogenic mechanisms and
therapeutic approaches [39].
Fertility, growth, and physical appearance were identical
to the controls. CCL2 overexpression did not result in
abnormalities in the mice that were fed a regular chow diet.
However, adding fat to the diet during a short period of
time caused diUerences in body weight, adipocyte size, dis-
turbances in glucose and lipid metabolism, premature death,
and liver alterations that included a higher predisposition to
fatty liver disease and signi^cant changes in mitochondrial
biogenesis and autophagy. Additionally, we explored bone
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
Mediators of In7ammation 13
M1 markers M2 markers
GM-CSF M-CSF GM-CSF M-CSF
F
o
ld
 c
h
an
ge
 i
n
 C
C
R
2 
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
C
R
2 
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 A
rg
in
as
e
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 A
rg
in
as
e
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 E
M
R
1
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 E
M
R
1
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
G
F
1
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
G
F
1
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
L
-1
0
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
L
-1
0
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
D
20
6
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
D
20
6
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 G
A
S6
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 G
A
S6
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 T
N
F
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 T
N
F
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
N
H
B
A
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 I
N
H
B
A
m
R
N
A
 e
xp
re
ss
io
n
Wild type
F
o
ld
 c
h
an
ge
 i
n
 i
N
O
S
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 i
N
O
S
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
C
R
7
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
C
R
7
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 E
G
L
N
3
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 E
G
L
N
3
m
R
N
A
 e
xp
re
ss
io
n
CCL2 transgenic
Wild type
CCL2 transgenic
2.0
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
4
3
2
1
0
4
3
2
1
0
5
4
3
2
1
0
5
4
3
2
1
0
40
30
20
10
0
40
30
20
10
0
6
4
2
0
6
4
2
0
9
6
3
0
9
6
3
0
10
8
6
4
2
0
10
8
6
4
2
0
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
3
2
1
0
3
2
1
0
6
4
2
0
6
4
2
0
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
∗
∗
∗
∗
∗
∗
∗∗
Figure 10: Relative mRNA expression in transgenic mice with respect to WT mice of selected markers for M1 and M2 macrophages in
cells treated in vitro with either GC-MSF or M-CSF. Acronyms used were C-C chemokine receptor type 2 (CCR2), TNF훼, Inhibin, beta A
(INHBA), inducible nitric oxide synthase (iNOS), C-C chemokine receptor type 7 (CCR7), Egl nine homolog 3 (EGLN3), Arginase (ARG),
EGF module-containing mucin-like hormone receptor EMR1 (F4/80), insulin growth factor-1 (IGF1), IL-10, the mannose receptor CD206,
and Growth arrest-speci^c 6 (GAS6).
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
14 Mediators of In7ammation
2.0
1.5
1.0
0.5
0.0
(a)
(b)
(c)
2.0
1.5
1.0
0.5
0.0
F
o
ld
 c
h
an
ge
 i
n
 C
C
L
2 
m
R
N
A
 e
xp
re
ss
io
n
F
o
ld
 c
h
an
ge
 i
n
 C
C
L
2 
m
R
N
A
 e
xp
re
ss
io
n
GM-CSF M-CSF
CCL2 transgenic
Wild type
CCL2 transgenic
Wild type
∗
GM-CSF
WT
40
30
20
10
0
WT TG TG WT TG
2500
2000
1000
1500
500
0
30
25
20
15
10
5
0
IL
-1
0 
(n
g/
10
6
ce
ll
s)
C
C
L
2 
(n
g/
10
6
ce
ll
s)
∗
∗
∗
T
N
F
훼
(n
g/
10
6
ce
ll
s)
∗∗∗
WTWT TG TG
40
30
20
10
0
C
C
L
2 
(n
g/
10
6
ce
ll
s)
∗
Untreated
LPS
Untreated
LPS
WT TG
30
25
20
15
10
5
0
T
N
F
훼
(n
g/
10
ce
ll
s)
Untreated
LPS
∗∗
2500∗∗
2000
1000
1500
500
0
IL
-1
0 
(n
g/
10
6
ce
ll
s)
M-CSF
Figure 11: [e relative CCL2 mRNA expression (a) and the secretion in supernatants of selected cytokines in bone marrow-derived
macrophages of transgenic and WT cells treated in vitro with either GC-MSF (b) or M-CSF (c).
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marrow macrophages under diUerent in vitro conditions,
and we found that CCL2 overexpression aUects functional
plasticity.
In previous studies, CCL2 has been considered a
chemokine secreted by adipose tissue (adipokine), but sys-
temic CCL2 overexpression regulates white adipose tissue
(WAT) mass and size without apparent eUects in brown adi-
pose tissue (BAT). WAT serves primarily as lipid storage, and
BAT is used for heat generation.[e balance between the two
adipose tissues aUects the whole-body energy homeostasis,
and the development and severity of obesity [40]. A higher
production of CCL2 is not only a consequence of obesity
but is most likely an exacerbating factor of diet-induced
alterations. [e roles of CCL2 in the aetiology of obesity
and diabetes, the regulatory mechanisms, and the eUect of
therapies that inhibit CCL2 production have been recently
reviewed [4, 41]. We have also found diUerences between fat
cells in diUerent adipose tissue depots and the heterogeneity
of adipocytes within the same depots. Further examination
of this issue is necessary because a diUerent pattern of gene
expression could explain the diUerential development of
various types of adipose tissue [42, 43]. Moreover, this is
closely associated with the pattern of fat distribution, the
extent of obesity, and consequently the impact of diUerent fat
depots on the severity of metabolic complications [44, 45].
[e size and number of hepaticmacrophages signi^cantly
diUers between transgenic and KO mice when detected
with antibodies directed against F4/80. Curiously, this is an
extracellular antigen of unknown function that belongs to
a subgroup of the G-protein-coupled receptors [46]. [e
changes in macrophages morphology could represent con-
comitant changes in function and whether the macrophages
are resident or recruited. [is is further substantiated by the
fact that these transgenic mice were prone to develop fatty
liver disease and the KO mice were protected. [e role of
increased CCL2 is not yet understood, but the recruitment
of macrophages seems to be important in diUerent animal
models. In KO mice there is an increased expression of
peroxisome proliferator-activated receptors accompanied by
the induction of fatty acid metabolism-related genes and the
inhibition of pro-in7ammatory cytokine production [47–49].
We con^rmed that the eUect of fat in the pathogenesis of fatty
liver disease [49, 50] is in7uenced by the amount of available
CCL2 and that the linkage between chemokines and hepatic
lipid metabolism is plausible.
[e characterisation of bone marrow-derived cells in the
transgenic mice indicates that CCL2 overexpression aUects
the transition in the secretory function of macrophages
(or the M1-M2 paradigm as a simpli^ed descriptor of the
functional plasticity). [is is illustrated by diUerences in
GM-CSF and M-CSF, which are cytokines that diUerentiate
macrophages in vitro with distinct morphology and in7am-
matory function [51, 52]. [e modulation of the phenotypic
and functional diUerences in macrophage polarisation by
CCL2 overexpression denotes a shim towards lower pro-
in7ammatory activity [53]. CCL2 decreased the expression
of CCR7 in M1 and decreased the expression of CCR2, IGF1,
CD206, IL-10, andGAS6 inM2. In cells under LPS treatment,
however, CCL2 overexpression increased the secretion of
IL-10 and TNF훼 with respect to WT controls. [ese changes
could represent a quantitatively determinant factor in the
development of macrophage-induced metabolic alterations.
It should be highlighted that a high percentage of total
body resident macrophages are present in the liver and that
adipose tissue is amajor site for the accumulation of recruited
macrophages [54, 55].
Notably, CCL2 is involved, directly and/or through the
induced metabolic alterations, in mitochondrial biogenesis
and autophagy.We addCCL2 to the growing list of nonessen-
tial regulators of mechanisms that divide and fuse mitochon-
dria [56]. [e balance between rejuvenation and elimination
of damaged mitochondria via autophagy is aUected by both
the presence of CCL2 overexpression and the increased
availability of energy.[e antagonistic and balanced activities
of the fusion and ^ssionmachineries are constantly providing
responses to in7ammation to tightly regulate homeostasis of
the organism [57, 58].[is is expected becausemitochondrial
diseases are associated with metabolic alterations. Appar-
ently, there is a shim towards fusion in CCL2 overexpres-
sion to maximise ATP synthesis. Contrarily, morphological
^ndings in CCL2 de^cient mice, which are independent of
high-fat diet, suggest a perfect balance [59, 60]. A certain
unbalance is expected in in7ammatory conditions and other
energy-dependent disturbances via mitochondrial dysfunc-
tion [61, 62]. [is is important because mitochondria and
the access to energy (calorie restriction or increased dietary
fat) play a pivotal role mediated by the mechanistic target of
Rapamycin (MTOR) in decidingwhether liver cells live or die
[63].
In transgenic mice, autophagy was increased with respect
to WT and KO mice, which is particularly important
because autophagy aUects immune responses as a result of
degradative, biogenetic, and secretory activities that respond
to various inputs via MTOR [64, 65]. Autophagy might
control the infection of certain pathogens but also prevents
excessive in7ammatory reactions in the host [66]. As shown
in autophagy-de^cient macrophages, autophagy removes
a number of proin7ammatory stimuli [67–69]. [erefore,
increased liver autophagy during CCL2 overexpression could
be interpreted as an eUort from the host to avoid the
deleterious action of continuous in7ammation.
Links between autophagy and in7ammation have also
been found in immune functions aUecting several diseases,
opening a new dimension in the understanding of the mul-
tifactorial basis of noncommunicable diseases. For example,
increasing macrophage autophagy protects patients with
advanced atherosclerosis [70]. It has also been reported that
CCL2 controls the extent of autophagy in human prostate
cancer [71], and autophagy is pivotal for the survival and
diUerentiation of monocytes [72].
Finally, CCL2 overexpression resulted in premature death
when combined with a high-energy intake. [ese ^ndings
require more extensive examination, and the cause of death
remains obscure. Mice progressively lost interest in the envi-
ronment, reduced activity, and their intake of food decreased.
No chronic disease was evident, and there were no signs
of sepsis or major infection. It is tempting to consider the
possibility of premature aging, and future investigations will
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include the characterisation of a senescence-associated secre-
tory phenotype, particularly in pro-in7ammatory cytokine
enrichment [73] and the pro-in7ammatory phenotype that
accompanies aging [74, 75].
5. Conclusions, Perspectives, and Limitations
[is animal model raises a number of questions about the
prevalent diseases responsible for limiting the quality of
modern life. Additionally, this model provides a link between
in7ammation and metabolism and suggests targets for the
management of diseases in which there is a clear CCL2 over-
expression. Speci^cally, this model can help to uncover the
role of CCL2 in mitochondrial dysfunction, autophagy, and
functionality of macrophages and aging in combination with
excessive energy intake. Information gained could be useful
for designing new mechanism-based therapeutic strategies.
None of the described eUects appear in mice that are
fed a regular diet, and this fact highlights the importance of
calorie restriction for health. [erefore, the nutrient-sensing
MTOR pathway seems to be crucial for the management
of noncommunicable diseases. Consequently, drugs mod-
ulating MTOR are obvious candidates for assessment. For
example, experiments on cancer, aging, and viral infections
strongly suggest that this is the case for metformin [76–
78]. [is antidiabetic drug activates AMPK and inhibits
MTORwith potent antiin7ammatory actions.[e usefulness
of rapamycin, an MTOR inhibitor, and similar drugs in
cancer prevention has been assayed [79]. Aspirin decreases
in7ammation, inhibits the MTOR pathway, decreases cancer
incidence, and may reduce the burden of atherosclerosis
[13, 80]. Lastly, although studies are scarce, angiotensin-
II-blockers and beta-blockers, widely used in hypertensive
patients, can also prevent the activation of the MTOR
pathway and the incidence of chronic diseases [81].
[e potential indications for these drugs are mostly
related to chronic diseases in which in7ammation plays a
crucial role.[is animalmodel could be used to further select
candidates and suggests a number of mechanistic questions
for future study. Particularly, we consider this model as a
valuable contribution to our evolving comprehension of the
interphase between autophagy and in7ammation. However,
we acknowledge that care must be taken in analysing the
results of studies performed in animal models and that
further research eUort is necessary to fully characterize our
observations. To name a few, possible eUects of sex should
be studied and metabolic alterations should be con^rmed
with the use of metabolic cages and more speci^c methods
to detect signi^cant diUerences. Particularly, CCL2 may have
a higher in7uence if there is a relative contribution from
diUerent type of cells, particularly from immune cells [72].
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A, displays a schematic view of human CCL2 gene region that includes its regulatory region 
and the most prominent elements identified. The Ccl2 gene transgenic vector includes the 
murine CCL2 gene and the comparative position of human ubiquitin promoter (B); sequence is 
provided in C. 
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Supplementary material S2, details of the sequence of other main elements used in 
the construction of the vector, corresponding to the manuscript: 
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effect of high energy intake and continuous low-grade 
inflammation? 
Esther Rodríguez-Gallego, Marta Riera-Borrull, Anna Hernández-Aguilera, Roger 
Mariné-Casadó, Anna Rull, Raúl Beltrán-Debón, Fedra Luciano-Mateo, Javier A. 
Menéndez
1
, Alejandro Vazquez-Martin
1
, Juan J. Sirvent
2
, Vicente Martín-Paredero
3
, 
Angel L. Corbí
4
, Elena Sierra-Filardi
4
, Gerard Aragonès, Anabel García-Heredia, Jordi 
Camps, Carlos Alonso-Villaverde
5
, Jorge Joven* 
The sequence of main elements used in the construction of the vector is described according to 
the following, color-based legend. For clarity, flanking regions were also included. 
 
5’homology arm 465-3467 
MCS 3475-3495 
UbiC promoter 3500-4709 
loxP site 4724-4757 
STOP cassette 4768-6101 
loxP site 6102-6135 
genomic fragment of CCL2 gene (frag) 6150-9056 
         exon1 6468-6628 
         exon2 7374-7491 
         exon3 7817-8343 
SV40pA 9090-9318 
FRT site 9331-9378 
PGK promoter 9388-9906 
Neo CDS 9974-10777 
Splice donor (SD) 10799-11005 
Instability signal (IS) 11006-11059 
FRT site 11090-11137 
MCS 11209-11230 
3’homology arm 11231-14260 
        1 AAACCGTCTA TCAGGGCGAT GGCCCACTAC GTGAACCATC ACCCTAATCA AGTTTTTTGG 
       61 GGTCGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG GAGCCCCCGA TTTAGAGCTT 
      121 GACGGGGAAA GCCGGCGAAC GTGGCGAGAA AGGAAGGGAA GAAAGCGAAA GGAGCGGGCG 
      181 CTAGGGCGCT GGCAAGTGTA GCGGTCACGC TGCGCGTAAC CACCACACCC GCCGCGCTTA 
      241 ATGCGCCGCT ACAGGGCGCG TCCCATTCGC CATTCAGGCT GCGCAACTGT TGGGAAGGGC 
      301 GATCGGTGCG GGCCTCTTCG CTATTACGCC AGCTGGCGAA AGGGGGATGT GCTGCAAGGC 
      361 GATTAAGTTG GGTAACGCCA GGGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTG 
      421 AATTGTAATA CGACTCACTA TAGGGCGAAT TGGGTACCGG CGCGCCTAGC GACCTAAACC 
      481 ATTATTAATA TCAAATTAAC CATCAAAACA CTTTCCTCTC AATATGCTGC ACACAAACCT 
      541 CCTCCTGGAA CCTCCTCCAT CTGGATCCTC CCCAATCAAA AGTATAGGTA TTTAACATAT 
      601 AAGCAAGGAA GTAATGTAAA CATGACCTTG GTCACAAATA TGTCATCTAA AAACAATTTA 
      661 GTCAAGGTAT GGAGGAAATT CGAGAACCTG AATCTTTTTA AGTATTTTGA GCACAGGAAC 
      721 AATTGGCAAA AGGAATCCAG GTATAGACAA AACCCAGAGC CCAGAGCTCT GGGCGAAAAA 
      781 TGAGTTGCTG GTGAAGACGT TACACAAGTA ACATGAGAAA GCAGAAAATG CAGGTCATCC 
      841 ACGCACCCCT GACCCAGGCC AGCAGGGCGG GCTGCAGCAT CAGTACACAG GAGAAAGATC 
      901 CTTATTCCTA AGAATGAGAA AGGCAAAGGC GCCCGATAGA ATAAATTAGC ATAGAAGGGG 
      961 CTTTCCCAGG AGTTAAAACT TTCCTTCTGA GCGATTACCT ACTAAAACCA GGGCTTTTGC 
     1021 CCACTACCAT TTACCTAGGA TCTTGGCTTG CACGGATTCA TAGGGGCATA TCCCTCCCCC 
     1081 TCTTCTTTAG AGTCGTTCTT AAAAGATCGC TCTCCACGCC CTAGGCAGGG AAAACGACAA 
     1141 AATCTGGCTC AATTCCAGGC TAGAACCCTA CAAATTCAAC AGGGATATCG CAAGGATACT 
     1201 GGGGCATACG CCACAGGGAG TCCAAGAATG TGAGGTGGGG GTGGCGAAGG TAATGTCTTT 
     1261 GGTGTGGGAA AAGCAGCAGC CATCTGAGAT AGGAACTGGA AAACCAGAGG AGAGGCGTTC 
     1321 AGGAAGATTA TGGAGGGGAG GACTGGGCCC CCACGAGCGA CCAGAGTTGT CACAAGGCCG 
     1381 CAAGAACAGG GGAGGTGGGG GGCTCAGGGA CAGAAAAAAA AGTATGTGTA TTTTGAGAGC 
     1441 AGGGTTGGGA GGCCTCTCCT GAAAAGGGTA TAAACGTGGA GTAGGCAATA CCCAGGCAAA 
     1501 AAGGGGAGAC CAGAGTAGGG GGAGGGGAAG AGTCCTGACC CAGGGAAGAC ATTAAAAAGG 
     1561 TAGTGGGGTC GACTAGATGA AGGAGAGCCT TTCTCTCTGG GCAAGAGCGG TGCAATGGTG 
     1621 TGTAAAGGTA GCTGAGAAGA CGAAAAGGGC AAGCATCTTC CTGCTACCAG GCTGGGGAGG 
     1681 CCCAGGCCCA CGACCCCGAG GAGAGGGAAC GCAGGGAGAC TGAGGTGACC CTTCTTTCCC 
     1741 CCGGGGCCCG GTCGTGTGGT TCGGTGTCTC TTTTCTGTTG GACCCTTACC TTGACCCAGG 
     1801 CGCTGCCGGG GCCTGGGCCC GGGCTGCGGC GCACGGCACT CCCGGGAGGC AGCGAGACTC 
     1861 GAGTTAGGCC CAACGCGGCG CCACGGCGTT TCCTGGCCGG GAATGGCCCG TACCCGTGAG 
     1921 GTGGGGGTGG GGGGCAGAAA AGGCGGAGCG AGCCCGAGGC GGGGAGGGGG AGGGCCAGGG 
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     1981 GCGGAGGGGG CCGGCACTAC TGTGTTGGCG GACTGGCGGG ACTAGGGCTG CGTGAGTCTC 
     2041 TGAGCGCAGC GGGCGGCGGC CGCCCCTCCC CCGGCGGCGG CAGCGGCGGC AGCGGCGGCA 
     2101 GCTCACTCAG CCCGCTGCCC GAGCGGAAAC GCCACTGACC GCACGGGGAT TCCCAGTGCC 
     2161 GGCGCCAGGG GCACGCGGGA CACGCCCCCT CCCGCCGCGC CATTGGCCTC TCCGCCCACC 
     2221 GCCCCACACT TATTGGCCGG TGCGCCGCCA ATCAGCGGAG GCTGCCGGGG CCGCCTAAAG 
     2281 AAGAGGCTGT GCTTTGGGGC TCCGGCTCCT CAGAGAGCCT CGGCTAGGTA GGGGATCGGG 
     2341 ACTCTGGCGG GAGGGCGGCT TGGTGCGTTT GCGGGGATGG GCGGCCGCGG CAGGCCCTCC 
     2401 GAGCGTGGTG GAGCCGTTCT GTGAGACAGC CGGGTACGAG TCGTGACGCT GGAAGGGGCA 
     2461 AGCGGGTGGT GGGCAGGAAT GCGGTCCGCC CTGCAGCAAC CGGAGGGGGA GGGAGAAGGG 
     2521 AGCGGAAAAG TCTCCACCGG ACGCGGCCAT GGCTCGGGGG GGGGGGGGCA GCGGAGGAGC 
     2581 GCTTCCGGCC GACGTCTCGT CGCTGATTGG CTTCTTTTCC TCCCGCCGTG TGTGAAAACA 
     2641 CAAATGGCGT GTTTTGGTTG GCGTAAGGCG CCTGTCAGTT AACGGCAGCC GGAGTGCGCA 
     2701 GCCGCCGGCA GCCTCGCTCT GCCCACTGGG TGGGGCGGGA GGTAGGTGGG GTGAGGCGAG 
     2761 CTGGACGTGC GGGCGCGGTC GGCCTCTGGC GGGGCGGGGG AGGGGAGGGA GGGTCAGCGA 
     2821 AAGTAGCTCG CGCGCGAGCG GCCGCCCACC CTCCCCTTCC TCTGGGGGAG TCGTTTTACC 
     2881 CGCCGCCGGC CGGGCCTCGT CGTCTGATTG GCTCTCGGGG CCCAGAAAAC TGGCCCTTGC 
     2941 CATTGGCTCG TGTTCGTGCA AGTTGAGTCC ATCCGCCGGC CAGCGGGGGC GGCGAGGAGG 
     3001 CGCTCCCAGG TTCCGGCCCT CCCCTCGGCC CCGCGCCGCA GAGTCTGGCC GCGCGCCCCT 
     3061 GCGCAACGTG GCAGGAAGCG CGCGCTGGGG GCGGGGACGG GCAGTAGGGC TGAGCGGCTG 
     3121 CGGGGCGGGT GCAAGCACGT TTCCGACTTG AGTTGCCTCA AGAGGGGCGT GCTGAGCCAG 
     3181 ACCTCCATCG CGCACTCCGG GGAGTGGAGG GAAGGAGCGA GGGCTCAGTT GGGCTGTTTT 
     3241 GGAGGCAGGA AGCACTTGCT CTCCCAAAGT CGCTCTGAGT TGTTATCAGT AAGGGAGCTG 
     3301 CAGTGGAGTA GGCGGGGAGA AGGCCGCACC CTTCTCCGGA GGGGGGAGGG GAGTGTTGCA 
     3361 ATACCTTTCT GGGAGTTCTC TGCTGCCTCC TGGCTTCTGA GGACCGCCCT GGGCCTGGGA 
     3421 GAATCCCTTC CCCCTCTTCC CTCGTGATCT GCAACTCCAG TCTTTCTGGT ACCTCTAGAC 
3481ATATGTTAAT TAAATCGATG GCCTCCGCGC CGGGTTTTGG CGCCTCCCGC GGGCGCCCCC 
     3541 CTCCTCACGG CGAGCGCTGC CACGTCAGAC GAAGGGCGCA GCGAGCGTCC TGATCCTTCC 
     3601 GCCCGGACGC TCAGGACAGC GGCCCGCTGC TCATAAGACT CGGCCTTAGA ACCCCAGTAT 
     3661 CAGCAGAAGG ACATTTTAGG ACGGGACTTG GGTGACTCTA GGGCACTGGT TTTCTTTCCA 
     3721 GAGAGCGGAA CAGGCGAGGA AAAGTAGTCC CTTCTCGGCG ATTCTGCGGA GGGATCTCCG 
     3781 TGGGGCGGTG AACGCCGATG ATTATATAAG GACGCGCCGG GTGTGGCACA GCTAGTTCCG 
     3841 TCGCAGCCGG GATTTGGGTC GCGGTTCTTG TTTGTGGATC GCTGTGATCG TCACTTGGTG 
     3901 AGTAGCGGGC TGCTGGGCTG GCCGGGGCTT TCGTGGCCGC CGGGCCGCTC GGTGGGACGG 
     3961 AAGCGTGTGG AGAGACCGCC AAGGGCTGTA GTCTGGGTCC GCGAGCAAGG TTGCCCTGAA 
     4021 CTGGGGGTTG GGGGGAGCGC AGCAAAATGG CGGCTGTTCC CGAGTCTTGA ATGGAAGACG 
     4081 CTTGTGAGGC GGGCTGTGAG GTCGTTGAAA CAAGGTGGGG GGCATGGTGG GCGGCAAGAA 
     4141 CCCAAGGTCT TGAGGCCTTC GCTAATGCGG GAAAGCTCTT ATTCGGGTGA GATGGGCTGG 
     4201 GGCACCATCT GGGGACCCTG ACGTGAAGTT TGTCACTGAC TGGAGAACTC GGTTTGTCGT 
     4261 CTGTTGCGGG GGCGGCAGTT ATGGCGGTGC CGTTGGGCAG TGCACCCGTA CCTTTGGGAG 
     4321 CGCGCGCCCT CGTCGTGTCG TGACGTCACC CGTTCTGTTG GCTTATAATG CAGGGTGGGG 
     4381 CCACCTGCCG GTAGGTGTGC GGTAGGCTTT TCTCCGTCGC AGGACGCAGG GTTCGGGCCT 
     4441 AGGGTAGGCT CTCCTGAATC GACAGGCGCC GGACCTCTGG TGAGGGGAGG GATAAGTGAG 
     4501 GCGTCAGTTT CTTTGGTCGG TTTTATGTAC CTATCTTCTT AAGTAGCTGA AGCTCCGGTT 
     4561 TTGAACTATG CGCTCGGGGT TGGCGAGTGT GTTTTGTGAA GTTTTTTAGG CACCTTTTGA 
     4621 AATGTAATCA TTTGGGTCAA TATGTAATTT TCAGTGTTAG ACTAGTAAAT TGTCCGCTAA 
     4681 ATTCTGGCCG TTTTTGGCTT TTTTGTTAGA CGCCACCATG CATATAACTT CGTATAGCAT 
     4741 ACATTATACG AAGTTATGGC GCGCCGATCC TCGGGGACAC CAAATATGGC GATCTCGGCC 
     4801 TTTTCGTTTC TTGGAGCTGG GACATGTTTG CCATCGATCC ATCTACCACC AGAACGGCCG 
     4861 TTAGATCTGC TGCCACCGTT GTTTCCACCG AAGAAACCAC CGTTGCCGTA ACCACCACGA 
     4921 CGGTTGTTGC TAAAGAAGCT GCCACCGCCA CGGCCACCGT TGTAGCCGCC GTTGTTGTTA 
     4981 TTGTAGCTGC TACTGTTATT TCTGGCACTT CTTGGTTTTC CTCTTAAGTG AGGAGGAACA 
     5041 TAACCATTCT CGTTGTTGTC GTTGATGCTT AAATTTTGCA CTTGTTCGCT CAGTTCAGCC 
     5101 ATAATATGAA ATGCTTTTCT TGTTGTTCTT ACGGAATACC ACTTGCCACC TATCACCACA 
     5161 ACTAACTTTT TCCCGTTCCT CCATCTCTTT TATATTTTTT TTCTCGAGGG ATCTTTGTGA 
     5221 AGGAACCTTA CTTCTGTGGT GTGACATAAT TGGACAAACT ACCTACAGAG ATTTAAAGCT 
     5281 CTAAGGTAAA TATAAAATTT TTAAGTGTAT AATGTGTTAA ACTACTGATT CTAATTGTTT 
     5341 GTGTATTTTA GATTCCAACC TATGGAACTG ATGAATGGGA GCAGTGGTGG AATGCCTTTA 
     5401 ATGAGGAAAA CCTGTTTTGC TCAGAAGAAA TGCCATCTAG TGATGATGAG GCTACTGCTG 
     5461 ACTCTCAACA TTCTACTCCT CCAAAAAAGA AGAGAAAGGT AGAAGACCCC AAGGACTTTC 
     5521 CTTCAGAATT GCTAAGTTTT TTGAGTCATG CTGTGTTTAG TAATAGAACT CTTGCTTGCT 
     5581 TTGCTATTTA CACCACAAAG GAAAAAGCTG CACTGCTATA CAAGAAAATT ATGGAAAAAT 
     5641 ATTCTGTAAC CTTTATAAGT AGGCATAACA GTTATAATCA TAACATACTG TTTTTTCTTA 
     5701 CTCCACACAG GCATAGAGTG TCTGCTATTA ATAACTATGC TCAAAAATTG TGTACCTTTA 
     5761 GCTTTTTAAT TTGTAAAGGG GTTAATAAGG AATATTTGAT GTATAGTGCC TTGACTAGAG 
     5821 ATCATAATCA GCCATACCAC ATTTGTAGAG GTTTTACTTG CTTTAAAAAA CCTCCCACAC 
     5881 CTCCCCCTGA ACCTGAAACA TAAAATGAAT GCAATTGTTG TTGTTAACTT GTTTATTGCA 
     5941 GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTTTT 
     6001 TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGGATC 
     6061 TGACATGGTA AGTAAGCTTG GGCTGCAGGT CGAGGGACCT AATAACTTCG TATAGCATAC 
     6121 ATTATACGAA GTTATGCGGC CGCGAATTCA AAGCAGAGCC ACTCCATTCA CACTTGTGGT 
     6181 CACAGTAGTA CAATTACTGC CAATTCTTCC CTCTTTCCCC CCCCCCCCCC CTACTCCCTG 
     6241 CGCAGCTTCA TTTGCTCCCA GGAGTGGCTA GAAAAATACC AAATTCCAAC CCACAGTTTC 
     6301 TCTCTTCCAC TTCCTGGAAA CACCCGAGGG CTCTGCACTT ACTCAGCGGA TTCAACTTCC 
     6361 ACTTTCCATC ACTTATCCAG GGTGATGCTA CTCCTTGGCA CCAAGCACCC TGCCTGACTC 
     6421 CACCCCCCTG GCTTACAATA AAAGGCTGCC TCAGAGCAGC CAGAAGTGCA GAGAGCCAGA 
     6481 CGGGAGGAAG GCCAGCCCAG CACCAGCACC AGCCAACTCT CACTGAAGCC AGCTCTCTCT 
     6541 TCCTCCACCA CCATGCAGGT CCCTGTCATG CTTCTGGGCC TGCTGTTCAC AGTTGCCGGC 
     6601 TGGAGCATCC ACGTGTTGGC TCAGCCAGGT GAGACCCCCC CAGCTCCCTT CCCAGCATAT 
     6661 CACCCCATTT TTGAATTGTC GTGGATTGTG ATAGCATAGT CTCACATGGT CAGGTACTTT 
     6721 TTTTTTTTTC TTTAACCAAG ATAAGGAGCA TAAAGAAGGA AGGACAAAGA GCCAACCCAA 
     6781 TTACAAGATT GCTTCTGGAA AGCAACTAGA ATTTTAATTG TTAGATCTAA ATTTGGAATC 
     6841 ACACCTTCAT ATAGTTCCTG TTCCAGTTAC TTCCCTCAGT ATTTGGGAAC CTGGGTGATC 
     6901 AAACAGAGGC TTGGGTTGGT GCCTTTTTCC AGATAGAGGA GAAAGGGGAA GAGATCCAAG 
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     6961 ATCCGAGCTG TGTTTCACCC AGCCCTGCTT CCAGAGATAG CAGCTTAGCG GAGGTGGTTG 
     7021 GGATCAGAGA TACTCATGAT TTGATTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTGC 
     7081 AGCCTACAGT AATGTACTCA GGTAATCTTC TCAGGTCATA GTAATTTGAC TTCTAACTCC 
     7141 CCCAAATGAC AGTCCCCAGA GTCACATAGT TTTAATGGCA TCCCTCTACC CAAGACTGTG 
     7201 AGCCTACTTT AAGCTGCAAA TAACTGAGTC TGTTGTCAAA GATCACATCC CAGATCTGAT 
     7261 GTATTGGCAT TTATATCCCA TCCTGCTGAA ACTGCCTTCT CCCCGTGGTC CTTCTCTTCT 
     7321 CTAAGGTCAG AAGCATCTTT CCTGTCCTAA TGTGCTTCTC TTTTACTCTC CAGATGCAGT 
     7381 TAACGCCCCA CTCACCTGCT GCTACTCATT CACCAGCAAG ATGATCCCAA TGAGTAGGCT 
     7441 GGAGAGCTAC AAGAGGATCA CCAGCAGCAG GTGTCCCAAA GAAGCTGTAG TGTGAGTTAC 
     7501 ATACCCCGGC CCTCCCTGGT CCAAAGGTTT TTCCTTAAGA ACAAGGGATG GTCCTCATAT 
     7561 ACTTATAGTC AGTCACACAC TCAGATCCAA TGGGGAAACC AAGGCCAAGA AGGCAAAGGC 
     7621 AGTTCTCAAC AGCATTGTCT CTATGGCTGC TGTTCAGGCC CTTTCTACTC CACAAGCTTA 
     7681 TCTTAGAAAA CCTGCAGGAG AAGCAGGTCA CTTTGAGTCC CCTTTTTCTA CCTGCCCTCC 
     7741 CCCGCTGAGC TCTACACAGC CCCTCCATGT ATACCAGACT GAACTTCATC TAACAGTGTC 
     7801 TTTTCTCTTC CCACAGTTTT GTCACCAAGC TCAAGAGAGA GGTCTGTGCT GACCCCAAGA 
     7861 AGGAATGGGT CCAGACATAC ATTAAAAACC TGGATCGGAA CCAAATGAGA TCAGAACCTA 
     7921 CAACTTTATT TAAAACTGCA TCTGCCCTAA GGTCTTCAGC ACCTTTGAAT GTGAAGTTGA 
     7981 CCCGTAAATC TGAAGCTAAT GCATCCACTA CCTTTTCCAC AACCACCTCA AGCACTTCTG 
     8041 TAGGAGTGAC CAGTGTGACA GTGAACTAGT GTGACTCGGA CTGTGATGCC TTAATTAATA 
     8101 TTAAACTTAT TTAACTTATT GATGTTATGG TATTCCCTTT CATGAATACT AAAATTTCTT 
     8161 AAATGCAAGG TGTGGATCCA TTTTTCCCTC TCTGTGAATC CAGATTCAAC ACTTTCAATG 
     8221 TATGAGAGAT GAATTTTGTA AAGATGAATG GGTAAACTTT GTGTTTGAGA TTCCAAGGTA 
     8281 TTGTTTAAAA TATTATTATG GATATTCCTT ATTATTAAAA GAAATATATT ATTTTTGTAC 
     8341 ACCAGTCTGA CTTTGAGTGT TTTCTTGAGG GAAACTGCAA AGCTGAGAGT ATATAAGCTT 
     8401 GGAGAGCAAC ACAGGTTGGG ACACATATTG TGGGGGAACA GGAGAGTGAA TGGCCCACTC 
     8461 TTTTGTATTG AATGGTCTTA TCTGAGTGTC ATAGACTCTT CAAGATGGGG CCCAGTCAGG 
     8521 GATGCTAGTA CCATTGTTTT GGTCCCTAGC ATTGCTTCTC AGATACATGC TCAACAAAAG 
     8581 CCCCAGTCCT TCCCAGTCAC ATGTCCTAGT TGCCCTTTAA CTGGGATACA TCACTTCCAT 
     8641 CTACAGCTCT GCAATTTATA ATTCTCTAAC TGCATAGGTA GTTCAGACAG TGGAGAACAG 
     8701 ACGGGAGACT TAACCATCTT CTATAGGAAG GTTATGGTAA TGCTTCCTAG AGAGAGGAAG 
     8761 ACATGAACTT ATCCTTGATA ATGGTTAGTT TTATAGGAAA AAAAACACAA AAGCATTAAG 
     8821 GAAAACTGGT AGGTGGGGGA AATTATCCAA AAATAGAAAT GAAAATGGTG TGTACATTAA 
     8881 ACGGGGAAGA GCGAGGGAAA CCATCCGATG GAGCTGCATG TATATCAAGA GATGGGGATT 
     8941 TTTCAAGAGG AAGCTCAATA CAGGGTTTGG AATAGGAAGG TGAGAACATG GTATTCCCTC 
     9001 GGACCTATAA TTTAAAGGAT AAGTTGAAAC TCTTCGGTCC AATAAAGAGG GAGGGAGAAT 
     9061 TCAGATCTGG TACCGATATC AAGCTTAACT GATCATAATC AGCCATACCA CATTTGTAGA 
     9121 GGTTTTACTT GCTTTAAAAA ACCTCCCACA CCTCCCCCTG AACCTGAAAC ATAAAATGAA 
     9181 TGCAATTGTT GTTGTTAACT TGTTTATTGC AGCTTATAAT GGTTACAAAT AAAGCAATAG 
     9241 CATCACAAAT TTCACAAATA AAGCATTTTT TTCACTGCAT TCTAGTTGTG GTTTGTCCAA 
     9301 ACTCATCAAT GTATCTTAAC GCTTAATTAA GAAGTTCCTA TTCCGAAGTT CCTATTCTCT 
     9361 AGTAAGTATA GGAACTTCTG GCGAATTAAT TCTACCGGGT AGGGGAGGCG CTTTTCCCAA 
     9421 GGCAGTCTGG AGCATGCGCT TTAGCAGCCC CGCTGGGCAC TTGGCGCTAC ACAAGTGGCC 
     9481 TCTGGCCTCG CACACATTCC ACATCCACCG GTAGGCGCCA ACCGGCTCCG TTCTTTGGTG 
     9541 GCCCCTTCGC GCCACCTTCT ACTCCTCCCC TAGTCAGGAA GTTCCCCCCC GCCCCGCAGC 
     9601 TCGCGTCGTG CAGGACGTGA CAAATGGAAG TAGCACGTCT CACTAGTCTC GTGCAGATGG 
     9661 ACAGCACCGC TGAGCAATGG AAGCGGGTAG GCCTTTGGGG CAGCGGCCAA TAGCAGCTTT 
     9721 GCTCCTTCGC TTTCTGGGCT CAGAGGCTGG GAAGGGGTGG GTCCGGGGGC GGGCTCAGGG 
     9781 GCGGGCTCAG GGGCGGGGCG GGCGCCCGAA GGTCCTCCGG AGGCCCGGCA TTCTGCACGC 
     9841 TTCAAAAGCG CACGTCTGCC GCGCTGTTCT CCTCTTCCTC ATCTCCGGGC CTTTCGACCT 
     9901 GCAGCCTGTT GACAATTAAT CATCGGCATA GTATATCGGC ATAGTATAAT ACGACAAGGT 
     9961 GAGGAACTAA ACCATGGGAT CGGCCATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC 
    10021 CGCTTGGGTG GAGAGGCTAT TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA 
    10081 TGCCGCCGTG TTCCGGCTGT CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT 
    10141 GTCCGGTGCC CTGAATGAAC TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC 
    10201 GGGCGTTCCT TGCGCAGCTG TGCTCGACGT TGTCACTGAA GCGGGAAGGG ACTGGCTGCT 
    10261 ATTGGGCGAA GTGCCGGGGC AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT 
    10321 ATCCATCATG GCTGATGCAA TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCATT 
    10381 CGACCACCAA GCGAAACATC GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT 
    10441 CGATCAGGAT GATCTGGACG AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG 
    10501 GCTCAAGGCG CGCATGCCCG ACGGCGATGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT 
    10561 GCCGAATATC ATGGTGGAAA ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG 
    10621 TGTGGCGGAC CGCTATCAGG ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG 
    10681 CGGCGAATGG GCTGACCGCT TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG 
    10741 CATCGCCTTC TATCGCCTTC TTGACGAGTT CTTCTGAGGC CGGCCCCACG CGTCCACCTT 
    10801 TGTTGTTGGA TATGCCCTTG ACTATAATGA GTACTTCAGG GATTTGAATG TAAGTAATGC 
    10861 TTTTTTTTTT CTCGCTCTCA TTTTTCAAAA ACCCACATAA AAATTGAGGA AAGGGAAGAA 
    10921 TTGTTTTCTC CTTCCAGCAC CTCGTAATTT GACCCGACTG ATGGTTCCCA TTAGTCACAT 
    10981 AAAGCTGTAG TCAAGTACAG ACGTCAGTAA TATTTATATA TTTATATTTT TAAAATATTT 
    11041 ATTTATTTAT TTATTTAAGT TAATTAGTGA AGGGCGAGCT TGAGGATCTG AAGTTCCTAT 
    11101 TCCGAAGTTC CTATTCTCTA GTAAGTATAG GAACTTCGGA TCGTTGAAGA AGGAGGTGGG 
    11161 ATGCTTAATT AAGCTTGTCG ACTCTAGATT GCGGCCGCGG CGCGCCATCG ATGAATTCGA 
    11221TATCGGCCGGCCGAAGATGG GCGGGAGTCT TCTGGGCAGG CTTAAAGGCT AACCTGGTGT 
    11281 GTGGGCGTTG TCCTGCAGGG GAATTGAACA GGTGTAAAAT TGGAGGGACA AGACTTCCCA 
    11341 CAGATTTTCG GTTTTGTCGG GAAGTTTTTT AATAGGGGCA AATAAGGAAA ATGGGAGGAT 
    11401 AGGTAGTCAT CTGGGGTTTT ATGCAGCAAA ACTACAGGTT ATTATTGCTT GTGATCCGCC 
    11461 TCGGAGTATT TTCCATCGAG GTAGATTAAA GACATGCTCA CCCGAGTTTT ATACTCTCCT 
    11521 GCTTGAGATC CTTACTACAG TATGAAATTA CAGTGTCGCG AGTTAGACTA TGTAAGCAGA 
    11581 ATTTTAATCA TTTTTAAAGA GCCCAGTACT TCATATCCAT TTCTCCCGCT CCTTCTGCAG 
    11641 CCTTATCAAA AGGTATTTTA GAACACTCAT TTTAGCCCCA TTTTCATTTA TTATACTGGC 
    11701 TTATCCAACC CCTAGACAGA GCATTGGCAT TTTCCCTTTC CTGATCTTAG AAGTCTGATG 
    11761 ACTCATGAAA CCAGACAGAT TAGTTACATA CACCACAAAT CGAGGCTGTA GCTGGGGCCT 
    11821 CAACACTGCA GTTCTTTTAT AACTCCTTAG TACACTTTTT GTTGATCCTT TGCCTTGATC 
    11881 CTTAATTTTC AGTGTCTATC ACCTCTCCCG TCAGGTGGTG TTCCACATTT GGGCCTATTC 
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    11941 TCAGTCCAGG GAGTTTTACA ACAATAGATG TATTGAGAAT CCAACCTAAA GCTTAACTTT 
    12001 CCACTCCCAT GAATGCCTCT CTCCTTTTTC TCCATTTATA AACTGAGCTA TTAACCATTA 
    12061 ATGGTTTCCA GGTGGATGTC TCCTCCCCCA ATATTACCTG ATGTATCTTA CATATTGCCA 
    12121 GGCTGATATT TTAAGACATT AAAAGGTATA TTTCATTATT GAGCCACATG GTATTGATTA 
    12181 CTGCTTACTA AAATTTTGTC ATTGTACACA TCTGTAAAAG GTGGTTCCTT TTGGAATGCA 
    12241 AAGTTCAGGT GTTTGTTGTC TTTCCTGACC TAAGGTCTTG TGAGCTTGTA TTTTTTCTAT 
    12301 TTAAGCAGTG CTTTCTCTTG GACTGGCTTG ACTCATGGCA TTCTACACGT TATTGCTGGT 
    12361 CTAAATGTGA TTTTGCCAAG CTTCTTCAGG ACCTATAATT TTGCTTGACT TGTAGCCAAA 
    12421 CACAAGTAAA ATGATTAAGC AACAAATGTA TTTGTGAAGC TTGGTTTTTA GGTTGTTGTG 
    12481 TTGTGTGTGC TTGTGCTCTA TAATAATACT ATCCAGGGGC TGGAGAGGTG GCTCGGAGTT 
    12541 CAAGAGCACA GACTGCTCTT CCAGAAGTCC TGAGTTCAAT TCCCAGCAAC CACATGGTGG 
    12601 CTCACAACCA TCTGTAATGG GATCTGATGC CCTCTTCTGG TGTGTCTGAA GACCACAAGT 
    12661 GTATTCACAT TAAATAAATA AATCCTCCTT CTTCTTCTTT TTTTTTTTTT TAAAGAGAAT 
    12721 ACTGTCTCCA GTAGAATTTA CTGAAGTAAT GAAATACTTT GTGTTTGTTC CAATATGGTA 
    12781 GCCAATAATC AAATTACTCT TTAAGCACTG GAAATGTTAC CAAGGAACTA ATTTTTATTT 
    12841 GAAGTGTAAC TGTGGACAGA GGAGCCATAA CTGCAGACTT GTGGGATACA GAAGACCAAT 
    12901 GCAGACTTTA ATGTCTTTTC TCTTACACTA AGCAATAAAG AAATAAAAAT TGAACTTCTA 
    12961 GTATCCTATT TGTTTAAACT GCTAGCTTTA CTTAACTTTT GTGCTTCATC TATACAAAGC 
    13021 TGAAAGCTAA GTCTGCAGCC ATTACTAAAC ATGAAAGCAA GTAATGATAA TTTTGGATTT 
    13081 CAAAAATGTA GGGCCAGAGT TTAGCCAGCC AGTGGTGGTG CTTGCCTTTA TGCCTTTAAT 
    13141 CCCAGCACTC TGGAGGCAGA GACAGGCAGA TCTCTGAGTT TGAGCCCAGC CTGGTCTACA 
    13201 CATCAAGTTC TATCTAGGAT AGCCAGGAAT ACACACAGAA ACCCTGTTGG GGAGGGGGGC 
    13261 TCTGAGATTT CATAAAATTA TAATTGAAGC ATTCCCTAAT GAGCCACTAT GGATGTGGCT 
    13321 AAATCCGTCT ACCTTTCTGA TGAGATTTGG GTATTATTTT TTCTGTCTCT GCTGTTGGTT 
    13381 GGGTCTTTTG ACACTGTGGG CTTTCTTTAA AGCCTCCTTC CTGCCATGTG GTCTCTTGTT 
    13441 TGCTACTAAC TTCCCATGGC TTAAATGGCA TGGCTTTTTG CCTTCTAAGG GCAGCTGCTG 
    13501 AGATTTGCAG CCTGATTTCC AGGGTGGGGT TGGGAAATCT TTCAAACACT AAAATTGTCC 
    13561 TTTAATTTTT TTTTTAAAAA ATGGGTTATA TAATAAACCT CATAAAATAG TTATGAGGAG 
    13621 TGAGGTGGAC TAATATTAAA TGAGTCCCTC CCCTATAAAA GAGCTATTAA GGCTTTTTGT 
    13681 CTTATACTTA ACTTTTTTTT TAAATGTGGT ATCTTTAGAA CCAAGGGTCT TAGAGTTTTA 
    13741 GTATACAGAA ACTGTTGCAT CGCTTAATCA GATTTTCTAG TTTCAAATCC AGAGAATCCA 
    13801 AATTCTTCAC AGCCAAAGTC AAATTAAGAA TTTCTGACTT TTAATGTTAA TTTGCTTACT 
    13861 GTGAATATAA AAATGATAGC TTTTCCTGAG GCAGGGTCTC ACTATGTATC TCTGCCTGAT 
    13921 CTGCAACAAG ATATGTAGAC TAAAGTTCTG CCTGCTTTTG TCTCCTGAAT ACTAAGGTTA 
    13981 AAATGTAGTA ATACTTTTGG AACTTGCAGG TCAGATTCTT TTATAGGGGA CACACTAAGG 
    14041 GAGCTTGGGT GATAGTTGGT AAAATGTGTT TCAAGTGATG AAAACTTGAA TTATTATCAC 
    14101 CGCAACCTAC TTTTTAAAAA AAAAAGCCAG GCCTGTTAGA GCATGCTTAA GGGATCCCTA 
    14161 GGACTTGCTG AGCACACAAG AGTAGTTACT TGGCAGGCTC CTGGTGAGAG CATATTTCAA 
    14221 AAAACAAGGC AGACAACCAA GAAACTACAG TTAAGGCCGG CCGCGGTGGA GCTCCAGCTT 
    14281 TTGTTCCCTT TAGTGAGGGT TAATTTCGAG CTTGGCGTAA TCATGGTCAT AGCTGTTTCC 
    14341 TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA CGAGCCGGAA GCATAAAGTG 
    14401 TAAAGCCTGG GGTGCCTAAT GAGTGAGCTA ACTCACATTA ATTGCGTTGC GCTCACTGCC 
    14461 CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATTAA TGAATCGGCC AACGCGCGGG 
    14521 GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG CTCACTGACT CGCTGCGCTC 
    14581 GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG GCGGTAATAC GGTTATCCAC 
    14641 AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA 
    14701 CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCCTG ACGAGCATCA 
    14761 CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC 
    14821 GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC TTACCGGATA 
    14881 CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT CATAGCTCAC GCTGTAGGTA 
    14941 TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA 
    15001 GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGA 
    15061 CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT ATGTAGGCGG 
    15121 TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGGA CAGTATTTGG 
    15181 TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT CTTGATCCGG 
    15241 CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC AAGCAGCAGA TTACGCGCAG 
    15301 AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG CTCAGTGGAA 
    15361 CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT TCACCTAGAT 
    15421 CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT AAACTTGGTC 
    15481 TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC TATTTCGTTC 
    15541 ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG GCTTACCATC 
    15601 TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG ATTTATCAGC 
    15661 AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT CCTGCAACTT TATCCGCCTC 
    15721 CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT AGTTCGCCAG TTAATAGTTT 
    15781 GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA CGCTCGTCGT TTGGTATGGC 
    15841 TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA TGATCCCCCA TGTTGTGCAA 
    15901 AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG CCGCAGTGTT 
    15961 ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT GTCATGCCAT CCGTAAGATG 
    16021 CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTA TGCGGCGACC 
    16081 GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG CCACATAGCA GAACTTTAAA 
    16141 AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC TCAAGGATCT TACCGCTGTT 
    16201 GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT CTTTTACTTT 
    16261 CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT GCCGCAAAAA AGGGAATAAG 
    16321 GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT CAATATTATT GAAGCATTTA 
    16381 TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA ATAAACAAAT 
    16441 AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTAAA TTGTAAGCGT TAATATTTTG 
    16501 TTAAAATTCG CGTTAAATTT TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC 
    16561 GGCAAAATCC CTGTTTAAAC TCGCGACGCG TTATAAATCA AAAGAATAGA CCGAGATAGG 
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The Knock-in Construct Design, from plasmid to electroporation 
 
1. Overview 
1.1 Vector backbone 
The following plasmid (named Ubi-Neo) was used for construction of the targeting vector. 
 
 
 
1.2 Construction fragments 
Named frag arm, contained the genomic fragment of the gene to be introduced (Ccl2).  
 
2. frag arm (Generation, Diagnostics and Sequencing) 
 
2.1 Production 
Using the following primers, the genomic fragment of Ccl2 gene was amplified by PCR. 
 
Template: C57BL/6 genomic DNA 
P_01 5’ AGAATTCAAAGCAGAGCCACTCCATTCACAC 
EcoRI  Homology 
 
P_02 5’ TGAATTCTCCCTCCCTCTTTATTGGACCGAAG 
EcoRI  Homology 
 
Product: 2921 bp 
Ubi-Neo 
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 2.2 Cloning into pPCR 
a) Sequencing with PBadF01 or PBadR02 
The PCR product was cloned into pPCR and screened by sequencing to confirm clones with the 
correct insert. 
 
 
 
 
b) Full Sequencing 
Once end sequencing identified clones, a full sequence was completed using the following 
primers. 
 
 
2.3 Cloning into the targeting vector 
a) Restriction enzyme digest for cloning 
Both frag arm vector (containing Ccl2 gene) and the Ubi-Neo vector, were digested with EcoRI 
for cloning Ccl2 gene into Ubi-Neo vector (just where the Stuffer fragment was placed). 
The resulting vector was named Ubi-frag-Neo 
 
0  
 
 
 
b) Screen by Sequencing 
Clones containing the insert could be screened by end sequencing with P335_11 and PNeoR10 
primers: 
 
 
frag arm 
frag arm 
frag arm 
Ubi-Neo 
Ubi-frag-Neo 
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3. Cloning into the ROSA 26 vector 
 
3.1 Cloning into the targeting vector 
a) Restriction enzyme digest for cloning 
ClaI restriction enzyme was used for cloning the constructed fragment (Ubi-frag-Neo) into the 
ROSA26 vector (which contained homologous sequences to ROSA26). 
 
 
 
 
 
 
 
b) Screen by Sequencing 
Clones that contained the insert (the targeting vector), were screened by end sequencing with 
the following primers 
 
 
 
 
Ubi-frag-Neo 
ROSA26 vector 
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4. Complete Targeting Vector 
 
4.1 Final sequencing 
To assess the targeting vector integrity, final sequencing was performed using the primers 
identified in the following graphic: 
 
 
 
4.2 Restriction enzyme digest for Quality Control 
Targeting vector was digested with several restriction enzymes as quality control strategy: 
 
 
 
 
4.3 Restriction enzyme digest for electroporation 
Finally, targeting vector was digested with AclI to obtain a suitable vector for electroporation into 
stem cells 
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Supplementary material S6, disturbances in glucose metabolism, corresponding to the 
manuscript: 
 
Ubiquitous transgenic overexpression of C-C 
chemokine ligand 2: a model to assess the combined 
effect of high energy intake and continuous low-grade 
inflammation? 
 
Esther Rodríguez-Gallego, Marta Riera-Borrull, Anna Hernández-Aguilera, Roger 
Mariné-Casadó, Anna Rull, Raúl Beltrán-Debón, Fedra Luciano-Mateo, Javier A. 
Menéndez
1
, Alejandro Vazquez-Martin
1
, Juan J. Sirvent
2
, Vicente Martín-Paredero
3
, 
Angel L. Corbí
4
, Elena Sierra-Filardi
4
, Gerard Aragonès, Anabel García-Heredia, Jordi 
Camps, Carlos Alonso-Villaverde
5
, Jorge Joven* 
Oral glucose tolerance tests displayed a significant effect of high fat, high-cholesterol diet on 
insulin resistance even with a short-term manipulation. However, differences among strains fed 
the same diet were negligible either in 16 an 24 weeks old (A, B). Plasma glucose was higher in 
CCL2 overexpressors than in other strains and the effect of diet was also more evident (C).  
These differences disappeared when the dietary tratement was for 14 weeks (D). * P<0.05 with 
respect to relevant pair. 
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Supplementary material S7, expression of fatty acid synthase and AMPK in the liver, 
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Representative immunoblottings in the liver of transgenic and KO mice fed chow diet 
(A,C,D) and high-fat diet (B,E, F) of FASN and activated AMPK and the respective 
calculations (C-F) . 
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Supplementary material S8  The effect of high fat diet and overexpression of CCL2 
in the size, number and morphology of liver macrophages after 14 weeks of dietary 
treatment, corresponding to the manuscript: 
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Dietary fat (right column) and CCL2 expression modify the size, number and morphology of 
liver macrophages with respect to those fed a chow diet (left column) as assessed with F4/80 
staining. Values for stained area and length of macrophages (A-D) are illustrated with 
representative microphotographs from transgenic (E,F), WT (G,H) and KO mice (I,J). 
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Supplementary material S9, Transgenic mice that overexpress CCL2 die 
prematurely when fed high-fat diet, corresponding to the manuscript: 
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Transgenic mice fed high-fat diet died prematurely after a progressive decrease in 
weight and activity (A,B). The size of the spleen in transgenic animals was higher than 
in controls and there were abundant megakariocytes (C, D). The livers were also higher 
in transgenic mice where steatosis and signs of regenerative tissue and apoptotic nuclei 
were numerous (E,F)  
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
 UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
Publications 
1. Hernández-Aguilera A, Sepúlveda J, Rodríguez-Gallego E, Guirro M, García-Heredia A, 
Cabré N, Luciano-Mateo F, Fort-Gallifa I, Martín-Paredero V, Joven J, Camps J. 
Immunohistochemical analysis of paraoxonases and chemokines in arteries of patients 
with peripheral artery disease; Int J Mol Sci. 2015 May 18;16(5):11323-38. doi: 
10.3390/ijms1605113 
2. Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, Rodríguez-Gallego E, Bosch J, Martín B, 
Llorens R, Joven J, Menéndez J. Oncometabolic mutation IDH1 R132H confers a 
metformin-hypersensitive phenotype; Oncotarget. 2015 Mar 30. [Epub ahead of print] 
3. Calvo N, Beltrán-Debón R, Rodríguez-Gallego E, Hernández-Aguilera A, Guirro M, 
Mariné-Casadó R, Millá L, Alegret JM, Sabench F, del Castillo D, Vinaixa M, Rodríguez 
MA, Correig X, García-Alvarez R, Menéndez JA, Camps J, Joven J; Liver fat deposition and 
mitochondrial dysfunction in morbid obesity: An approach combining metabolomics 
with liver imaging and histology; World Journal of Gastroenterology; 2015; Accepted for 
publication.  
4. Rull A, Hernandez-Aguilera A, Fibla M, Sepulveda J, Rodríguez-Gallego E, Riera-Borrull 
M, Sirvent JJ, Martín-Paredero V, Menendez JA, Camps J, Joven J. Understanding the role 
of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia 
threatening the lower extremities. Vasc Med. 2014 Dec;19(6):442-51.  
 
5. Joven J, Guirro M, Mariné-Casadó R, Rodríguez-Gallego E, Menéndez JA. Autophagy is 
an inflammation-related defensive mechanism against disease. Adv Exp Med Biol. 2014; 
824:43-59.  
 
6. Menendez JA, Quirantes-Piné R, Rodríguez-Gallego E, Cufí S, Corominas-Faja B, Cuyàs E, 
Bosch-Barrera J, Martin-Castillo B, Segura-Carretero A, Joven J. Oncobiguanides: 
Paracelsus' law and nonconventional routes for administering diabetobiguanides for 
cancer treatment. Oncotarget. 2014. Volumen 5. 2344 - 2348.  
 
7. Camps, J., Rodríguez-Gallego, E., García-Heredia, A., Triguero, I., Riera-Borrull, M., 
Hernández-Aguilera, A., Luciano-Mateo, F., Fernández-Arroyo, S., Joven, J.. 
Paraoxonases and chemokine (C-C motif) ligand-2 in noncommunicable diseases. 
Advances In Clinical Chemistry. 2014. Volumen 63. 247 - 308.  
 
8. Rodríguez-Gallego, E., Guirro, M., Riera-Borrull, M., Hernández-Aguilera, A., Mariné-
Casadó, R., Fernández-Arroyo, S., Beltrán-Debón, R., Sabench, F., Hernández, M., del 
Castillo, D., Menendez, J.A., Camps, J., Ras, R., Arola, L., Joven, J.. Mapping of the 
circulating metabolome reveals a-ketoglutarate as a predictor of morbid obesity-
associated non-alcoholic fatty liver disease. International Journal Of Obesity. 2014.  
9. Joven J, March I, Espinel E, Fernández-Arroyo S, Rodríguez-Gallego E, Aragonès G, 
Beltrán-Debón R, Alonso-Villaverde C, Rios L, Martin-Paredero V, Menendez JA, Micol V, 
Segura-Carretero A, Camps J. Hibiscus sabdariffa extract lowers blood pressure and 
improves endothelial function. Molecular Nutrition & Food Research. 2014. Volumen 58 
1374-1378.  
 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
10. Oliveras-Ferraros, C., Vazquez-Martin, A., Cuyàs, E., Corominas-Faja, B., Rodríguez-
Gallego, E., Fernandez-Arroyo, S., Martin-Castillo, B., Joven, J., Menendez, J.A.. Acquired 
resistance to metformin in breast cancer cells triggers transcriptome reprogramming 
toward a degradome-related metastatic stem-like profile. Cell Cycle 2014. Volumen 13. 
1132 - 1144.  
11. Joven, J., Micol, V., Segura-Carretero, A., Alonso-Villaverde, C., Menéndez, J.A., 
Aragonès, G., Barrajón-Catalán, E., Beltrán-Debón, R., Camps, J., Cufí, S., Fernández-
Arroyo, S., Fernández-Gutiérrez, A., Guillén, E., Herranz-López, M., Iswaldi, I., Lozano-
Sánchez, J., Martin-Castillo, B., Oliveras-Ferraros, C., Pérez-Sánchez, A., Rodríguez-
Gallego, E., Rull, A., Saura, D., Vázquez-Martín, A.. Polyphenols and the Modulation of 
Gene Expression Pathways: Can We Eat Our Way Out of the Danger of Chronic Disease?. 
Critical Reviews In Food Science And Nutrition. 2014. Volumen 54. 985 - 1001.  
12. Rull, A., Geeraert, B., Aragonès, G., Beltrán-Debón, R., Rodríguez-Gallego, E., García-
Heredia, A., Pedro-Botet, J., Joven, J., Holvoet, P., Camps, J.. Rosiglitazone and 
fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A 
transcriptomic and metabolomic study. Journal Of Proteome Research. 2014. Volumen 
13. 1731 - 1743. 20.  
13. Rodríguez-Gallego, E., Riera-Borrull, M., Hernández-Aguilera, A., Mariné-Casadó, R., 
Rull, A., Beltrán-Debón, R., Luciano-Mateo, F., Menendez, J.A., Vazquez-Martin, A., 
Sirvent, J.J., Martín-Paredero, V., Corbí, A.L., Sierra-Filardi, E., Aragonès, G., García-
Heredia, A., Camps, J., Alonso-Villaverde, C., Joven, J.. Ubiquitous transgenic 
overexpression of C-C Chemokine Ligand 2: A model to assess the combined effect of 
high energy intake and continuous low-grade inflammation. Mediators Of 
Inflammation 2013. Volumen 2013.  
14. Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IA, Dorca J, Martínez 
S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, 
Segura-Carretero A, Joven J, Martin-Castillo B, Menéndez JA. Dietary restriction-resistant 
human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to 
metformin. Oncotarget. 2013 Aug 21. 
15. Fernández-Sender  L, Alonso-Villaverde C, Rull A, Rodríguez-Gallego E, Riera-Borrull M, 
Hernández-Aguilera A, Camps J, Beltrán-Debón R, Aragonès G, Menéndez JA, Joven J. A 
possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a 
cross-sectional study. AIDS Res. Ther. 2013 May 9;10(1):11 
16. Hernández-Aguilera A, Rull A, Rodríguez-Gallego E, Riera-Borrull M, Luciano-Mateo F, 
Camps J, Menéndez JA, Jorge Joven. Mitochondrial Dysfunction: A Basic Mechanism in 
Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities. 
Mediators Inflamm. 2013 
17. Menéndez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltrán-Debón R, Borrás-Linares 
I, Camps J, Corominas-Faja B, Cufí S, Fernández-Arroyo S, Garcia-Heredia A, Hernández-
Aguilera A, Herranz-López M, Jiménez-Sánchez C, López-Bonet E, Lozano-Sánchez J, 
Luciano-Mateo F, Martin-Castillo B, Martin-Paredero V, Pérez-Sánchez A, Oliveras-
Ferraros C, Riera-Borrull M, Rodríguez-Gallego E, Quirantes-Piné R, Rull A, Tomás-Menor 
L, Vazquez-Martin A, Alonso-Villaverde C, Micol V, Segura-Carretero A. Xenohormetic 
and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: A new 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
family of gerosuppressant agents.Cell Cycle. 2013 Feb 15;12(4):555-78. doi: 
10.4161/cc.23756. Epub 2013 Jan 31. 
18. Joven J, Menéndez J, Fernandez-Sender L, Espinel E, Rull A, Beltrán-Debón R, Rodríguez-
Gallego E, Riera-Borrull M, Pedro-Botet J, Alonso-Villaverde C, Camps J, Aragonès G. 
HIV Med. 2013 Apr;14(4):233-40. doi: 10.1111/hiv.12000. Epub 2012 Nov 21. 
19. Rull A, Aragonès G, Beltrán-Debón R, Rodríguez-Gallego E, Camps J, Joven J. Exploring 
PPAR modulation in experimental mice. Methods Mol Biol. 2013;952:253-73. doi: 
10.1007/978-1-62703-155-4_19. 
20. Joven J, Rull A, Rodriguez-Gallego E, Camps J, Riera-Borrull M, Hernández-Aguilera A, 
Martin-Paredero V, Segura-Carretero A, Micol V, Alonso-Villaverde C, Menéndez JA. 
Multifunctional targets of dietary polyphenols in disease: a case for the chemokine 
network and energy metabolism. Food Chem Toxicol. 2013 Jan;51:267-79. doi: 
10.1016/j.fct.2012.10.004. Epub 2012 Oct 11. 
21. Aragonès G, Pardo-Reche P, Fernández-Sender L, Rull A, Beltrán-Debón R, Rodríguez-
Gallego E, Camps J, Joven J, Alonso-Villaverde C. The deleterious influence of tenofovir-
based therapies on the progression of atherosclerosis in HIV-infected patients. 
Mediators Inflamm. 2012;2012:372305. doi: 10.1155/2012/372305. Epub 2012 May 7. 
22. Joven J, Espinel E, Rull A, Aragonès G, Rodríguez-Gallego E, Camps J, Micol V, Herranz-
López M, Menéndez JA, Borrás I, Segura-Carretero A, Alonso-Villaverde C, Beltrán-Debón 
R. Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and 
miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. Biochim 
Biophys Acta. 2012 Jul;1820(7):894-9. doi: 10.1016/j.bbagen.2012.03.020. Epub 2012 
Apr 5. 
23. Aragonès G, Ercilla A, Barreda M, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Alonso-
Villaverde C, Camps J, Joven J. Human Duffy blood group alloantigen system influences 
the measurement of monocyte chemoattractant protein-1 (MCP-1) in serum but not in 
plasma. Clin Lab. 2012;58(1-2):185-8. 
24. Camps J, García-Heredia A, Rull A, Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, 
Rodríguez-Gallego E, Joven J. PPARs in Regulation of Paraoxonases: Control of Oxidative 
Stress and Inflammation Pathways. PPAR Res. 2012;2012:616371. 
25. Aragonès G, Alonso-Villaverde C, Pardo-Reche P, Rull A, Beltran-Debon R, Rodriguez-
Gallego E, Fernandez-Sender L, Camps J, Joven J. Antiretroviral treatment-induced 
dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 
polymorphism. BMC Med Genet. 2011, 12:120. 
26. Joven J, Espinel E, Rull A, Beltrán-Debón R, Aragonès G, Rodríguez-Gallego E, Camps J, 
Pedro-Botet J, Sans T, Menéndez JA, Alonso-Villaverde C. Serum fatty acid synthase 
concentration is increased in patients with hepatitis viral infection and may assist in the 
prediction of liver steatosis. J Clin Virol. 2011. 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
Intellectual and industrial property 
1. Diagnóstico de esteatosis hepática no alcohólica. Nº Solicitud P2947ES00. Universitat 
Rovira i Virgili.  
2. Ratones Cisgénicos sobreporductores de MCP-1. Nº Solicitud P201330418. Universitat 
Rovira i Virgili. 
Congress attendance 
1. 83rd European Atherosclerosis Society Congress, Glasgow, 2015. Poster Oral 
presentation  
2. 82nd European Atherosclerosis Society Congress, Madrid, 2014. Poster Oral 
presentation  
3. EASL The International Liver Congress. London, 2014. Poster. 
4. 1er Congreso Médico-Quirúrgico de la Obesidad, Madrid, 2013. Poster 
5. Fórum CEICS (Campus d’Excel·lència Internacional Cataluña Sur), Tarragona-Reus, 2013 
CEICS (Campus de Excelencia Internacional Cataluña Sur). Attendee 
6. 80th EAS Congress, Milan (Italy), 24-28 Maig, 2012. Poster Oral presentation 
7. EASL The International Liver Congress, Barcelona (Spain), 18-22 April, 2012. Poster 
8. Fórum CEICS (Campus de Excelencia Internacional Cataluña Sur), Tarragona-Reus, 2011 
CEICS (Campus de Excelencia Internacional Cataluña Sur). Attendee 
9. Sesiones Científicas del Centro Catalán de la Nutrición 2011: Alimentos funcionales. 
CCNIEC, Reus,   2011. CNIEC (Centre Català de la Nutrició de l'Institut d'Estudis Catalans). 
Attendee 
10. XXIII Congrés de la Societat Catalana de Cardiologia, 2011. Poster 
11. 4th International Conference on Paraoxonases, Vilaseca, 2010. Organitzation 
12. 34th FEBS Congress, Praga, 2009. Poster 
13. Barcelona Biomed Conference, Barcelona, 2009. Attendee 
14. 5th Workshop on Biomedical Genomics and Proteomics, Badalona, 2008. Attendee 
15. SEBBM, Bilbao, 2008. Attendee 
16. III Congreso Interuniversitario de Biotecnología, León, 2008. Attendee 
17. 33th FEBS Congres, Athens, 2008. Attendee 
 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
  
UNIVERSITAT ROVIRA I VIRGILI 
INFLAMMATION AND ENERGY METABOLISM IN OBESITY: THE SEARCH FOR BIOMARKERS AND 
NOVEL THERAPEUTIC STRATEGIES. 
Esther Rodríguez Gallego 
Dipòsit Legal: T 1337-2015
